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SUMMARY 
 
Immunocompromised individuals are at increased risk of developing invasive 
pneumococcal disease (IPD). We have previously shown that IPD sufferers 
have defective in vitro B-cell responses to a T-independent antigen mimic 
(αδdex), relative to healthy controls. We hypothesized that similar defects will 
be found in HIV-infected individuals, who continue to be at greater risk of IPD 
despite antiretroviral therapy, and in Monoclonal Gammopathy of 
Undetermined Significance (MGUS) patients. 
 
Lymphocytes enriched from whole blood were cultured with αδdex alone and 
combined with anti-CD3, to assess both direct T- and B-cell effects, and T-
cell help to B-cells. T- and B-cell activation and proliferation were assessed 
using standardised flow cytometry. B-cell subsets were stratified by CD19, 
CD10, CD20, CD21 and CD27 into plasmablasts, activated memory cells, 
resting memory cells, naive, and tissue-like memory cells. 
 
Results from 16 HIV-infected individuals [mean CD4 count 677.63/mm3, 
undetectable viral loads] showed no change in overall CD19+ B-cell 
activation but increased proliferation upon T-cell-helped pneumococcal-
stimulation, compared to age-, sex- and ethnicity-matched controls. 
However, αδdex elicited significantly higher (p ≤ 0.05) activation in 
plasmablasts in HIV-infected individuals compared to healthy controls. 
Furthermore, MGUS patients expressed significantly lower CD25 on CD8+ T-
cells compared to healthy controls, following stimulation with anti-CD3 and 
anti-CD28 (p ≤ 0.01). Age, sex and ethnicity were also found to influence T- 
and B-cell responses to polyclonal-stimulation in healthy individuals. 
 
Although activation of CD19+ B-cells was similar between HIV-infected 
adults and healthy controls, polyclonal B-cell stimulation reveals a persisting 
hyperactivation defect in the plasmablast B-cell compartment in HIV infection 
despite virological suppression. The findings in this study may indicate 
impaired immune control of pathogens such as S. pneumoniae in 
immunocompromised individuals. 
4 
 
ACKNOWLEDGEMENTS 
 
 
Thank you to the God of Science. 
 
Thank you Daddy. I’m grateful that even though you aren’t here to see me 
finish this journey, everything you instilled in me guided me throughout.  
 
Thank you Dr. Marina Khingoyan Asani. Mummy. You are my rock. 
 
Thank you Fesa, Safi, Sifa, Mauwa, my nieces and nephews. Thank you Dr. 
Salumu Selemani and Johnny Selemani. Thank you my dear family for your 
support over the years. I love you all very much. 
 
Thank you Prof. Andy Heath, Dr.Thushan de Silva, Dr. Helen Marriott, Prof. 
David Dockrell, Dr. Rachel Foster, and Prof. John Snowden. I am grateful for 
your intellectual input into the development of my research. 
 
Thank you to the Florey Institute for Host-Pathogen Interactions for funding 
my PhD. And many thanks to the Research Nurses at the Royal Hallamshire 
Hospital who always helped me with smiles on their faces: Mary, Lynne, 
Sarah, Debbie and Charlie. 
 
My dear friends in the lab: Sayali, Apoorva, Emily, Lucy, Chloe, Katie, Sue 
and Jon. And those who extended love and friendship from outside the lab:  
Billy, Divya, Yetunde, Ayomide, Blessings, Tosin, Amina, Fatima, Gossy and 
Black Twitter.  Thank you Bayo, Isaac, and Sandra. We miss you. I thank 
you all so much. 
 
Thank you Paul C., Paul M., Baz, Joby, Lorena, Jen, Mohasin and James 
Wing. I’m grateful for the various bits and bobs you’ve so kindly assisted me 
with over the years. 
 
 
5 
 
Thank you, 
 
To the Teachers 
Not one word has ever been wasted. Those that have gone unused in the 
stories carved in Science have been used through other creative mediums. 
And all these stories have needed telling. 
 
To the Tempest 
Ars longa, vita brevis. Life and death fall within the continuum of existence. 
And legacies and energies and Trinities will forever hold us as one. We may 
be broken multiple times but life is the Art of putting together broken pieces 
into beautiful new forms. 
 
To the Temples 
From the chimes of the town hall that sang me lullabies to the various homes 
that have shrouded me with safety. The inanimate are often the best of 
friends. 
 
And finally, to the Testimony ahead.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
‘The best is yet to come...’ 
- Carolyn Leigh 
 
6 
 
TABLE OF CONTENTS 
 
Summary ....................................................................................................... 3 
Acknowledgements ...................................................................................... 4 
List of Figures ............................................................................................ 11 
List of Tables .............................................................................................. 19 
Abbreviations ............................................................................................. 21 
Chapter One: Literature overview ............................................................. 23 
1.1  Streptococcus pneumoniae and pneumococcal infections  .................. 24 
1.1.1  Streptococcus pneumoniae  ........................................................ 24 
1.1.2  Burden of pneumococcal disease .............................................. 26 
1.1.3 Groups at risk of pneumococcal infection ................................... 29 
1.1.3.1  Risk factors and genetics ..................................................... 29 
1.1.3.2  Immunocompromised individuals ........................................ 30 
1.2  Current pneumococcal vaccinations...................................................... 31 
       1.2.1  Mechanism of function of pneumococcal  vaccines .................... 31 
       1.2.2  Vaccine composition and efficacy ............................................... 32 
       1.2.3  Pneumococcal vaccine responses in HIV/other risk groups ....... 35 
1.3  Immunity ................................................................................................ 37 
       1.3.1  Immune responses to S. pneumoniae infection .......................... 37 
       1.3.2  T- and B-cell responses in adaptive immunity ............................. 38 
1.4  Rationale for study ................................................................................ 40 
1.5  Hypothesis and aims of the research .................................................... 41 
 
Chapter Two: Methodology ....................................................................... 43 
2.1 Subject recruitment  ............................................................................... 44 
2.1.1  HIV-infected patients  .................................................................. 44 
2.1.2  Patients with Monoclonal Gammopathy of Undetermined   
Significance (MGUS) ................................................................................... 44 
1.1.3 Heal thy cont ro ls  .................................................................... 44 
2.2  Collection of blood samples .................................................................. 45 
7 
 
2.3  Lymphocyte enrichment from whole blood  ........................................... 46 
2.4  Cell proliferation assay ......................................................................... 47 
2.5  T- and B-cell stimulation ....................................................................... 49 
2.5.1  Stimulation of T-cells  .................................................................. 49 
2.5.1  Stimulation of B-cells  ................................................................. 50 
2.5.2.1 Anti-IgD-conjugated dextran (αδdex) .................................... 50 
           2.5.2.2 Streptococcus pneumoniae ................................................... 50 
2.6 Viability assays ...................................................................................... 51 
2.6.1 Cel l  death  ................................................................................. 51 
2.6.2  Apoptosis .................................................................................... 52 
2.7 Multicolour flow cytometry ...................................................................... 53 
2.7.1 LSRI I  f low cytometer  ............................................................ 53 
2.7.2 Staining extracellular markers of phenotype and activation  ........ 54 
2.7.3 F luorochrome se lect ion  ....................................................... 55 
2.7.4 Post -acquis i t ion analys is  .................................................... 57 
2.8 Statistical analysis .................................................................................. 62 
 
Chapter Three: The effect of age, sex and ethnicity on T- and B-cell 
responses ................................................................................................... 63 
3.1  Introduction ........................................................................................... 64 
3.2  Methods ................................................................................................ 68 
3.3  Results .................................................................................................. 70 
       3.3.1 CD3-stimulation of T-cells and IgD-stimulation of B-cells results in 
activation  ..................................................................................................... 70 
       3.3.2  Age significantly affects stimulated CD4+ T-cell, and unstimulated 
CD19+ B-cell activation  ............................................................................... 78 
       3.3.3  Sex and ethnicity influence CD4+ T- and CD19+ B-cell 
proliferation and activation  .......................................................................... 82 
              3.3.3.1 The effects of sex on CD4+ T- and CD19+ B-cell responses 
 ..................................................................................................................... 82 
8 
 
              3.3.3.2 The effects of ethnicity on CD4+ T- and CD19+ B-cell 
responses  .................................................................................................... 85 
3.4  Discussion of findings ............................................................................ 93 
       3.4.1 T- and B-cell responses to the validated immunologic assay  ...... 93 
       3.4.2  Age as an inherent influencer of T- and B-cell responses ........... 95 
       3.4.3  Sex-based variation in T- and B-cell responses  ......................... 96 
       3.4.4  Variations in T- and B-cell responses based on ethnicity  ........... 97 
3.5  Conclusion .......................................................................................... 100 
 
Chapter Four: T- and B-cell responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation ........................... 101 
4.1  Introduction ......................................................................................... 102 
4.2  Methods .............................................................................................. 108 
       4.2.1 Expansion of the stimulation assay  ........................................... 108 
       4.2.2 Recruitment of patients and controls  ......................................... 112 
4.3  Results ................................................................................................ 116 
       4.3.1 Characteristics of patient recruits and matched controls ............ 116 
       4.3.2 Variations in CD4+ T-cell responses to the stimulation assay, 
between HIV-infected individuals and matched controls  ........................... 119 
       4.3.3 CD3-stimulated hyperactivation in the CD8+ T-cells of HIV-infected 
individuals compared to matched controls  ................................................ 127 
       4.3.4 Increased proliferation in the CD19+ B-cells of HIV-infected 
individuals compared to matched controls after T-cell-helped pneumococcal-
stimulation  ................................................................................................. 135 
4.4  Discussion of findings .......................................................................... 145 
       4.4.1 Clinical characteristics of patient recruits  .................................. 145 
       4.4.2 CD4+ T-cell responses in HIV-infected individuals compared to 
matched controls  ....................................................................................... 145 
       4.4.3  CD8+ T-cell responses in HIV-infected individuals compared to 
matched controls  ....................................................................................... 147 
       4.4.4  CD19+ B-cell responses in HIV-infected individuals compared to 
matched controls  ....................................................................................... 148 
4.5  Conclusion .......................................................................................... 150 
9 
 
 
Chapter Five: B-cell subset responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation ........................... 151 
5.1  Introduction ......................................................................................... 152 
5.2  Methods .............................................................................................. 155 
5.3  Results ................................................................................................ 158 
       5.3.1 The effect of culture and stimulation on CD19+CD10- B-cell subset 
compartments  ........................................................................................... 158 
       5.3.2 Differences in B-cell subsets between HIV-infected individuals and 
matched controls after polyclonal and pneumococcal stimulation ............. 162 
5.4  Discussion of findings ......................................................................... 183 
       5.4.1 Culture does not affect B-cell subset distribution  ...................... 183 
       5.4.2 Subtle defects uncovered in the B-cell subsets of HIV-infected 
individuals  ................................................................................................. 183 
5.5  Conclusion .......................................................................................... 186 
 
Chapter Six: The effect of polyclonal and pneumococcal stimulation on 
T- and B-cells in a cohort of MGUS patients ......................................... 187 
6.1  Introduction ......................................................................................... 188 
6.2  Methods .............................................................................................. 191 
6.3  Results ................................................................................................ 193 
6.4  Discussion of findings ......................................................................... 220 
6.5  Conclusion .......................................................................................... 221 
 
Chapter Seven: Discussion..................................................................... 222 
7.1 Main findings  ....................................................................................... 223 
7.1.1  Chapter 3- The effect of age, sex and ethnicity on T- and B-cell 
responses  ........................................................................................... 223 
7.1.2 Chapter 4- T- and B-cell responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation  ................................. 224 
7.1.3 Chapter 5- B-cell subset responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation  ................................. 225 
10 
 
7.1.4 Chapter 6- The effect of polyclonal and pneumococcal stimulation 
on T- and B-cells in a cohort of MGUS patients  ....................................... 225 
7.2 Methodological criticisms  .................................................................... 226 
7.2.1  Chapter 3- The effect of age, sex and ethnicity on T- and B-cell 
responses  ........................................................................................... 226 
7.2.2 Chapter 4- T- and B-cell responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation  ................................. 226 
7.2.3 Chapter 5- B-cell subset responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation  ................................. 227 
7.2.4 Chapter 6- The effect of polyclonal and pneumococcal stimulation 
on T- and B-cells in a cohort of MGUS patients  ....................................... 228 
7.3 Future work and clinical considerations  ............................................... 228 
7.3.1  Chapter 3- The effect of age, sex and ethnicity on T- and B-cell 
responses  ........................................................................................... 228 
7.3.2 Chapter 4- T- and B-cell responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation  ................................. 228 
7.3.3 Chapter 5- B-cell subset responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation  ................................. 229 
7.3.4 Chapter 6- The effect of polyclonal and pneumococcal stimulation 
on T- and B-cells in a cohort of MGUS patients  ....................................... 230 
7.4 Overall considerations  ......................................................................... 231 
 
References  ............................................................................................... 232 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
LIST OF FIGURES 
 
 
Chapter One 
Figure 1.1: Trend line showing the incidence per 100 000 people, of IPD over 
a 15 year period for all age groups in the UK, highlighting the introduction of 
PCV into the UK vaccine scheme……………..……………………..…………28 
Figure 1.2: Cellular mechanisms by which PPV23 and PCV7/13 
function…………………………………………………………………………….32 
Figure 1.3:  T- and B-cell development and interactions thereafter……....…39 
 
Chapter Two 
Figure 2.1: Flow diagram illustrating the sequential steps used in the 
methodology of this project………………………………………………………45 
Figure 2.2: Proliferation of a stimulated sample (B) on the FlowJo 
Proliferation platform is indicated as subsequent peaks (in pink) formed to 
the left of generation 0- the parent generation (shown in coral)…...……..…48 
Figure 2.3: Flow cytometry gating strategy used to eliminate all unwanted 
cells/signals from the final data set.………………… ………..………………..58 
 
Figure 2.4: Representative dot plots of positively labelled CD19+ (A) B-cell, 
and CD4+ (B) and CD8+ T-cell populations (C) relative to their respective 
Fluorescence-Minus-One (FMO) gating controls (B for CD19+ B-cells, A for 
CD4+ T-cells, and D for CD8+ T-cells).………………………………..………60 
 
Figure 2.5: Representative dot plots of positively labelled CD19+ (A) and 
CD10+ B-cell populations (C) relative to their respective Fluorescence-
Minus-One (FMO) gating controls (B for CD19+ B-cells and D for CD10+ B-
cells)………….………………………………………………………….……..….61 
 
Figure 2.6: Representative dot plots showing B-cell subsets (A) and further 
separation of the Q1 quadrant into Plasmablasts and Activated Memory cells 
(B).................................................................................................................62 
 
Chapter Three 
Figure 3.1: Frequency (A) and proliferation (B) of CD4+ T-cells following in 
vitro CD3-stimulation alone, in combination with CD28-costimulation, and 
αδdex………………………………………………………………………….…...72 
 
Figure 3.2: Activation of CD4+ T-cells in terms of CD25 (A) and HLA-DR 
expression (B) following in vitro CD3-stimulation alone, in combination with 
CD28-costimulation, and αδdex ………………………….…………….………73 
 
Figure 3.3: Frequency (A) and proliferation (B) of CD19+ B-cells following in 
vitro IgD-stimulation with αδdex alone, and in the presence of T-cell help...74 
 
12 
 
Figure 3.4: Activation of CD19+ B-cells in terms of CD86 (A) and CD25 
expression (B) following in vitro IgD-stimulation with αδdex alone, and in the 
presence of T-cell help …………………………………….………………….75 
 
Figure 3.5: Activation of CD19+ B-cells in terms of HLA-DR expression, 
following in vitro IgD-stimulation with αδdex alone, and in the presence of T-
cell help ……………………………………………………………………….…76 
 
Figure 3.6: Correlation of age with in vitro CD4+ T-cell activation, in terms of 
CD25 expression, under unstimulated conditions (A), with CD3-stimulation 
alone (B) and combined with αδdex (C).……………………..…………78 - 79 
 
Figure 3.7: Correlation of age with in vitro CD19+ B-cell activation, in terms 
of CD86 expression, under unstimulated conditions (A), with αδdex-
stimulation alone (B) and T-cell help (C).… ………………………….…80 - 81 
 
Figure 3.8: The effect of sex on CD4+ T-cell activation under unstimulated 
conditions (A), with CD3-stimulation alone (B) and combined with αδdex 
(C)……..……………………………………………………………………………83 
 
Figure 3.9: The effect of sex on CD19+ B-cell activation under unstimulated 
conditions (A), with αδdex-stimulation alone (B) and T-cell help (C)…….…84 
 
Figure 3.10: The effect of ethnicity on in vitro CD4+ T-cell frequencies under 
un-stimulated and stimulated conditions …………..…………………………86 
 
Figure 3.11: The effect of ethnicity on in vitro CD4+ T-cell proliferation under 
un-stimulated and stimulated conditions ……………..………………………87 
 
Figure 3.12: The effect of ethnicity on in vitro CD4+ T-cell activation, in terms 
of CD25 expression, under un-stimulated and stimulated conditions.……..88 
 
Figure 3.13: The effect of ethnicity on in vitro CD19+ B-cell frequencies 
under un-stimulated and stimulated conditions………………………….……89 
 
Figure 3.14: The effect of ethnicity on in vitro CD19+ B-cell proliferation 
under un-stimulated and stimulated conditions…………………………..……90 
 
Figure 3.15: The effect of ethnicity on in vitro CD19+ B-cell activation, in 
terms of CD86 expression, under un-stimulated and stimulated conditions 
………………………………………………………………………………………91 
 
Figure 3.16: The effect of ethnicity on in vitro CD19+ B-cell activation, in 
terms of CD25 expression, under un-stimulated and stimulated conditions 
……………………………………………………………………………….……..92 
 
 
 
 
 
13 
 
Chapter Four 
Figure 4.1: Proliferation (A) and activation (B) of CD19+ B-cells after in vitro 
stimulation using four different concentrations of heat-killed S. pneumoniae 
D39 strain (HKD39). ………………………….………………………...………109 
 
Figure 4.2: Frequency (A) and activation (B) of CD19+ B-cells after in vitro 
stimulation using 1μg/ml of αδdex and MOI 10 of HKD39.………..…110 - 111 
 
Figure 4.3: Workflow for patient recruitment during this project (A)……….113 
 
Figure 4.4i: Percentage frequencies of in vitro CD4+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions.…………………………. ……………………………………...…….119 
 
Figure 4.4ii: Tracking data showing the changes in in vitro CD4+ T-cell 
frequencies in HIV-infected individuals (A) and matched controls (B) upon 
stimulation………………………………………………………………………..120 
 
Figure 4.5i: Proliferation of in vitro CD4+ T-cells in HIV-infected individuals 
and matched controls under un-stimulated and stimulated conditions ..….121 
 
Figure 4.5ii: Tracking data showing the changes in in vitro CD4+ T-cell 
proliferation in HIV-infected individuals (A) and matched controls (B) upon 
stimulation………………………………………………………………………..122 
 
Figure 4.6i: CD25 expression on in vitro CD4+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions …….…………………………………………………………….……123 
 
Figure 4.6ii: Tracking data showing the changes in in vitro CD4+ T-cell CD25 
expression in HIV-infected individuals (A) and matched controls (B) upon 
stimulation…………………………………………………………………….….124 
 
Figure 4.7i: HLA-DR expression on in vitro CD4+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions………………………………………………………………….…..…125 
 
Figure 4.7ii: Tracking data showing the changes in in vitro CD4+ T-cell HLA-
DR expression in HIV-infected individuals (A) and matched controls (B) upon 
stimulation………..……………………………………………………………....126 
 
Figure 4.8i: Percentage frequencies of in vitro CD8+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions…………………………………………………………………..…....127 
 
Figure 4.8ii: Tracking data showing the changes in in vitro CD8+ T-cell 
frequencies in HIV-infected individuals (A) and matched controls (B) upon 
stimulation……………………………………………………………………….128 
 
14 
 
Figure 4.9i: Proliferation of in vitro CD8+ T-cells in HIV-infected individuals 
and matched controls under un-stimulated and stimulated conditions…....129 
 
Figure 4.9ii: Tracking data showing the changes in in vitro CD8+ T-cell 
proliferation in HIV-infected individuals (A) and matched controls (B) upon 
stimulation……………………………………………………………………….130 
 
Figure 4.10i: CD25 expression on in vitro CD8+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions…….….…………………………………………………………….…131 
 
Figure 4.10ii: Tracking data showing the changes in in vitro CD8+ T-cell 
CD25 expression in HIV-infected individuals (A) and matched controls (B) 
upon 
stimulation…………………………..…………………………………………....132 
 
Figure 4.11i: HLA-DR expression on in vitro CD8+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions….…………………………………………………………………..…133 
 
Figure 4.11ii: Tracking data showing the changes in in vitro CD8+ T-cell 
HLA-DR expression in HIV-infected individuals (A) and matched controls (B) 
upon stimulation…..…………………………………..……………...………....134 
 
Figure 4.12i: Percentage frequencies of in vitro CD19+ B-cells in HIV-
infected individuals and matched controls under un-stimulated and 
stimulated conditions……………………………………………....……………135 
 
Figure 4.12ii: Tracking data showing the changes in in vitro CD19+ B-cell 
frequencies in HIV-infected individuals (A) and matched controls (B) upon 
stimulation……………..…………….……………………………………..…....136 
 
Figure 4.13i: Proliferation of in vitro CD19+ B-cells in HIV-infected individuals 
and matched controls under un-stimulated and stimulated conditions……137 
 
Figure 4.13ii: Tracking data showing the changes in in vitro CD19+ B-cell 
proliferation in HIV-infected individuals (A) and matched controls (B) upon 
stimulation…………………………..……………………….………………......138 
 
Figure 4.14i: CD86 expression on in vitro CD19+ B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions…………………………………………………………………..….…139 
 
Figure 4.14ii: Tracking data showing the changes in in vitro CD19+ B-cell 
CD86 expression in HIV-infected individuals (A) and matched controls (B) 
upon stimulation……….…….……………………………………..…..……....140 
 
Figure 4.15i: CD25 expression on in vitro CD19+ B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions ..………………………………………………………………….…..141 
15 
 
 
Figure 4.15ii: Tracking data showing the changes in in vitro CD19+ B-cell 
CD25 expression in HIV-infected individuals (A) and matched controls (B) 
upon stimulation……….………….……………………..…………………......142 
 
Fig 4.16i: HLA-DR expression on in vitro CD19+ B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions………….…………………………………………..…………………143 
 
Figure 4.16ii: Tracking data showing the changes in in vitro CD19+ B-cell 
HLA-DR expression in HIV-infected individuals (A) and matched controls (B) 
upon stimulation….………………………………………………………..…....144 
 
Chapter Five 
Figure 5.1: Gating strategy to separate B-cell subsets………..……………156 
 
Figure 5.2: Gating strategy showing a CD19+CD10-Caspase+ population in 
a 20% ethonal-treated apoptosis positive control (B) and an un-stimulated 
control (C), relative to an unstained control (A)………………………………157 
 
Figure 5.3i: Proliferation of in vitro Plasmablasts and Activated Memory B-
cells in HIV-infected individuals and matched controls under un-stimulated 
and stimulated conditions…………………………...…………………....……163 
 
Figure 5.3ii: Tracking data showing the changes in in vitro Plasmablast and 
Activated Memory B-cell proliferation in HIV-infected individuals (A) and 
matched controls (B) upon stimulation…………………………………..……164 
 
Figure 5.4i: CD86 expression on in vitro Plasmablasts and Activated Memory 
B-cells in HIV-infected individuals and matched controls under un-stimulated 
and stimulated conditions………………………………...….………..……….165 
 
Figure 5.4ii: Tracking data showing the changes in in vitro Plasmablast and 
Activated Memory B-cell CD86 expression in HIV-infected individuals (A) and 
matched controls (B) upon stimulation……………….………..………..……166 
 
Figure 5.5i: Proliferation of in vitro Plasmablasts in HIV-infected individuals 
and matched controls under un-stimulated and stimulated conditions ...…167 
 
Figure 5.5ii: Tracking data showing the changes in in vitro Plasmablast 
proliferation in HIV-infected individuals (A) and matched controls (B) upon 
stimulation……………………………………………………………………….168 
 
Figure 5.6i: CD86 expression on in vitro in HIV-infected individuals and 
matched controls under un-stimulated and stimulated conditions ………..169 
 
Figure 5.6ii: Tracking data showing the changes in in vitro Plasmablast CD86 
expression in HIV-infected individuals (A) and matched controls (B) upon 
stimulation……..……………………………………...…………………..…..…170 
 
16 
 
Figure 5.7i: Proliferation of in vitro Activated Memory B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions…………………………………………...……………………..……171 
 
Figure 5.7ii: Tracking data showing the changes in in vitro Activated Memory 
B-cell proliferation in HIV-infected individuals (A) and matched controls (B) 
upon stimulation……………………………………………...…………..……172 
 
Figure 5.8i: CD86 expression on in vitro Activated Memory B-cells in HIV-
infected individuals and matched controls under un-stimulated and 
stimulated conditions…………………………..…………………………….…173 
 
Figure 5.8ii: Tracking data showing the changes in in vitro Activated Memory 
B-cell CD86 expression in HIV-infected individuals (A) and matched controls 
(B) upon stimulation……………………………..………………………..……174 
 
Figure 5.9i: Proliferation of in vitro Naive B-cells in HIV-infected individuals 
and matched controls under un-stimulated and stimulated conditions.…..175 
 
Figure 5.9ii: Tracking data showing the changes in in vitro Naive B-cell 
proliferation in HIV-infected individuals (A) and matched controls (B) upon 
stimulation…………………………………………………………………….…176 
 
Figure 5.10i: CD86 expression on in vitro Naive B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions……..…………………………………………………………..……..177 
 
Figure 5.10ii: Tracking data showing the changes in in vitro Naive B-cell 
CD86 expression in HIV-infected individuals (A) and matched controls (B) 
upon stimulation……………………………………..…………………..………178 
 
Figure 5.11i: Percentage frequencies of caspase positive Plasmablasts (PB) 
and Activated Memory (AM) B-cells, AMs alone, and Naïve B-cells under un-
stimulated and αδdex-stimulated conditions……………………………….…179 
 
Figure 5.11ii: Tracking data showing the changes in percentage frequencies 
of in vitro caspase positive Plasmablast and Activated Memory B-cells in 
HIV-infected individuals (A) and matched controls (B) upon stimulation….180 
 
Figure 5.11iii: Tracking data showing the changes in percentage frequencies 
of in vitro caspase positive Activated Memory B-cells in HIV-infected 
individuals (A) and matched controls (B) upon stimulation…………………181 
 
Figure 5.11iv: Tracking data showing the changes in percentage frequencies 
of in vitro caspase positive Naive B-cells in HIV-infected individuals (A) and 
matched controls (B) upon stimulation…………………………………..……182 
 
 
 
 
17 
 
Chapter Six 
Figure 6.1i: Percentage frequencies of in vitro CD4+ T-cells in MGUS 
patients and matched controls under un-stimulated and stimulated 
conditions…………………………………………………………………..…….194 
 
Figure 6.1ii: Tracking data showing the changes in in vitro CD4+ T-cell 
frequencies in MGUS patients (A) and matched controls (B) upon 
stimulation…………………………………………………………………….….195 
 
Figure 6.2i: Proliferation of in vitro CD4+ T-cells in MGUS patients and 
matched controls under un-stimulated and stimulated conditions ………...196 
 
Figure 6.2ii: Tracking data showing the changes in in vitro CD4+ T-cell 
proliferation in MGUS patients (A) and matched controls (B) upon 
stimulation……………………………………………………………………..…197 
 
Figure 6.3i: CD25 expression on in vitro CD4+ T-cells in MGUS patients and 
matched controls under un-stimulated and stimulated conditions ….…….198 
 
Figure 6.3ii: Tracking data showing the changes in in vitro CD4+ T-cell CD25 
expression in MGUS patients (A) and matched controls (B) upon 
stimulation…………………………………………………………………….…199 
 
Figure 6.4i: HLA-DR expression on in vitro CD4+ T-cells in MGUS patients 
and matched controls under un-stimulated and stimulated conditions…...200 
 
Figure 6.4ii: Tracking data showing the changes in in vitro CD4+ T-cell HLA-
DR expression in MGUS patients (A) and matched controls (B) upon 
stimulation………………………………………………………………………..201 
 
Figure 6.5i: Percentage frequencies of in vitro CD8+ T-cells in MGUS 
patients and matched controls under un-stimulated and stimulated conditions 
……….………………………………………………………………………...…202 
 
Figure 6.5ii: Tracking data showing the changes in in vitro CD8+ T-cell 
frequencies in MGUS patients (A) and matched controls (B) upon 
stimulation………………………………………………………………………..203 
 
Figure 6.6i: Proliferation of in vitro CD8+ T-cells in MGUS patients and 
matched controls under un-stimulated and stimulated conditions…………204 
 
Figure 6.6ii: Tracking data showing the changes in in vitro CD8+ T-cell 
proliferation in MGUS patients (A) and matched controls (B) upon 
stimulation……………………………………………………………………….205 
 
Figure 6.7i: CD25 expression on in vitro CD8+ T-cells in MGUS patients and 
matched controls under un-stimulated and stimulated conditions…...……206  
 
18 
 
Figure 6.7ii: Tracking data showing the changes in in vitro CD8+ T-cell CD25 
expression in MGUS patients (A) and matched controls (B) upon stimulation 
…………………………………………………………………………………….207 
 
Figure 6.8i: HLA-DR expression on in vitro CD4+ T-cells in MGUS patients 
and matched controls under un-stimulated and stimulated conditions …...208 
 
Figure 6.8ii: Tracking data showing the changes in in vitro CD8+ T-cell HLA-
DR expression in MGUS patients (A) and matched controls (B) upon 
stimulation…………………………………………………………………….….209 
 
Figure 6.9i: Percentage frequencies of in vitro CD19+ B-cells in MGUS 
patients and matched controls under un-stimulated and stimulated conditions 
…………………………………………………………………………..………...210 
 
Figure 6.9ii: Tracking data showing the changes in in vitro CD19+ B-cell 
frequencies in MGUS patients (A) and matched controls (B) upon 
stimulation………………………………………………………………………..211 
 
Figure 6.10i: Proliferation of in vitro CD19+ B-cells in MGUS patients and 
matched controls under un-stimulated and stimulated conditions ………...212 
 
Figure 6.10ii: Tracking data showing the changes in in vitro CD19+ B-cell 
proliferation in MGUS patients (A) and matched controls (B) upon 
stimulation………………………………………………………………………..213 
 
Figure 6.11i: CD25 expression on in vitro CD19+ B-cells in MGUS patients 
and matched controls under un-stimulated and stimulated conditions …..214 
 
Figure 6.11i: Tracking data showing the changes in in vitro CD19+ B-cell 
CD25 expression in MGUS patients (A) and matched controls (B) upon 
stimulation……………………………………………………………………….215 
 
Figure 6.12i: CD86 expression on in vitro CD19+ B-cells in MGUS patients 
and matched controls under un-stimulated and stimulated conditions …..216 
 
Figure 6.12ii: Tracking data showing the changes in in vitro CD19+ B-cell 
CD86 expression in MGUS patients (A) and matched controls (B) upon 
stimulation……………………………………………………………………….217 
 
Figure 6.13i: HLA-DR expression on in vitro CD19+ B-cells in MGUS patients 
and matched controls under un-stimulated and stimulated conditions …...218 
 
Figure 6.13ii: Tracking data showing the changes in in vitro CD19+ B-cell 
HLA-DR expression in MGUS patients (A) and matched controls (B) upon 
stimulation…………………………………………………………………….…219 
 
  
19 
 
LIST OF TABLES 
 
 
Chapter One 
Table 1: Target groups of the current pneumococcal vaccines recommended 
by the Joint Committee on Vaccination and Immunisation…………………..35 
 
Chapter Two 
Table 2.1: Multicolour flow cytometry panels used in this project for the 
detection of T- and B-cell phenotypic and activation markers (A), and B-cell 
subsets (B)………………………………………………………………...…55 - 56 
 
Chapter Three 
Table 3.1: Brief description of the workflow and outcome measures for 
results presented in chapter three……………………….…………………....69 
 
Table 3.2: Descriptive statistics showing the age, sex and ethnicity of 12 
individuals used to investigate T- and B-cell responses to a validated 
stimulation assay…………………………………………………………….…..70 
 
Table 3.3: Age range of 106 individuals used to investigate the correlative 
effects of age on T- and B-cell responses to CD3- and αδdex-stimulation 
respectively……………………………………………………………….……...77 
 
Table 3.4: Age range of 100 individuals used to investigate the in vitro effects 
of sex on T- and B-cell responses to CD3- and IgD-stimulation 
respectively……………………………………………………………………....82 
 
Table 3.5: Age range of 18 individuals used to investigate the in vitro effects 
of ethnicity on T- and B-cell responses to CD3- and αδdex-stimulation 
respectively………………………………………………………………………85 
 
Chapter Four 
Table 4.1: Antiretroviral therapy (ART) drug classifications from the US 
Department of Health and Human Services (2017)………………………... 114 
 
Table 4.2: Brief description of the workflow and outcome measures for 
results presented in chapter four……………………….....……………..……115 
 
Table 4.3: Characteristics of the HIV-infected cohort recruited for this study, 
with matched controls……………………………………..…….…………..….116 
 
Table 4.4: Clinical characteristics of the HIV-infected individuals who 
participated in this study…………………………….…………………..…...…117 
 
 
Chapter Five 
Table 5.1: Brief description of the workflow and outcome measures for 
results presented in chapter five…………………………….……………... 155 
 
20 
 
Table 5.2: The effect of culture on the frequency distribution of B-cell subsets 
(n = 4)……………………………… ……..…………………………………......159 
 
Table 5.3: The effect of stimulation on the frequency distribution of, and 
CD86 expression on, B-cell subsets (n = 4)………………….. ………..……160 
 
Table 5.4: Comparison of B-cell subset frequency distribution trends between 
the present study and Moir and Fauci’s study (2013)………….……………161 
 
Chapter Six 
Table 6.1: Brief description of the workflow and outcome measures for 
results presented in chapter six…………………………………...………......192 
 
Table 6.2: Characteristics of the MGUS cohort recruited for this study, with 
matched controls…………………………………………..……………….……193 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
21 
 
        ABBREVIATIONS 
 
αδdex  Anti-IgD conjugated dextran 
AIDS Acquired Immune Deficiency Syndrome 
AM Activated Memory Cells 
APC  Antigen presenting cell 
APO-1 Apoptosis antigen-1 
ART Antiretroviral Therapy 
ASC Antibody-secreting cell 
BAL Broncheoalveolar lavage 
BCR  B-cell receptor 
cART Combination Antiretroviral Therapy 
CD Cluster of Differentiation 
CDC  Centers for Disease Control and Prevention 
CFSE  Carboxyfluorescein diacetate succinimidyl ester 
CRM197 Non-toxic Diphtheria toxin mutant 
FACS  Fluorescence activated cell sorting 
FCRL4 Fc receptor-like protein 4 
FMO Fluorescence-Minus-One 
FSC-A Forward scatter area 
GALT Gut-associated lymphoid tissue 
HAART Highly Active Antiretroviral Therapy 
HCMV Human Cytomegalovirus 
HIV Human Immunodeficieny Virus 
HKD39 Heat-killed Streptococcus pneumoniae D39 strain 
IgA Immunoglobulin class A 
IgD  Immunoglobulin class D 
IgG Immunoglobulin class G 
IgM  Immunoglobulin class M 
IFN-γ  Interferon gamma 
IL Interleukin 
IPD Invasive Pneumococcal Disease 
JCVI 
Joint Committee on Vaccination and 
Immunisation 
KC  Keratinocyte-derived chemokine 
MenC Meningococcal C 
MFI  Median fluorescence intensity 
MGUS 
Monoclonal Gammopathy of Undetermined 
Significance 
MHC Major histocompatibility complex proteins 
MOI Multiplicity of infection 
MM Mutliple Myeloma 
M. tuberculosis Mycobacterium tuberculosis 
NHS National Health Service 
NOD 
Nucleotide-binding oligomerisation domain-like 
receptors 
N. meningitidis Neisseria meningitidis 
NF-κB  
Nuclear factor kappa-light-chain-enhancer of 
activated B-cells 
NVT Non-vaccine-type pneumococci 
PB Plasmablasts 
PBMC  Peripheral blood mononuclear cells 
PBS  Phosphate buffered saline 
PCV Pneumococcal Conjugate Vaccine 
22 
 
ABBREVIATIONS 
PD-1 Programmed cell death protein 1 
PPV Pneumococcal Pneumococcal Vaccine 
RHH Royal Hallamshire Hospital 
RM Resting Memory Cells 
RPMI Roswell Park Memorial Institute medium 
SSC-A  Side scatter area 
S. pneumoniae  Streptococcus pneumoniae 
STH Sheffield Teaching Hospitals 
TCR  T-cell receptor 
TD  T-cell dependent 
Tfh T follicular helper cell 
TH  Helper T-cell 
TH1  Helper T-cell subset 1 
TH17 Helper T-cell subset 17 
TI  T-cell independent 
TLM Tissue-like Memory Cells 
TLR Toll-like receptor 
TNF Tumour necrosis factor 
µl  Microliter 
µM  Micromolar 
µg  Microgram 
ViD Amine Reactive Viability Dyes 
WHO World Health Organisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER ONE: LITERATURE 
OVERVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
The increased risk of pneumococcal disease in immunocompromised 
individuals has been described in the literature widely. In order to form a 
rationale for this present study, a literature review on the cause of 
pneumococcal disease (caused by Streptococcus pneumoniae), groups at 
risk of disease, normal and immunocompromised immunity, and current 
vaccine schemes as well as gaps in the literature are presented below. 
 
1.1  Streptococcus pneumoniae and pneumococcal infections 
1.1.1  Streptococcus pneumoniae 
 
Streptococcus pneumoniae is a gram-positive bacterium that exists either 
as a single entity, a paired diplococcus, or in short chains. It is a 
facultative anaerobe, and can either be encapsulated or lack a capsule. 
The capsular polysaccharide elicits a type-specific antibody response in 
infected hosts which is protective, and should ordinarily clear the host of 
infection. This antibody response may also provide further protection 
against closely related serotypes. Currently, 97 serotypes of S. 
pneumoniae have been identified (CDC, 2012, Geno et al., 2015) with 
some serotypes being more predominant in particular  geographical  
locations  than others (Alonsodevelasco et al., 1995). 
 
The identification of these pneumococcal serotypes was facilitated by the 
use of type-specific  sera,  and  the serotypes were classified  by  the  so-
called  ‘Danish’  and  ‘American’ systems (Lund, 1960), the former being 
more widely used today. In the Danish nomenclature, serotype 
classification is based on structural differences in polysaccharide capsule, 
and antigenic characteristics. This polysaccharide capsule increases the 
virulence of the strain (Alonsodevelasco et al., 1995, Avery and Dubos, 
1931), and virulence is caused by interfering with the hosts’ phagocytic 
responses. In mice it has been shown that virulence is directly proportional 
to the amount of capsular polysaccharide produced by the pneumoccocci, 
in vitro (Macleod and Krauss, 1950). Some antigenic components of the 
S. pneumoniae polysaccharide capsules themselves are the virulence 
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factors and may be capable of eliciting antibody response 
( J e d r z e j a s ,  2 0 0 1 ) .  
 
S. pneumoniae also inhibits growth of Haemophilus influenzae and N. 
meningitidis, in vitro. This effect is most probably due to hydrogen peroxide 
produced by the pneumococci (Pericone et al., 2000). Indeed, in 1922 
MacLeod and Gordon showed that pneumococci produce hydrogen 
peroxide which accumulates in culture and may interfere with the growth of 
other bacteria, including Staphylococcus aureus (McLeod and Gordon, 
1922). Furthermore, S. pneumoniae growth was shown to increase upon 
co-culture with N. meningitides, while N. meningitidis growth decreased 
(Pericone et al., 2000), suggesting a positive relation between these two 
pathogens in favour of S. pneumoniae (Bogaert et al., 2004). 
 
Pneumococcal carrier status is defined by the colonisation of the 
nasopharynx with pneumococci. These may occasionally invade the 
bloodstream or surrounding tissues in colonized individuals (Simell et al., 
2012). Thus, disease onset is preceded by pneumococcal carriage, though 
only a small proportion of carriers will go on to develop invasive disease 
(Simell et al., 2012). However, reports imply that exposure results in an 
immunizing effect (Musher et al., 1997, Melegaro et al., 2006, Lipsitch et al., 
2005), particularly with Th17-cells being shown to play a crucial role in 
clearing the nasopharynx of pneumococci in mouse models (Lu et al., 2008, 
Zhang et al., 2009, Trzcinski et al., 2008, Wang et al., 2014).  
 
Transmission of pneumococci mostly occurs from children to adults with 
longer periods of carriage being associated with pneumococcal  serotypes  
of  lower  immunogenicity  (Mehr and Wood, 2012) . Generally, a good 
immune response localized in the mucosa can clear initial pathogens 
(Harabuchi et al., 1994) with salivary IgA antibodies being locally produced 
to target pneumococcal capsular polysaccharides (Simell et al., 2002). 
Repeated exposure to the pneumococci should result in cumulative 
immunity over time. There is evidence for the development of serotype-
independent antibody responses in children due to previous nasopharyngeal 
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carriage of pneumococci, which may likely confer cumulative immunity on 
these individuals into adulthood. Further, new colonisation in the children is 
reduced thereafter (Granat et al., 2009). 
 
Concerns that have been raised regarding pneumococcal disease and 
treatment are vaccine coverage, treatment strategy (Bogaert et al., 2004) 
and multi-drug resistance (Whitney et al., 2000). The first concern 
highlights the limitations of current vaccine coverage which poses the future 
risk of non-vaccine serotypes causing disease. The second is related to 
the hypothesis that minimizing invasion whilst  leaving nasopharyngeal 
colonies unharmed may be a better approach than eliminating these 
colonies altogether. This poses the risk of future colonisation by more 
virulent strains (Bogaert et al., 2004). These concerns are further 
confounded by the genetic capabilities of the bacteria themselves. S. 
pneumoniae has been shown to have extremely high rates of recombination 
in a single infection due to horizontal gene transfer (HGT) (Hiller et al., 
2010). These high levels of homologous recombination in pneumococcal 
populations will likely result in the generation of vaccine escape strains, 
increasing the problem at hand (Donkor et al., 2011). Thus the need to 
understand mechanisms of susceptibility and infection   for   the   
improvement   of   treatment   strategies   cannot   be   over- emphasized. 
This is especially due to the current global burden of pneumococcal 
disease. 
 
1.1.2  Burden of pneumococcal disease 
 
As of 2013, the World Health Organisation (WHO) listed pneumonia as the 
worldwide leading cause of mortality in children, killing 1.1 million  children 
below 5  years of  age  annually ( W H O ,  2 0 1 3 b ) .  Bacterial 
meningitis also heavily affects children, and entire populations. A factor 
confounding prognosis is that clinical symptoms alone cannot distinguish 
whether meningitis cases are caused by pneumococcal or meningococcal 
CHAPTER ONE 
27 
 
infections (WHO, 2013a). The former and latter being caused by 
Streptococcus pneumoniae and Neisseria meningitidis, respectively. 
 
Older age and underlying disease have been linked to higher mortality rates 
due to invasive pneumococcal pneumonia. Pneumococcal disease is 
described as invasive when S. pneumoniae  is isolated  from  sites that 
should  ordinarily be sterile, such as pleural fluid, cerebrospinal fluid, or 
blood (Feikin et al., 2000) as well as the joints and bone tissue. Invasive 
Pneumococcal Disease (IPD) includes bacteraemia, septicaemia, 
pneumonia (which can also be non-invasive), meningitis, septic arthritis and 
osteomyelitis (NHS, 2012). The C e n t e r s  f o r  D i s e a s e  C o n t r o l  
a n d  P r e v e n t i o n  ( CDC) estimates that  in the post-PCV era, 62% of 
IPDs worldwide are caused by only 10 pneumococcal serotypes (CDC, 
2012) . Non-invasive pneumococcal infections are those  occurring  outside  
major  organs,  such  as  bronchitis,  otitis  media  and sinusitis (NHS, 
2012).  
 
It has been estimated that S. pneumoniae is responsible for 11% of deaths 
in children below the age of 5, with a high proportion of these deaths 
occurring in Africa and Asia (O'Brien et al., 2009).   It is thus obvious that 
the burden of pneumococcal disease while widespread, is especially 
pronounced in developing countries (Scott, 2007). This may be due to the 
inclusion of the 7-valent  Protein-Conjugated  Pneumococcal  Vaccine 
(PCV7) on the vaccine scheme for children in developed countries, which is 
not the case in many developing countries ( O ' B r i e n  e t  a l . ,  2 0 0 9 ,  
M e h r  a n d  W o o d ,  2 0 1 2 ) . However it is more likely due to the higher 
rates of pneumococcal carriage on the African continent, with the five most 
common serotypes in Sub-Saharan Africa being amongst the seven 
serotypes causing IPD in children on a global scale (Usuf et al., 2014). 
 
In 2002 in England and Wales, there were close to 5800 pneumococcal 
hospitalisation cases (Me le ga ro  e t  a l . ,  2006 ) . Statistics taken over 
the period of a decade (1996-2006) in England and Wales also revealed 
that cases of IPD for all age groups peaked seasonally over winter months. 
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This study also investigated the trends in IPD pre- and post- conjugate 
vaccine introduction. A significant observation was that not only incidence, 
but also serotype distribution changed over time, with highest burden of 
disease affecting the two extremes of age: children below one year, and the 
elderly. A decrease in disease due to serotype 14, and increase due to 
serotype 1 was also observed (Trot te r  e t  a l . ,  2010) .  
 
The incidence of IPD in the UK over the period of 15 years is shown in fig. 
1.1. 
 
Figure 2.1: Trend line showing the incidence per 100 000 people, of IPD 
over a 15 year period for all age groups in the UK, highlighting the 
introduction of PCV into the UK vaccine scheme.    
                                                                                                                                                                                                                    
This trend line was constructed based on statistics obtained from Trotter 
et al. (2010) and the European Centre for Disease Prevention and Control 
(ECDC) annual epidemiological reports on communicable diseases (ECDC, 
2007, ECDC, 2010, ECDC, 2013). The trendline shows a decrease in IPD 
incidence after the introduction of PCV into childhood vaccination schemes, 
boosting herd immunity (Millar et al., 2008).  
An aspect in pneumococcal research which requires further investigation is 
why certain groups, particularly those with underlying disease, are at an 
increased risk of succumbing to pneumococcal infection. 
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1.1.3 Groups at risk of pneumococcal infection 
1.1.3.1  Risk factors and genetics 
 
About 50% of healthy people live with pneumococci colonies in their throats 
(Lund, 1960). While many individuals carry these colonies, they do not 
develop disease. This leads to the question, what risk factors cause disease 
onset? It is apparent that some individuals seem to be more susceptible to 
pneumococcal infections, and later disease, compared to others.  Risk 
factors associated  with increased  pneumococcal  infections  includes  
genetics,  socio-economic status (Greenwood, 1999),  HIV infection, 
especially with low  CD4  counts,  previous  occurrence  of  pneumonia, 
cirrhosis, co-infection with hepatitis C, smoking, Injecting Drug Use (IDU), 
Pulmonary Tuberculosis (TB) and Chronic Obstructive Pulmonary Disease 
(COPD) (Pedersen et al., 2011). 
 
In terms of genetics, polymorphisms in the human C reactive protein (which 
binds the C polysaccharide on the S. pneumoniae cell wall) have been 
associated with IPD in White individuals (Roy et al., 2002). Surfactant 
protein D (SFTPD) variants have also   been   associated   with   IPD  
(Lingappa et al., 2011)  with   genetic polymorphisms also playing a role in 
meningococcal disease outcome (Brouwer and van de Beek, 2009). 
However, a meta-analysis integrating several genetic studies conducted 
across the world concluded that pneumococcal and meningococcal disease 
susceptibility has not been satisfactorily linked with any polymorphisms, 
beyond any reasonable doubt, mostly due to methodological flaws and 
small sample sizes (Brouwer et al., 2009). 
 
In the US, pneumococcal infections from 1995-1998 were found to be 
highest in children below the age of 2, elderly people 65 years of age or 
older, and Black people (who had 2.6 times higher incidence rates than 
among White people)(Robinson et al., 2001). There is also a high mortality 
rate of the elderly due to pneumonia in England (Trotter et al., 2008). It is 
apparent that globally age is also a predisposing factor to severe 
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pneumococcal infection. However, of particular interest to us was the 
burden of pneumococcal disease in immunocompromised individuals. 
 
1.1.3.2  Immunocompromised individuals 
 
With regards to underlying disease, HIV increases risk of pneumococcal 
infection with pneumococcal-specific immune dysregulation shown in 
asymptomatic HIV-infected individuals ( G l e n n i e  e t  a l . ,  2 0 1 1 ) . 
Pneumococcal bacteraemia isolation rates were also higher in HIV-infected 
individuals in a population-based study in Kenya (Feikin et al., 2010). 
Therefore it is known that HIV-infection places affected individuals at an 
increased risk of succumbing to pneumococcal disease.  
 
Immunity is also impaired in cancer patients. It has recently been shown that 
patients with advanced solid cancers have lower absolute numbers of B-
cells, T-cells and some T-cell subsets, as well as natural killer (NK) cells, 
relative to healthy controls (Noguchi et al., 2014). Patients with 
haematological malignancies (across a spectrum from Monoclonal 
Gammopathy of Undetermined Significance; MGUS, to asymptomatic and 
symptomatic myeloma- discussed in chapter six) are also susceptible to 
community- and hospital-acquired S. pneumoniae infections when they go 
into hospital for treatments (Kumashi et al., 2005). Further, individuals with 
sickle cell disease (SCD), especially children below the age of 3, are at an 
increased risk of bacterial meningitis (mostly caused by S. pneumoniae) 
(Overturf, 2003, Barrettc.E, 1971). Since the introduction of the routine 
pneumococcal conjugate vaccine (PCV) however, rates of IPD have been 
shown to decrease in children with SCD who are less than 5 years old in 
Tennessee, USA (Halasa et al., 2007). This increases hope for better 
prognosis as IPD vaccine therapies keep improving. 
 
After  the  licensing  of    PCV  in  the  UK  in  2001,  a  study  carried  out  
using Systems Biology modeling suggested that the 2004 vaccine prices 
would not be economically justified in the long run (Melegaro and 
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Edmunds, 2004). This sheds light on the financial aspect of disease 
treatment, further emphasizing the need not only to improve vaccine 
efficacy, but also cost. 
 
 
1.2  Current pneumococcal vaccinations 
1.2.1  Mechanism of function of pneumococcal  vaccines 
 
As of 2013, the pneumococcal vaccination scheme includes two vaccines: 
the Pneumococcal Polysaccharide Vaccine (PPV) and the Pneumococcal 
Conjugate Vaccine (PCV). The vaccines function by different biochemical 
mechanisms. The purified S. pneumoniae capsules contained in PPV, being 
a thymus-independent type 2 (TI-type 2) antigen, cross-links several B cell 
receptors (BCRs). This induces B-cell activation and proliferation thereafter, 
and the production of IgM by short-lived plasma cells. This response to 
invading bacteria is rapid. Due to the low immunogenicity of PPV in 
children, purified  capsular  polysaccharides  were  conjugated  to  
diphtheria proteins (CRM197 mutant), thereby increasing the immunogenicity 
of the PCV vaccine as a whole and  rendering  memory ( G o l d b l a t t ,  
2 0 0 0 ) . 
 
Not only does PCV elicit IgM production, but the diphtheria proteins which 
are T-cell-dependent antigens elicit T-cell help. These T-helper cells 
produce cytokines which induce the production of IgG by long-lived plasma 
cells (immunoglobulin switching). T-cell help induces the production of 
antibodies that are more functionally versatile, and have a higher 
affinity for the antigen (Murphy, 2012). Thus, this T-cell help in PCV elicits 
an immune response in children. The mechanism of function of PPV and 
PCV are depicted in fig. 1.2. 
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Figure 1.2: Cellular mechanisms by which PPV23 and PCV7/13 function. 
The T-independent purified capsule crosslinks B-cell receptors, eliciting 
proliferation of B-cells, and production of IgM (A). The T-dependent 
diphtheria proteins in the conjugate vaccine elicit T-cell help, resulting in a 
more specific reaction due to the production of IgG (B). This occurs in 
addition to IgM produced as a result of capsular polysaccharide stimulation 
of B cells. 
 
1.2.2  Vaccine composition and efficacy 
 
The Joint Committee on Vaccination and Immunisation (JCVI) has several 
recommendations pertaining to dosage administration for these vaccinations 
dependent upon an individual’s state of health, and age (JCVI, 2011, JCVI, 
2013, PHE, 2013).  
 
PPV was first licensed in the USA in 1977. The 23-valent PPV (PPV23) 
contains purified polysaccharide capsule from each serotype covered, and 
no adjuvant. Serotypes covered by this vaccine, which cause 85-90% of 
IPD in adults, are 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. PPV23 is administered to 
adults 65 years of age and older and high-risk individuals younger than this 
(IAC, 2013). PPV23 should follow intramuscular administration rather than 
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inhalation, as inhaled vaccine does not elicit a significant antibody response 
(Gordon  e t  a l . ,  2008 ) .   PPV23 has been found to be effective and 
economical in a low risk elderly cohort in England and Wales, though 
protection was found to wane after 5 years (Andrews et al., 2012). A 
booster is thus required five years after the initial vaccination ( I A C ,  
2 0 1 3 ) as the antigens do not induce memory in the immune system (WHO, 
2008). 
 
The foundation for the modern conjugate vaccine was set in 1929, when 
Avery and Goebel showed that a purified polysaccharide from S. 
pneumoniae (on its own with low immunogenicity) conjugated to a protein 
carrier, had an enhanced immunogenicity (Avery and Goebel, 1929, 
Goldblatt, 2000). Nearly 60 years later in 1987, Haemophilus influenzae 
type b (Hib) conjugate vaccine would be the first glycoconjugate vaccine 
licensed for use in humans in the USA ( G o l d b l a t t ,  2 0 0 0 ) . After 
introduction of this vaccine routinely, a sharp decline in Hib invasive disease 
was observed in children in different parts of the world ( P e l t o l a  e t  
a l . ,  1 9 9 2 ,  B o o y  e t  a l . ,  1 9 9 4 ,  S a n t o s h a m  e t  a l . ,  1 9 9 1 ) .  
Thus, interest in the potential of reducing IPD incidence in children by the 
use of conjugate vaccines peaked. 
 
PCV7 (containing serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) was the 
vaccine recommended for children 24-59 months of age (IAC, 2013) in the 
early 2000s. The routine use of this vaccine in children across Europe led to 
a decline in disease caused by vaccine serotypes. In the United States also, 
the vaccine was found to be effective against IPD in both healthy and 
chronically ill children (Whitney et al., 2006). However, the occurrence of 
serotypes 1, 3, 6A, 7F and 19A in isolates since the introduction of the 
vaccine stressed the importance for these serotypes to be included in future 
vaccines (Isaacman et al., 2010). 
 
In 2010 Pfizer Inc. licensed a new Wyeth Pharmaceuticals-manufactured 
vaccine. Prevnar 13® pneumococcal 13-valent conjugate vaccine 
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(Diphtheria CRM197 protein) (PCV13) covers serotypes 1, 3, 5, 6A, 7F, and 
19A in addition to PCV7 serotypes and can also be administered to children 
60-71 months who suffer from comorbidities. PCV13 is usually administered 
as a single dose, followed by a booster a few months later (IAC, 2013). 
Pfizer conducted clinical trials on a cohort of 7000 children, producing data 
supporting IPD prevention in young children who had received PCV13 
(Pfizer, 2013a). A Prevnar 13® vaccine for use for adults 50 years of age 
and older has also been manufactured, and is delivered as a single dose 
(Pfizer, 2013b). 
 
The elicitation of immunoglobulin G (IgG) anti-capsular antibody ≥ 0.35 µg/ml 
by PCV13 in a study cohort comprising infants (Bryant et al., 2010) 
showed compliance with recommendations made by the WHO in 2003, 
describing this antibody concentration as the IgG reference value conferring 
protection against IPD (Paradiso, 2009). Recent studies have also shown 
that PCV13 could potentially protect against serotypes 6C and 7A which are 
not covered by the vaccine, but closely related to vaccine-covered serotypes 
(Cooper et al., 2011). Thus the PCV vaccine scheme for children is highly 
advantageous for their own protection against IPD, and also the indirect 
protection of older children and adults by herd immunity (Whitney et al., 
2003, Pilishvili et al., 2010). 
 
In terms of nasopharyngeal carriage of pneumococci after vaccination, PCV7 
has been shown to have a dose-dependent effect on vaccine-specific 
serotype carriage in a cohort of Fijian children. There was an inverse 
relationship between dose of PCV7 and vaccine type carriage. Additionally, 
despite eliciting an antibody response, boosting with PPV23 did not impact 
pneumococcal nasopharyngeal carriage ( R u s s e l l  e t  a l . ,  2 0 1 0 ) . 
 
Though use of the PCV7 vaccine in England and Wales led to a decrease in 
IPD in spite of serotype replacement, the biggest concern regarding the 
continued use of these vaccines covering limited serotypes still remains the 
potential surge in non-vaccine type (NVT) IPD (Miller et al., 2011). Table 1 
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summarises information regarding the vaccines currently used to prevent 
pneumococcal disease. 
Table 1: Target groups of the current pneumococcal vaccines 
recommended by the Joint Committee on Vaccination and 
Immunisation*  
 
Pneumococcal 
Vaccine 
Streptococcus 
pneumoniae 
strains covered 
Target group Recommended dose 
Pneumococcal 
Polysaccharide 
Vaccine (PPV23) 
1, 2, 3, 4, 5, 6B, 
7F, 8, 9N, 9V, 10A, 
11A, 12F, 14, 15B, 
17F, 18C, 19A, 
19F, 20, 22F, 23F 
and 33F 
1.Individuals ≥ 65 years 
of age. 
 
 
2.Individuals with long-
term health conditions 
who are at higher risk of 
developing 
pneumococcal disease. 
3.Children > 2 years of 
age who have higher risk 
of developing 
pneumococcal disease. 
1.One injection 
administered (which may be 
followed by a booster > 3 
years later). 
2.More than one dose: 
second dose administered > 
3 years after first. 
Pneumococcal 
Conjugate 
Vaccine (PCV13) 
1, 3, 4, 5, 6A, 6B, 
7F, 9V, 14, 18C, 
19A,19F, and 23F 
1.Children < 2 years of 
age. 
 
 
 
 
 
 
 
 
 
2.Children ≥ 2 to 17 
years of age. 
3.Adults ≥ 18 years of 
age. 
1.Three injections to be 
given: first at six weeks; 
subsequent two injections to 
be given at least one month 
apart. Booster to be given 
from 11 to 15 months of 
age. Infants from 7 to 11, 
and 12 to 23 months receive 
two injections which are 
spaced by one and two 
months respectively. 
2.One injection 
administered. 
3.One injection 
administered. 
 
*Information gathered from (PHE, 2013, JCVI, 2011, JCVI, 2013, 
NHS, 2016a, NHS, 2016b, Pfizer, 2017, Pfizer, 2018) 
 
In spite of the impact pneumococcal vaccines have had on disease, there 
still remain reported cases of vaccine failure. 
 
1.2.3  Pneumococcal vaccine responses in HIV/other risk groups 
 
Although Highly Active Anti-Retroviral Therapy (HAART) has decreased 
pneumonia in  HIV-infected  children,  IPD  still  poses  a  significant  health  
risk  to  the  HIV-infected (Micheloud et al., 2012). The administration of 
PCV7 to HIV-infected Ugandan adults yielded significantly increased IgG 
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levels in the study cohort (Miiro et al., 2005). Further, PCV7 was found to 
be protective against serotype 6A in HIV-infected adolescents and adults 
who had previously had IPD (F rench  e t  a l . ,  2010 ) . 
 
As the efficacy of PPV23 to prevent IPD in HIV-infected adults is still 
suboptimal, PCV is now the preferred vaccine for administration to HIV-
infected individuals. However, vaccine failures in PPV23 and PCV7 have still 
been reported. A PPV23 vaccine failure was reported in a 22 year old female 
due to serotype 9 (Willocks et al., 1995), a 44 year old male due to serotype 
3 (Begemann and Policar, 2001) and a 13 year old boy (who had also 
received PCV7) due to serotype 18 C (Rives Ferreiro et al., 2008). These 
vaccine failures emphasize the need for vaccine optimisation in this high risk 
group. 
 
In 2001, Kroon and colleagues found that PCV elicits an impaired 
antibody response in HIV-infected adults compared to controls. Further, both 
the HIV- infected cohort and normal healthy subjects were found to produce 
higher antibody concentrations after receiving sequential PCV and PPV, as 
opposed to PPV alone (Kroon et al., 2000). Another study found that 
pneumococcal vaccine protected against IPD in White, but not Black HIV-
infected individuals (Breiman et al., 2000). Still, a more recent study did not 
find significant differences in antibody responses to both vaccines, between 
White and Black HIV-infected Americans who had equal health-care access 
(Crum-Cianflone et al., 2010). While in South Africa, PCV9 reduced IPD 
incidence in healthy and HIV-infected children.  However, the efficacy of  the  
vaccine  to  reduce  IPD first-episode incidence was higher in the healthy 
compared with  the HIV- infected children (Klugman et al., 2003). Though 
improvements have been made to both vaccines over the years since this 
study was published, it still stands to reason that HIV-infected individuals will 
still show an impaired response to the current vaccines due to their lowered 
immunity. 
 
Effective pneumococcal vaccine schedules for HIV-infected individuals are 
thus, still highly debated. The Immunisation Action Coalition (IAC) advises 
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that HIV- infected individuals should be given PCV13, followed by PPV23 
eight  weeks later. Though the vaccine may not elicit an adequate 
antibody response in this high risk group, administration is still 
recommended nonetheless (IAC, 2013). 
 
Taken together, these studies emphasize the need for constant improvement 
of pneumococcal vaccines, or the discovery of potential adjuvants which 
may facilitate antibody responses in high risk groups. Further, the reports of 
vaccine failures in high risk groups, and susceptibility to IPD due to impaired 
B-cell functioning in certain individuals emphasizes two points: first, more 
studies need to be undertaken in order to investigate how vaccines can be 
improved for the high risk groups. A nd second, to an extent B- cell 
defects in response to T-independent pneumococcal antigen mimics may 
be indicative of an increased susceptibility to IPD. 
 
1.3  Immunity 
1.3.1  Immune responses to S. pneumoniae infection 
 
As reviewed by Koppe et al. (2012), upon infection by S. pneumoniae, the 
human host employs both innate and adaptive immune responses to 
combat  infection. In terms of innate immunity, infecting S. pneumoniae is 
recognized by pattern recognition receptors (PRRs) including toll-like   
receptors (TLRs) and   nucleotide-binding oligomerisation domain receptors 
(NOD-like receptors or NLRs) on phagocytic cells: in particular, TLR 2 and 
4 and NOD2. These receptors induce the production of inflammatory 
mediators such as interleukins (IL-1β, IL6), tumour necrosis factor alpha 
(TNFα) and keratinocyte-derived chemokine (KC) (all NF-kB-dependent) 
while an as yet unidentified receptor induces the production of type I 
interferons (IFNs). Neutrophils and macrophages are also recruited for 
phagocytosis (Koppe et al., 2012). Lysozyme and β- defensin-2 (an anti-
microbial peptide) have also been shown to act against S. pneumoniae  in 
a synergistic manner  (Lee et al., 2004). The innate immune defense 
against S. pneumoniae also involves the C3 component of the complement 
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system. It plays a protective role in the first hours of infection in the lungs, 
and is thus required systemically (Kerr et al., 2005). 
 
Of particular interest to IPD prognosis and therapy is the adaptive immune 
response launched against the invading pathogen.  This is because these 
immune responses are mimicked by the current vaccines used for disease 
prevention. Generally the adaptive immune system launches its attack 
making use of highly specialized T-  and B-cell responses. The ultimate aim 
of this specific response is not only to clear the system of the invader, 
but also to induce immune  memory which  will  be  highly  protective  
should  future  infection  take place. 
 
1.3.2  T- and B-cell responses in adaptive immunity 
 
T- and B-cells originate from the common lymphoid progenitor in the bone 
marrow. They differentiate in the bone marrow and thymus respectively. A 
key feature of both these cells that set them apart from other blood cells is 
the expression of their respective antigen receptors, namely the T-cell 
receptor (TCR) and B-cell receptor (BCR). When a B-cell encounters an 
antigen (such as the S. pneumoniae polysaccharide capsule), it 
differentiates into a plasma cell, secreting antibodies for the clearance of 
that specific antigen (Murphy, 2012). 
 
B- cells constitutively express major histocompatibility complex class II 
(MHC class II) cell surface glycoproteins, which present exogenous 
antigens which have been proteolytically processed within the cell. The B-
cell is an Antigen Presenting Cell (APC) to T-helper (TH) cells. The β2 
domain on the MHC II molecule interacts with the phenotypic marker on TH 
cells, CD4, enhancing interaction between the B- and T-cells. The MHC II 
molecule binds to the TCR, which itself comprises a CD3 complex 
consisting of transmembrane accessory chains. After binding the MHCII 
molecule, the TCR accessory chains on the T- cell transduce signals. T- 
and B-cells are fully activated when co-stimulatory molecules such as 
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CD28 on the T- cell a n d  CD86 on the B- cell participate in cognate 
interactions (see review by (Chaplin, 2010) and figure 1.3). 
 
The CD40 molecule expressed on B-cell surfaces binds to the CD40 ligand 
on T-cells, encouraging growth and differentiation of the T-cells, and 
proliferation of B-cells and antibody class switching. This binding elicits an 
increased production of co-stimulatory molecules by B-cells (such as those 
in the B7 family), and is key to the response of B-cells to thymus-dependent 
(T-cell dependent, TD) antigens. Follicular helper T-cells (Tfh) secrete 
cytokines to regulate antibody production by B-cells, and proliferation 
(Murphy, 2012). Further, Th17-cells play a crucial role in clearing the 
nasopharynx of pneumococci in mouse models (Lu et al., 2008, Zhang et 
al., 2009, Trzcinski et al., 2008, Wang et al., 2014). The development of T- 
and B-cells, and interaction between them thereafter is depicted in fig. 1. 3.                                       
 
 
Figure 1.3:  T- and B-cell development and interactions thereafter.  The 
lymphoid stem cell progenitor for T- and B-cells originates in the bone 
marrow. The helper and cytotoxic T-cells are characterized by the 
expression of surface CD4 and CD8 respectively. The B-cell lineage goes 
through several stages characterized by the expression of certain cell 
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surface markers (cluster of differentiation (CD) and major histocompatibility 
complex (MHC) markers) as indicated in the diagram.  Short-lived plasma 
cells produce IgM, while long-lived plasma cells produce IgA, IgD, IgE and 
IgG. Noteworthy interactions between mature T- and B-cells, which induce 
the production of antibodies by long-lived plasma cells include the 
presentation of antigen by the MHC class II molecule on the B-cell to the 
TCR on the Tfh-cell (A), the binding of CD40 on the B-cell to the CD40 
ligand (CD40L) on the Tfh-cell (B) and the binding of co-stimulatory B7 on 
the B-cell to CD28 on the T-cell (C) which enhances the signal between 
MHCII and the TCR (Murphy, 2012). 
 
1.4  Rationale for study 
 
Taking the complex interplay between T-  and B-cells in response to 
infecting S. pneumoniae into consideration, it becomes clear that an 
adequate immune response is dependent upon proper cell functioning. 
Defective B-cell responses relative to control subjects have been reported by 
our group in a cohort of individuals (with no pneumococcal vaccine history) 
who had previously suffered from IPD  (Darton et al., 2011). Our group 
also uncovered a similar B- cell defect in previous sufferers of serogroup C 
meningococcal disease (Foster et al., 2009), and T- cell defect in 
meningococcal serogroup C vaccine (MCC) failures (Foster et al., 2010).  
 
The Darton (2011) and Foster (2009; 2010) studies employed polyclonal 
stimulation of T- and B- cells using a validated immunologic assay. Of 
particular interest to the present study was the Darton study, in which all 
previous sufferers of IPD had no known susceptibility to the disease. Relative 
to controls the patient group showed significantly lower B-cell activation in 
response to the B-cell polyclonal mimic (which was not overcome with T cell 
help) (Darton et al., 2011). Results from the Darton and Foster studies 
indicate respectively that predisposition to pneumococcal and meningococcal 
disease may, to a certain extent, be observed at a cellular level. The present 
CHAPTER ONE 
41 
 
study aimed to use the same immunologic assay to investigate potential 
defects in T- and/or B-cells in two patient groups as outlined below. 
 
1.5  Hypothesis and aims of the research 
 
Research question: Do HIV-infected patients and haematological 
malignancy patients have a defect in B- (and T-) cell activation and 
proliferation (relative to normal healthy controls) that could predispose them 
to pneumococcal infection? 
 
The study aimed to: 
 
1. Investigate the stringency required for matching controls to patients 
in terms of age, sex and ethnicity. 
 
2. Compare the effectiveness of the in vitro T- and B-cell response in 
adults with immunosuppressive conditions : HIV and Monoclonal 
Gammopathy of Undetermined Significance (MGUS), with age-, 
sex- and ethnicity-matched controls, using a polyclonal TI-2 antigen 
(αδdex) and polyclonal TD antigen (anti-CD3) as stimulants. 
 
Specific objectives of the study were therefore to: 
 
1. Optimise a flow cytometry panel comprising phenotypic, proliferation 
and activation markers for T- and B-cells. 
 
2. Recruit a study group of sex- and ethnically diverse individuals to 
study the effects of age, sex and ethnicity on T- and B-cell responses. 
 
 
3. Expand the immunologic assay (Darton et al. 2011; Foster et al. 2009; 
Foster et al. 2010) to include pneumococcal-stimulation by using the 
D39-strain of Streptococcus pneumonia and thereafter to compare 
apoptosis levels in B-cells of patients and controls. 
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4. Recruit a cohort of HIV-infected adults (with matched controls) to study 
their in vitro T- and B-cell responses to polyclonal and pneumococcal 
stimulation. And lastly,  
 
 
5. Recruit a cohort of patients with Monoclonal Gammopathy of 
Undetermined Significance (MGUS) (with matched controls) to study 
their in vitro T- and B-cell responses to polyclonal and pneumococcal 
stimulation. 
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2.1 Subject recruitment  
 
2.1.1 HIV-infected patients 
 
HIV-infected patients were recruited from cohorts followed up in outpatient 
HIV clinics based at the Department of Infection and Tropical Medicine and 
Department of Genitourinary Medicine at the Sheffield Teaching Hospitals 
(STH) NHS Foundation Trust. Inclusion criteria for the study was as follows: 
HIV-1-infected adults ( 18 years), on antiretroviral therapy (ART), with 
undetectable blood HIV-1 viral load and CD4 count ≥ 350 cells/mm3 within 
the last six months. Patients were approached by their clinical team to gauge 
interest in the study during routine outpatient clinic visits, prior to informed 
consent being obtained by a study team member. All subjects provided 
written informed consent prior to blood donation and participation in the 
study. 
 
2.1.2 Patients with Monoclonal Gammopathy of Undetermined 
Significance (MGUS) 
 
Patients with Monoclonal Gammopathy of Undetermined Significance 
(MGUS) were recruited from cohorts under outpatient follow up within the 
Department of Haematology, STH. Patients were approached by their clinical 
team to gauge interest in the study during routine outpatient clinic visits, prior 
to informed consent being obtained by a study team member. All subjects 
provided written informed consent prior to blood donation and participation in 
the study. 
 
 
2.1.3 Healthy controls 
 
Healthy controls were recruited from STH and the University of Sheffield 
employees. Blood samples from age-, sex- and ethnicity-matched controls 
were obtained and run in parallel with all cases (HIV-infected and MGUS 
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patients). Age matching was undertaken so controls were within a 10 year 
range (I.e. +/- 5 years) of the case. All subjects provided written informed 
consent prior to blood donation and participation in the study.  
 
Ethical approval for this project was granted by the UK National Research 
Ethics Service Committee (14/YH/1118). The sequence of steps from patient 
recruitment to quantification of T- and B-cell responses is summarised in 
figure 2.1. 
 
 
Figure 2.1: Flow diagram illustrating the sequential steps used in the 
methodology of this project. 
Following the recruitment of informed and consenting patients and controls, 
blood was collected. Lymphocytes were enriched from these whole blood 
samples, and a validated immunologic assay optimised by our group (Foster 
et al., 2009) was performed to study in vitro T- and B-cell responses. These 
steps are detailed below. 
 
2.2 Collection of blood samples 
 
Peripheral blood samples were drawn by venepuncture in the Department of 
Infectious Diseases, Royal Hallamshire Hospital (RHH) and the Department 
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of Haematology, RHH. On average, 40 ml of blood was taken into a tube 
containing 80 μl heparin [Heparin (mucous) injection B.P. 5000 u/ml heparin 
sodium, Leo Labs, Ballerup]. 
 
 
2.3 Lymphocyte enrichment from whole blood 
 
Work on blood samples was conducted in a Class II Microflow Biological 
safety cabinet, using aseptic technique (in a Containment Level 3 laboratory 
when processing HIV-infected samples). The blood was diluted with an equal 
volume of a 1 x working solution of phosphate buffered saline (PBS) 
(Dulbecco A; Oxoid Limited, Basingstoke Hampshire) at room temperature. 
Two parts of blood were carefully layered onto one part of lymphocyte 
separation medium (Density 1.077 g/ml, BioWhittaker® Lonza, Walkersville) 
at a slanted angle, ensuring the blood mixture did not break the density 
gradient. Formation of layers was achieved through centrifugation (settings: 
time; 35 min, RCF; 400 xg, temperature; 20oC, acceleration and 
deceleration; 0). 
 
The interface between the top plasma layer and the bottom lymphocyte 
separation media contained the buffy coat layer (comprising the peripheral 
blood mononuclear cells-PBMCs). This layer was carefully removed using a 
plastic Pasteur pipette. Plasma was also taken out from the tubes and stored 
in sterile tubes on ice for later use.  
 
The extracted PBMCs were washed with 20 ml sterile chilled PBS four times 
(centrifugation settings: 10 min, RCF; 600 x g, temperature; 4oC, 
acceleration and deceleration; 9). After the last wash, the cells were re-
suspended in 1 ml cell culture media, which was made by adding 1 part of 
autologous plasma to 4 parts of RPMI 1640 [BioWhittaker®, Lonza, Verviers- 
supplemented with 200 μM L-glutamine (Lonza, Walkersville)].  
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Live PBMCs were counted using a 0.1 % Trypan blue solution (Sigma®, 
Sigma-Aldrich, St. Louis) and an improved Neubauer haemocytometer 
(Boeco, Hamburg) and made up to a final concentration of 1 x 107 cells/ml. 
For later use during the flow cytometry step, 2 x 106 unstained PBMCs were 
saved, while the rest were stained with the cell tracer dye- 
carboxyfluorescein diacetate succinimidyl ester (CFSE).  
 
 
2.4 Cell proliferation assay 
 
The well-established protocol using the CFSE reagent was used to track T- 
and B-cell proliferation, in vitro. This permeable dye diffuses into the cell 
cytoplasm, and the succinimidyl moiety forms a highly stable amide bond 
with intracellular amines. As cells divide, the dye splits equally between 
progeny (Lyons and Parish, 1994). It is used to track cell divisions in flow 
cytometry protocols by measuring the halving of fluorescent intensity after 
each subsequent division. CFSE is long-lived and can be tracked for up to 
eight T-cell divisions (Parish, 1999). 
 
According to the manufacturers’ instructions, a 10 mM CFSE (Vybrant® 
CFDA SE cell tracer kit, Invitrogen™, Molecular probes™, Oregon) stock 
solution was made by reconstituting the lyophilised CFSE reagent in 90 μl of 
sterile DMSO. Aliquots of CFSE were stored at -20oC. On the day when 
needed, 0.1 mM of CFSE was prepared from the frozen aliquots, using 
sterile PBS.  
 
After PBMCs were enriched and re-suspended in media (section 2.3), 20 μl 
of CFSE was added per 1 x 107 cells, giving a final concentration of 2 μM 
CFSE-dyed PBMCs. The PBMCs were immediately incubated at 37oC (5 % 
CO2) for 10 min (in the dark). The CFSE reaction was then quenched by the 
addition of equal volumes of cold autologous serum. The PBMCs were 
incubated at room temperature, in the dark, for another 10 min. After 
centrifugation (settings: time; 15 min, RCF; 600 xg, temperature; 4 oC), the 
PBMCs were washed three more times with prepared media (section 2.3). 
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After decantation of the supernatant, the PBMC pellet was re-suspended in 1 
ml media, and counted using 0.1% trypan blue solution as previously 
described (section 2.3).  
 
PBMCs were seeded at 1 x 106 cells per well, in a flat-bottomed tissue 
culture-treated, sterile 48-well plate (Costar, UK) in a final volume of 500 μl. 
The PBMCs were incubated at 37oC (5 % CO2) until the commencement of 
the flow cytometry protocol. 
 
Proliferation was detected using the 530/30 filter of the Blue 488 nm laser 
during the flow cytometry protocol (section 2.7.3). For the analysis of cell 
proliferation, the cell proliferation package on FlowJo version 7.6® was used: 
Each subsequent generation formed and emitting CFSE fluorescence is 
represented as a subsequent peak to the left of the parent generation (as 
seen in the representative histograms in figure 2.2). 
 
                                           
 
Figure 2.2: Proliferation of a stimulated lymphocyte sample (B) on the 
FlowJo Proliferation platform is indicated as subsequent peaks (in 
pink) formed to the left of generation 0- the parent generation (shown in 
coral). Each peak represents a new generation of cells. Generation 0 is also 
seen in the un-stimulated sample (A). An overlay of the un-stimulated and 
stimulated sample (C) gives a clearer indication of how many generations 
were induced upon stimulation. Image generated by the FlowJo 7.6® 
proliferation platform (section 2.7.4). 
 
A B C 
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Proliferation results in this study are reported in proliferation index, which is 
the ratio of the total number of divisions to the number of cells that had 
undergone division. As such, proliferation index is always greater than 1. 
This parameter was chosen to study cell proliferation as it only takes those 
cells which have responded and divided into consideration. 
 
Proliferation was studied using the proliferation platform provided within the 
FlowJo version 7.6® package (section 2.7.4). This platform superimposes 
adjustable gates onto the proliferation peaks detected. As a result the 
proliferation index is generated together with a root mean square (RMS) 
value. The process of assigning peaks influences the values, thus making 
the platform subjective to an extent. However, the ‘best fit’ peak was chosen 
based on the lowest RMS value generated (as prescribed in the FlowJo 
version 7.6® manual), thus rendering the proliferation values reliable.                               
 
Following staining of cells to track proliferation, cells were stimulated using 
the immunologic assay that our group optimized (Foster et al., 2009). This 
assay uses CD3-stimulation of T-cells and IgD-stimulation of B-cells (using a 
polyclonal antigen mimic) alone and in combination to study T- and B-cell 
responses, and T-cell help to B-cells. 
 
2.5 T- and B-cell stimulation 
2.5.1 Stimulation of T-cells 
 
T-cell activation was achieved by using plate-bound purified anti-human anti-
CD3 antibody (Geppert and Lipsky, 1987). Anti-CD3 has been widely 
reported as a T-cell stimulant, including in previous studies by our group 
(Darton et al., 2011, Foster et al., 2009, Foster et al., 2010, Preciado-Llanes 
et al., 2015) and is a polyclonal stimulant which engages the T-cell receptor 
(TCR). In addition, our group has also previously used a purified anti-human 
anti-CD28 antibody as an agonist to mimic further co-stimulatory interactions 
between the CD28 molecule and CD80/86 on B-cells (Foster et al., 2009).  
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At least 15 hr prior to seeding of cells, a 48-well sterile cell culture plate was 
pre-coated with 0.1 μg/ml anti-CD3 (Clone OKT3; Biolegend ®, San Diego) 
alone, or 0.5 μg/ml anti-CD3 in combination with 0.5  μg/ml anti-CD28 (Clone 
10F3; Invitrogen™, Frederick). These concentrations used were enough to 
elicit sub-optimal T-cell activation and proliferation responses, thus enabling 
the detection of even minute differences between patient and control 
responses. Pre-coated plates were incubated at 4oC and the wells containing 
anti-CD3 were washed three times with sterile PBS prior to seeding. Seeded 
cells were stimulated for 96 hr. 
 
2.5.2 Stimulation of B-cells  
 
2.5.2.1 Anti-IgD-conjugated dextran (αδdex) 
 
Anti-IgD-conjugated dextran (αδdex) is a B-cell receptor (BCR) cross-linking 
thymus-independent (TI-2) antigen mimic, which induces B-cell activation 
(Pecanha et al., 1991). This had been prepared as previously described 
(Pecanha et al., 1991, Rehe et al., 1990, Brunswick et al., 1988) and kindly 
provided by Dr. Andrew Lees, Biosynexus, Gaithersburg. 
 
B-cell stimulation was achieved by direct addition of 1 μg/ml αδdex to 1 x 106 
PBMCs as has been done by our group previously, for 96 hr (Foster et al., 
2009, Darton et al., 2011, Preciado-Llanes et al., 2015). 
 
  
2.5.2.2 Streptococcus pneumoniae 
 
While our group had investigated T- and B-cell responses using the above 
described polyclonal antigen mimics, the present study sought to expand this 
immunologic assay to include pneumococcal-stimulation. The aim of this was 
to detect Streptococcus pneumoniae-specific responses in our study cohort, 
and investigate potential differences in responses between patients and 
CHAPTER TWO 
51 
 
controls. Therefore, a pneumococcal strain was included amongst the 
stimulants in the immunologic assay. 
 
The D39 virulent serotype 2 strain of S. pneumoniae has been used 
extensively for infection studies, and is widely accepted as a model strain for 
pneumococcal pathogenicity studies. While being isolated over a century 
ago, the strain’s genomic sequence was only reported by Lanie and 
colleagues in 2007 (Lanie et al., 2007).  
 
For D39 stimulation experiments, frozen bacterial stock was allowed to thaw 
then heat-killed by placing the vial into a heating block maintained at 37oC for 
one hour. The stock was then washed twice with sterile PBS (centrifuge 
settings: time; 3 min, RCF; 500 xg) and re-suspended in RPMI. PBMCs were 
infected with D39 at an MOI of 10 (optimized and presented in chapter four).  
 
Our group had previously determined that a 96 hr time point (4 days) elicited 
maximal activation and proliferation before the cells begin to die (JB Wing 
and R Foster, unpublished data). Therefore, PBMCs were seeded at 1 x 106 
in a final volume of 500 μl of media and incubated at 37oC with CO2 levels at 
5% for 96 hr in a humidified atmosphere after the stimulations were 
performed.  
 
It was also critical to track the in vitro viability of all cell samples used in this 
study to ensure reliability and robustness of the final data set. 
 
 
 
2.6 Viability assays 
 
2.6.1 Cell death 
 
Cell viability was monitored by the use of the Live/Dead® Fixable Blue Dead 
cell stain kit (Molecular Probes®, Life Technologies™, Oregon). This reagent 
is one of the amine reactive viability dyes (ViD) and penetration is possible 
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only through damaged cell membranes. The dye forms a fluorescent product 
after irreversibly binding with amine groups within the damaged cell 
cytoplasm, and with those on the extracellular surface. This product remains 
stable even after fixation of the cells. On the basis that live cells would 
exclude the dye and have a much lower fluorescence due to only their 
surface amines binding dye, discrimination of dead cells is made possible 
(Perfetto et al., 2006, Perfetto et al., 2010). 
 
The Live/Dead® Fixable Blue Dead reagent was re-constituted according to 
the manufacturers’ instructions by adding 50 μl high-grade DMSO to the vial 
of lyophilised reagent. Aliquots of the dye were stored at -20oC. On the day 
when needed, a 1:500 dilution of dye in sterile fluorescence activated cell 
sorting (FACS) buffer: PBS with 0.1 % BSA [Sterile 30 % w/v solution in 
PBS, First Link (UK) Ltd], was made. This blue fixable/FACS solution was 
used as the medium in which all fluorochromes in the flow cytometry panel 
(section 2.7.2) were incorporated. 
 
2.6.2 Apoptosis 
 
Detection of apoptosis in live cells can be achieved by the use of 
fluorochrome labeled-caspase inhibitors. These probes irreversibly bind to 
activated caspases, enabling in situ apoptosis detection, and are compatible 
with flow cytometry protocols (Amstad et al., 2001). Protocols for 
maintenance of cell viability require temperatures of 37oC, while those for the 
binding of antibody-fluorochrome to cell markers are carried out on ice. 
Therefore the probe can be used just prior to an already established flow 
cytometry protocol. 
 
The violet live cell caspase probe (BD Biosciences, New Jersey) was used 
for the detection of apoptosis according to the manufacturers’ instructions. 
This probe detects caspases-1, -2, -3, -6, -8, -9 and -10. Use of this pan-
caspase probe would circumvent the risk of including only one marker of 
either the intrinsic or extrinsic apoptosis pathways (Elmore, 2007) within the 
flow cytometry panel. 
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The lyophilised probe was re-constituted with sterile DMSO at room 
temperature, and stored at -20oC in aliquots. On the day of use at the 94 hr 
time point, the relevant wells in the 48-well plate received 1 μl of the probe, 
and were immediately incubated at 37oC for one hour with CO2 levels at 5%. 
The PBMCs were carefully aspirated and lifted, and washed once with pre-
warmed RPMI supplemented with L-glutamine (settings: time; 5 min, RCF; 
500 xg, temperature; 20oC). Immediately after the wash, the PBMCs were re-
seeded in a total volume of 500 μl with pre-warmed RPMI supplemented with 
L-glutamine. They were then incubated at 37oC for one hour with CO2 levels 
at 5%, allowing any unbound probe to diffuse out. At the 96 hr time point, 
PBMCs were harvested. Labeling of phenotypic and activation markers, and 
quantification of these using flow cytometry, was carried out thereafter. 
 
 
 
2.7 Multicolour flow cytometry 
 
2.7.1 LSRII flow cytometer 
 
For this project the BD LSRII™ flow cytometer (BD Biosciences, New 
Jersey) at the University of Sheffield Medical School Flow Cytometry Core 
Facility was used. This machine has four lasers (blue, violet, UV and red) 
and numerous filters customised for the simultaneous detection of up to 
thirteen fluorochromes.  Also, the LSRII in the core facility is maintained by 
running multicolour beads on it daily for calibration, thus minimizing inter-run 
variation (Herzenberg et al., 2006). 
 
Spectral overlap is a normal occurrence in multicolour flow cytometry, hence 
compensation was necessary to correct for this. Compensation was carried 
out prior to sample runs using the BD FACSDiva™ software (BD 
Biosciences, New Jersey) operating in conjunction with cell-based single 
stains for the violet probe, UV live/dead blue fixable control, and CFSE; and 
anti-mouse compensation beads [BD™ CompBeads: anti-mouse Ig, k/ 
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Negative control (FBS) compensation particle set, BD Biosciences, New 
Jersey] for the rest of the fluorochromes.  
 
 
2.7.2 Staining extracellular markers of phenotype and activation 
 
Expression markers determining cell phenotype and activation were labeled 
with specific antibody-fluorochrome conjugates outlined in table 2.1 (A & B- 
section 2.7.3). All these conjugates were titrated prior to use on clinical 
samples in order to determine the optimal concentrations for use. It was 
determined that 1 μl (approximately 0.025 μg) per reaction (of approximately 
1 x 106 PBMCs) was sufficient for adequate labeling, for every antibody-
fluorochrome conjugate used. 
 
Cells were lifted off the 48-well plate by careful flushing with a pipette, and 
transferred to 1.1 ml Fluorescent Activated Cell Sorting (FACS) micro tubes 
(Elkay Laboratories, UK) for labeling. FACS buffer (PBS containing 1% Fetal 
Bovine Serum) was used to wash the samples three times (settings: time; 5 
min, RCF; 500 xg, temperature; 4 oC). 
 
Immunofluorescent staining was carried out by placing 80 μl of the staining 
master mix (containing all antibody-fluorochrome stains, and cell viability dye 
-section 2.6.1) directly into the micro tube. Therefore each antibody-
fluorochrome conjugate was present in a 1 in 80 ratio (with FACS buffer) 
within the staining master mix. The samples were incubated at 4oC in the 
dark then washed three more times with FACS buffer under the same 
settings. Lastly, all samples were fixed with 300 μl of 2 % paraformaldehyde 
(Fisher Scientific, Waltham) and analysed with flow cytometry thereafter. 
 
It was ensured that the phenotypic and activation markers used were 
compatible with the lasers in the LSRII, and also compatible with all other 
antibody-fluorochrome conjugates included per flow cytometry panel used in 
this study. Therefore at the commencement of the study, the markers and 
fluorochromes to be used were carefully selected. 
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2.7.3 Fluorochrome selection 
 
Optimisation of the most appropriate antibody-fluorochrome combinations for 
detection of phenotypic and activation markers within a single assay has 
been done previously by our group (Table 2.1; A). Over the course of this 
study however, more markers were included to cover the aims of this project. 
Table 2.1: Multicolour flow cytometry panels used in this project for the 
detection of T- and B-cell phenotypic and activation markers (A), and B-
cell subsets (B); where 1 μl of each antibody was used per test in a final 
volume of 80 μl. 
(A) 
Laser 
(Excitation 
wavelength 
nm) 
Filter Molecule Antigen 
location 
* 
Fluorochrome Clone Supplier 
Blue 
488 
530/30 Intracellular 
amines 
IC CFSE N/A Invitrogen™, 
Molecular 
probes™, 
Oregon 
575/26 CD25 EC R-phycoerythrin 
(PE) 
BC96 eBioscience 
Inc., San 
Diego 
780/60 CD19 EC PECy®7 HIB19 Invitrogen™, 
Camarillo 
Violet 
405 
450/40 CD8a EC Brilliant violet 
421™ 
RPA-
T8 
BD 
Biosciences, 
New Jersey 
525/50 CD86 EC Brilliant violet 
510™ 
2331 
(FUN-
1) 
BD 
Biosciences, 
New Jersey 
UV 
355 † 
405/20 1. Free 
cytoplasmic 
amines ‡ 
and 2. CD14 
1. IC and 
2. EC 
1. Live/Dead® 
Fixable Blue Dead 
cell stain kit and 2. 
BUV395 
1. N/A 
and 2. 
MPhiP9  
1. Molecular 
Probes®, Life 
Technologies
™, Oregon 
and 2. BD 
Biosciences, 
New Jersey 
Red 
633 
660/20 CD4 EC Allophycocyanin 
(APC) 
S3.5 Invitrogen™, 
Frederick 
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(B) 
Laser 
(Excitation 
wavelength 
nm) 
Filter Molecule Antigen 
location* 
Fluorochrome Clone Supplier 
Blue 
488 
530/30 Intracellular 
amines 
IC CFSE N/A Invitrogen™, 
Molecular 
probes™, 
Oregon 
575/26 CD21 EC R-phycoerythrin 
(PE) 
LT21 ThermoFisher 
Scientific, 
Massachusetts 
610/20 CD10 EC Qdot® 605 MEM-
78 
ThermoFisher 
Scientific, 
Massachusetts 
780/60 CD19 EC PE-Cy®7 HIB19 Invitrogen™, 
Camarillo 
Violet 
405 
450/40 Caspase-1, -
2, -3, -6, -8, -
9, -10 
IC Violet live cell 
caspase probe 
N/A BD 
Biosciences, 
New Jersey 
525/50 CD86 EC Brilliant violet 
510™ 
IT2.2 Biolegend, 
San Diego 
UV 
355 † 
405/20 1. Free 
cytoplasmic  
amines ‡ 
and 2. CD14 
1. IC and 
2. EC 
1. Live/Dead® 
Fixable Blue 
Dead cell stain 
kit and 2. 
BUV395 
1. N/A 
and 2. 
MPhiP9  
1. Molecular 
Probes®, Life 
Technologies
™, Oregon 
and 2. BD 
Biosciences, 
New Jersey 
Red 
633 
660/20 CD20 EC Allophycocyanin 
(APC) 
2H7 eBioscience 
Inc., San 
Diego 
730/45 HLA-DR EC Alexa Fluor® 
700 
L243 Biolegend, 
San Diego 
780/60 CD27 EC APC-Alexa 
Fluor® 750 
CLB-
27/1 
ThermoFisher 
Scientific, 
Massachusetts 
*IC: Intracellular and EC: Extracellular 
† The UV 405/20 filter was used as a ‘dump’ channel for the detection and 
elimination of all dead cells and CD14+ cells from the populations of interest. 
Hence, detection of these two unwanted populations was done together. 
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‡ Because all un-conjugated CFSE reagent passively diffuses out of the cell, 
CFSE is compatible with the Live/Dead® Fixable Blue Dead cell stain kit. 
Both reagents have been used successfully within the same flow cytometry 
panel in the literature (Perfetto et al., 2010) and by our group. 
 
Once flow cytometry was completed per experiment, raw data was analysed. 
Several gating strategies had to be used to eliminate debris and unwanted 
cell populations, leaving only cell populations of interest, as detailed below. 
  
2.7.4 Post-acquisition analysis 
 
Raw data obtained after flow cytometry was analysed using FlowJo version 
7.6® for MAC software (TreeStar Inc., Ashland).  
 
Bioexponential transformation (logical implementation) was used in order to 
enable visualisation of populations with negative values. Sequential gating 
was then applied to each individual experiment to eliminate debris, cell 
clumps, dead cells and CD14+ cell populations from the T- and B-cell 
populations of interest (figure 2.3).  
 
Proliferation values in this study are reported as proliferation indices (section 
2.4) while activation values are reported in Median Fluorescence Intensity 
(MFI).  
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Figure 2.3: Flow cytometry gating strategy used to eliminate all 
unwanted cells/signals from the final data set. Gates were constructed 
around cells leaving out debris (FSC-Area versus SSC-Area; A), followed by 
the gating of singlets to exclude cell clumps (FSC-Height versus FSC-Area; 
B). Using the optimised panels presented in table 2.1, the UV 405/40 filter 
was used as a dump channel for dead cells (being identified through the use 
of the live/dead® fixable blue dye) and the entire CD14+ population. 
Therefore, gates were constructed around live cells (C). Fluorescence-
Minus-One (FMO) controls (fig. 2.4) were used to construct gates around 
CD4+CD19- T-cells (D), CD8+ T-cells (E) and CD19+CD4- B-cells (D). The 
     
A B 
D 
C 
E 
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percentage of events recorded in each gate is also shown. Additionally, in 
the case of the B-cell subsets, gating focused solely on CD19+ B-cells, and 
subsets defined by markers outlined in table 2.1 (B) thereafter. 
 
FMO controls include every fluorochrome in a given flow cytometry panel, 
except one (Hulspas et al., 2009). Using FMO controls for gating ensures 
that gating thresholds set for the particular fluorochrome absent from the 
FMO are as precise as possible (Herzenberg et al., 2006).  
 
The FMO controls used to select cell populations of interest are shown in fig. 
2.4 to 2.6. Each experiment was performed with a full panel of FMO controls 
to ensure accurate gating per experiment. The FMO gating strategy for CD4+ 
and CD8+ T-cells, and CD19+ B-cells is presented in fig. 2.4. 
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Figure 2.4: Representative dot plots of positively labelled CD19+ (A) B-
cell, and CD4+ (B) and CD8+ T-cell populations (C) relative to their 
respective Fluorescence-Minus-One (FMO) gating controls (B for 
CD19+ B-cells, A for CD4+ T-cells, and D for CD8+ T-cells). The first 
three steps in the gating strategy presented in fig. 2.3 (A, B and C) were 
used prior to this FMO gating strategy. Also, this strategy was strictly used 
for the T- and B-cell panel presented in table 2.1 A. 
 
The flow cytometry panel optimised to quantify CD19+ B-cell subsets was 
gated based on FMO controls presented in fig. 2.5. 
 
 
 
 
 
CD4 
 
A B 
 
C D 
CD19 
CD8 
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Figure 2.5: Representative dot plots of positively labelled CD19+ (A) 
and CD10+ B-cell populations (C) relative to their respective 
Fluorescence-Minus-One (FMO) gating controls (B for CD19+ B-cells 
and D for CD10+ B-cells). The first three steps in the gating strategy 
presented in fig. 2.3 (A, B and C) were used prior to this FMO gating 
strategy. Also, this strategy was strictly used for the B-cell subset panel 
presented in table 2.1 B. 
 
Following the selection of the CD19+CD10- B-cell population, five B-cell 
subsets (fig. 2.6) were gated based on the CD27, CD21 and CD20 markers. 
Some of these subsets have been found to be perturbed in HIV-viraemic 
individuals (Moir and Fauci, 2013).                  
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Figure 2.6: Representative dot plots showing B-cell subsets (A) and 
further separation of the Q1 quadrant into Plasmablasts and Activated 
Memory cells (B).  Q1 comprises Plasmablasts (PB) and Activated Memory 
cells (AM), Q2; Resting Memory cells (RM), Q3; Naive B-cells, and Q4: 
Tissue-Like Memory cells (TLM) (Moir and Fauci, 2013). The Q1 
compartment was separated into PB and AM subsets using the CD20 
marker. As indicated by the gates, PBs are CD27hiCD21loCD20lo while AMs 
are CD27intCD21loCD20hi (Moir and Fauci, 2013, Wheatley et al., 2016). 
 
All raw data was then statistically analysed to investigate differential T- and 
B-cell responses between patients and controls. 
  
2.8 Statistical analysis 
 
All statistical analyses and graphics were done using the IBM SPSS statistics 
21 software (SPSS Inc., Illinois) and GraphPad Prism 7 (GraphPad Software, 
Inc., California). 
 
The Kolmogorov-Smirnov test was used to test for data normality. 
Thereafter, appropriate statistical tests were used to investigate differential 
responses between patients and controls. Statistical tests used are 
presented in detail per results chapter. 
 
 
A 
 
B 
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CD27 
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3.1  Introduction 
 
The case-control study design is frequently used in public health research. 
While matching of cases to controls lends efficiency to a study, there has 
been a forty-year discussion surrounding the advantages and disadvantages 
of stringent matching (Rose and van der Laan, 2009). Kupper and 
colleagues described how there is no benefit in matching non-confounding 
variables between cases and controls (Kupper et al., 1981). Garey stated 
that only factors considered strongly confounding will largely affect the 
efficiency of the study (Garey, 2004). Furthermore, while a case-control 
study of quality of life of Irritable Bowel Syndrome (IBS) sufferers compared 
to controls found similar results irrespective of matching or non-matching 
(Faresjo and Faresjo, 2010), matching reduced the study’s statistical power. 
Therefore, the use of case-control matching for research needs to be 
justified.  
 
To investigate subtle defects in T- and B-cell responses in two 
immunocompromised patient groups in this study (HIV-infected individuals 
and MGUS patients), it was planned to individually match each case to a 
specific control based on four factors: age, sex, ethnicity and date of sample 
acquisition. Wherein, responses per patient would be compared to 
responses from a control subject whom to our knowledge did not have the 
same disease state. This matching should cover for any pre-existing 
differences caused by these inherent factors, especially as day-to-day 
variability in the immunologic assay itself could skew data to a certain extent. 
Thus assays were always run with cases and controls on the same day, as 
had always been previously done by our group (Foster et al., 2009, Foster et 
al., 2010, Wing et al., 2012, Darton et al., 2011, Preciado-Llanes et al., 
2015). The next step was to ascertain how these factors affect immune 
responses, and if they were indeed potential confounders. 
 
Jager et al (2008) have described variables to be ‘potential confounders’ if 
they fulfil three criteria: 1. The variable must be a known risk factor for the 
disease; 2. It should have unequal distribution between exposed and non-
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exposed groups; and 3. It is not an effect of the exposure (Jager et al., 
2008). It is well established that the burden of pneumococcal disease affects 
infants below the age of two, elderly people above the age of 65 (Robinson 
et al., 2001, Trotter et al., 2008), and the immunocompromised (Feikin et al., 
2010, Kumashi et al., 2005, Overturf, 2003, Barrettc.E, 1971). Hence, it was 
decided that age-matching cases to controls in the present study would be 
appropriate. Indeed, Pearce (2016) stated that age-matching improves 
statistical precision in case-control studies (Pearce, 2016). 
 
Additionally, cellular and humoral immune responses tend to be impaired in 
the elderly. The number of T-cells in PBMCs has been shown to be lower 
with age (Utsuyama et al., 1992). Specifically, these numbers begin to 
significantly decline from the third decade of life, hold relatively constant 
through to the seventh decade, then deplete thereafter (Utsuyama et al., 
1992). Age-related immunosenescence is prominent in the T-cell population 
and can be accelerated by latent persistent human cytomegalovirus (HCMV) 
(Tu and Rao, 2016). The total number of CD19+ B-cells also decreases with 
age. These changes have vaccine-response implications  (Frasca et al., 
2011). Overall, the strong link between age and declining immunity further 
highlights the need for age-matching in case-control studies in immunological 
research. 
 
Susceptibility to diseases and vaccine responses are also influenced by sex, 
with men often being more susceptible towards infectious disease and 
women mounting higher humoral responses (Giefing-Kroell et al., 2015). This 
sex difference is further confounded by the effect of age on the levels of sex 
hormones produced (Giefing-Kroell et al., 2015). 
 
In 2012, Abdullah and colleagues found in vitro sex-specific differences in 
lymphocyte subsets of healthy adult humans. Males had higher levels of 
lymphocytes in whole blood. Regarding lymphocyte subsets enumeration 
from this whole blood, while males had higher levels of natural killer (NK) 
cells, females had higher levels of B-cells. Following culture, females showed 
a significant increase in B- and total T-cell percentages, whilst males showed 
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an increase in NK cells. However, upon stimulation with phytohaemagglutinin 
(PHA), males showed significantly higher total T-cell percentages whilst 
persisting with higher NK cells. On the other hand, females had higher total 
activated T-cells (CD69+). While the study cohort was small (n = 15), there 
are important implications from this study which can be extrapolated to sex-
matching in case-control studies (Abdullah et al., 2012). Sex influences 
immune cell responses, indicating a potential to affect data interpretation 
should sex-matching be omitted. 
 
Race of vaccinees following primary smallpox vaccination has been revealed 
to influence cell-mediated immune responses (Haralambieva et al., 2013). 
Caucasians had significantly higher total IFNƴ ELISPOT responses 
(p=0.010), CD8+ IFNƴ ELISPOT responses (p<0.001), secreted IL-2 
(p=0.003), and IFNα (p<0.001) compared to African-Americans and 
Hispanics. Haralambieva and colleagues (2013) also reported significantly 
higher total IFNƴ ELISPOT responses and higher IL-1β in men (both 
p<0.001) compared to women. Women had significantly higher secreted 
vaccinia-specific IL-2 (p<0.001) and IL-10 (p=0.017) compared to men. 
Whilst the clinical implications of these results remain unclear, a race and 
sex-based bias in immune responses to smallpox vaccination can be 
concluded. In a further study, racial/ethnic-influenced humoral immune 
responses were reported, following rubella vaccination (Haralambieva et al., 
2014). In this study conducted by Haralambieva and colleagues, individuals 
of European descent and/or Hispanic ethnicity showed significantly lower 
levels of rubella-specific neutralizing antibody levels (p < 0.001) compared to 
individuals of African descent. However, sex showed no consistent 
association with immune response. These two studies conducted by the 
Haralambieva group suggest an influence of sex and ethnicity on cellular-
mediated, and humoral immunity. This indicated the necessity for ethnicity-
matching in the present study. 
 
However, before embarking on studying how age, sex and ethnicity could 
affect in vitro T- and B-cell responses to the validated assay used widely in 
our laboratory (Foster et al., 2009, Foster et al., 2010, Darton et al., 2011, 
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Wing et al., 2012, Preciado-Llanes et al., 2015) it was essential to be able to 
reproduce our group results. 
 
Thus data gathered and presented in this chapter had two aims: Firstly, to 
reproduce results showing that plate-bound anti-CD3 stimulates activation in 
CD4+ T-cells and to reproduce our laboratory group results showing that T-
cell-independent Type 2 (TI-type 2) stimulation of B-cells using αδdex elicits 
significantly increased activation in these B-cells. Secondly, to ascertain if 
inherent factors- age, sex and ethnicity, would have any effect on T- and B-
cell responses to anti-CD3 and αδdex separately, and in combination. This 
information would underpin the stringency of matching the cases to controls 
during recruitment for this study. 
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3.2  Methods 
 
Blood donors were recruited from amongst the staff and students of the 
Medical School, Royal Hallamshire Hospital as described in chapter two 
(section 2.1). After informed consent was obtained, blood was drawn and 
PBMCs were cultured using aseptic technique. The immune assay was 
performed as described in chapter two (section 2.4 and 2.5). To increase the 
numbers in each study group in this chapter, data gathered by a member of 
our group, James Wing, was included in analysis with permission (as 
indicated in table 3.1). This data had not been previously analysed for age-
based correlations or sex-based variations in immune response. The two cell 
populations of interest in this chapter, CD4+ T-cells and CD19+ B-cells, were 
gated according to the strategy detailed in fig. 2.3 (chapter two). 
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Table 3.1: Brief description of the workflow and outcome measures for 
results presented in chapter three 
Aim Work Flow Outcome measures Results 
presented 
in figure: 
Study 
group 
number 
Data collected 
by 
Reproduce 
group 
results 
CD4+ T-cell responses to 
TCR-stimulant; anti-CD3 
alone, and in combination 
with αδdex, and αδdex + 
anti-CD28 respectively. 
CD4+ T-cell frequency, 
proliferation (based on 
CFSE proliferation 
index), and activation 
(based on CD25 and 
HLA-DR expression).  
3.1 – 3.2 12 Furaha Asani 
CD19+ B-cell responses 
to anti-IgD-stimulation 
using αδdex alone, and in 
combination with anti-
CD3, and anti-CD3 + anti-
CD28 respectively. 
CD19+ B-cell frequency, 
proliferation (based on 
CFSE proliferation 
index), and activation 
(based on CD86, CD25 
and HLA-DR 
expression). 
3.3 – 3.5 12 Furaha Asani 
Correlate 
age with 
immune 
responses 
CD4+ T-cell responses to 
TCR-stimulant; anti-CD3 
alone, and in combination 
with αδdex 
CD4+ T-cell CD25 
expression 
3.6 106 Furaha Asani (n = 
18); James Wing 
(n = 88) 
CD19+ B-cell responses 
to anti-IgD-stimulation 
using αδdex alone, and in 
combination with anti-CD3 
CD19+ B-cell CD86 
expression 
3.7 106 Furaha Asani (n = 
18); James Wing 
(n = 88) 
Investigate 
sex-based 
variations 
in immune 
responses 
CD4+ T-cell responses to 
TCR-stimulant; anti-CD3 
alone, and in combination 
with αδdex 
CD4+ T-cell CD25 
expression 
3.8 100 Furaha Asani (n = 
12); James Wing 
(n = 88) 
CD19+ B-cell responses 
to anti-IgD-stimulation 
using αδdex alone, and in 
combination with anti-CD3 
CD19+ B-cell CD86 
expression 
3.9 100 Furaha Asani (n = 
12); James Wing 
(n = 88) 
Investigate 
ethnicity-
based 
variations 
in immune 
responses 
CD4+ T-cell responses to 
TCR-stimulant; anti-CD3 
alone, and in combination 
with αδdex, and αδdex + 
anti-CD28 respectively. 
CD4+ T-cell frequency, 
proliferation (based on 
CFSE proliferation 
index), and activation 
(based on CD25 
expression).  
3.10 – 
3.12 
18 Furaha Asani 
CD19+ B-cell responses 
to anti-IgD-stimulation 
using αδdex alone, and in 
combination with anti-
CD3, and anti-CD3 + anti-
CD28 respectively. 
CD19+ B-cell frequency, 
proliferation (based on 
CFSE proliferation 
index), and activation 
(based on CD86 and 
CD25 expression). 
3.13 – 
3.16 
18 Furaha Asani 
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3.3  Results 
 
A healthy population, with demographics shown in table 3.2, was recruited to 
reproduce the in vitro T- and B-cell assay results that have been published 
from our laboratory (Foster et al., 2009, Darton et al., 2011).  
 
Table 3.2: Descriptive statistics showing the age, sex and ethnicity of 
12 individuals used to investigate T- and B-cell responses to a 
validated stimulation assay 
 Study group  
Number  12  
Mean age (Range)  
Median age 
27 (23 - 33)  
25.50 
Sex: Female 
       Male  
6 
6 
Ethnicity : Black  
               White  
6 
6  
 
 
3.3.1 CD3-stimulation of T-cells and IgD-stimulation of B-cells results in 
activation 
 
The initial phase of this project sought to validate an immunologic assay 
used by our laboratory showing significant up-regulation of CD25 expression 
in CD4+ T-cells following TCR-stimulation (Foster et al., 2009, Foster et al., 
2010, Preciado-Llanes et al., 2015) (fig. 3.2 A). Also, to validate B-cell 
activation as measured by CD86 and CD25 expression after polyclonal 
stimulation with αδdex, with and without T-cell help (Darton et al., 2011).  
 
It was essential to first determine what effect the stimulus had, if any, on the 
frequency distribution of the cells. While CD4+ T-cell frequencies remained 
unchanged upon stimulation (fig. 3.1) CD19+ B-cell frequencies significantly 
reduced upon αδdex-stimulation, relative to the un-stimulated control (fig. 
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3.3). As demonstrated by Darton et al. (2011) up-regulation of CD86 
expression in CD19+ B-cells was seen upon stimulation with a combination 
of αδdex, anti-CD3 and anti-CD28 (fig.3.4 A). A similar trend was seen for 
HLA-DR (fig. 3.5). 
 
Using the one-sample Kolmogorov-Smirnov test, data in figures 3.1 to 3.5 
were ascertained to be non-parametric. Thus the Kruskal-Wallis H test 
(which is the non-parametric equivalent of the Analysis of variance test) was 
used to study pair-wise variances between the un-stimulated and stimulated 
conditions. The p values shown were adjusted by Bonferroni correction, to 
correct for type I errors introduced by multiple comparisons. Data are 
presented as median values within confidence intervals. Stimulation 
concentrations used were as described in chapter 2 (section 2.4 and 2.5), 
and previously determined by our group (Foster et al., 2009, Foster et al., 
2010, Darton et al., 2011, Wing et al., 2012, Preciado-Llanes et al., 2015): 
1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in 
combination with 0.5μg/ml anti-CD28 for 96 hr.  
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Figure 3.1: Frequency (A) and proliferation (B) of CD4+ T-cells following 
in vitro CD3-stimulation alone, in combination with CD28-costimulation, 
and αδdex. Up-regulation in stimulated conditions was analysed relative to 
the un-stimulated control. Kruskal-Wallis H test with Bonferroni correction 
was used to study pair-wise variances (n = 12). Concentrations of stimulants 
used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in 
combination with 0.5μg/ml anti-CD28. 
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Figure 3.2: Activation of CD4+ T-cells in terms of CD25 (A) and HLA-DR 
expression (B) following in vitro CD3-stimulation alone, in combination 
with CD28-costimulation, and αδdex. Up-regulation in stimulated 
conditions was analysed relative to the un-stimulated control. Kruskal-Wallis 
H test with Bonferroni correction was used to study pair-wise variances (n = 
12). Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 
** 
*** 
** 
** * 
* 
A 
B 
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alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28.  
(Where * p ≤ 0.050, ** p ≤ 0.010, *** p ≤ 0.001). 
                     
Figure 3.3: Frequency (A) and proliferation (B) of CD19+ B-cells 
following in vitro IgD-stimulation with αδdex alone, and in the presence 
of T-cell help. Up-regulation in stimulated conditions was analysed relative 
to the un-stimulated control. Kruskal-Wallis H test with Bonferroni correction 
was used to study pair-wise variances (n = 12). Concentrations of stimulants 
* * 
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used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in 
combination with 0.5μg/ml anti-CD28. (Where * p ≤ 0.050).  
            
Figure 3.4: Activation of CD19+ B-cells in terms of CD86 (A) and CD25 
expression (B) following in vitro IgD-stimulation with αδdex alone, and 
in the presence of T-cell help. Up-regulation in stimulated conditions was 
analysed relative to the un-stimulated control. Kruskal-Wallis H test with 
** 
*** 
* 
*** A 
B 
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Bonferroni correction was used to study pair-wise variances (n = 12). 
Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 
alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28. 
(Where * p ≤ 0.050, ** p ≤ 0.010, *** p ≤ 0.001).  
        
Figure 3.5: Activation of CD19+ B-cells in terms of HLA-DR expression, 
following in vitro IgD-stimulation with αδdex alone, and in the presence 
of T-cell help. Up-regulation in stimulated conditions was analysed relative 
to the un-stimulated control. Kruskal-Wallis H test with Bonferroni correction 
was used to study pair-wise variances (n = 12). Concentrations of stimulants 
used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in 
combination with 0.5μg/ml anti-CD28. (Where * p ≤ 0.050, ** p ≤ 0.010, *** p 
≤ 0.001).  
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3.3.2 Age significantly affects stimulated CD4+ T-cell, and un-
stimulated CD19+ B-cell activation  
 
To investigate the effects of age on T- and B-cell responses, a group 
comprising 106 healthy individuals (table 3.3) was recruited for study. 
 
Table 3.3: Age range of 106 individuals used to investigate the 
correlative effects of age on T- and B-cell responses to CD3- and 
αδdex-stimulation respectively. The sex categorisation of a large portion 
of this study group were unknown, hence were unrecorded in the table. 
 
 Study group 
Number  106 
Mean age (Range)  
Median age 
32.02 (23 - 57) 
30.00  
 
Using the one-sample Kolmogorov-Smirnov test, data obtained from this  
study group yielded some sets that were parametric, and others which were 
non-parametric. As a result both parametric and non-parametric correlative 
tests: Pearson’s correlation and Spearman’s rho respectively, were used. 
 
Data are presented as scatter plots, with age on the x-axis and activation 
markers (in MFI) on the y-axis. Stimulation concentrations used were as 
described in chapter 2 (section 2.4 and 2.5): 1μg/ml of αδdex, 0.1μg/ml anti-
CD3 alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28. 
R2 values are shown on fig. 3.6 and 3.7 to indicate the percentage of 
activation values that can be predicted from the age data. Older individuals 
showed an increase in CD25 expression in CD4+ T-cells upon in vitro 
stimulation with anti-CD3 and αδdex (p ≤ 0.050; fig. 3.6C) compared to 
younger individuals. This occurred in spite of comparable CD4+ T-cell 
activation across all ages under un-stimulated conditions (fig. 3.6A). 
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Figure 3.6: Correlation of age with in vitro CD4+ T-cell activation, in 
terms of CD25 expression, under unstimulated conditions (A), with 
CD3-stimulation alone (B) and combined with αδdex (C). Spearman’s rho 
bivariate correlation for non-parametric data was used to determine this 
significance (n = 106).  Concentrations of stimulants used: 1μg/ml of αδdex, 
R2=0.011 
R2=0.023 
   * C 
B 
Age 
Age 
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0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 
0.5μg/ml anti-CD28. (Where * p ≤ 0.050).   
 
Under un-stimulated conditions, older individuals showed lower CD19+ CD86 
expression (p ≤ 0.050; fig. 3.7A) compared to younger individuals. 
Stimulation eliminated the significance of this activation response (fig. 3.7B 
and C). 
 
R2=0.071 
A    * 
Age 
CHAPTER THREE 
81 
 
                                
 
                                         
        
   
Figure 3.7: Correlation of age with in vitro CD19+ B-cell activation, in 
terms of CD86 expression, under unstimulated conditions (A), with 
αδdex-stimulation alone (B) and T-cell help (C). This un-stimulated CD86 
expression on B-cells shown in A drops off  around age 30. Spearman’s rho 
bivariate correlation for non-parametric data was used for A and B; Pearson 
R2=0.001 
R2=0.012 
B 
C 
Age 
Age 
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correlation for parametric data was used for C (n = 106). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. (Where * p ≤ 0.050). 
 
3.3.3 Sex and ethnicity influence CD4+ T- and CD19+ B-cell proliferation 
and activation  
 
Towards appropriately matching cases to controls in this study, a group of 
healthy individuals (table 3.4) was first studied to ascertain sex-based 
influences on in vitro T- and B-cell responses. Data are presented as median 
values within confidence intervals, with each data point corresponding to one 
individual. Stimulation concentrations used were as described in chapter 2 
(section 2.4 and 2.5): 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 
0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28. 
 
3.3.3.1 The effects of sex on CD4+ T- and CD19+ B-cell responses 
 
Table 3.4: Age range of 100 individuals used to investigate the in vitro 
effects of sex on T- and B-cell responses to CD3- and IgD-stimulation 
respectively. Ethnicities of a large portion of this study group were unknown, 
hence were unrecorded in the table. Age did not significantly differ between 
females and males. 
 
 Study group 
Number  100 
Mean age (Range)  
Median age 
31.63 (23 - 47)  
30.00 
Female 
Mean age (Range) 
Median age     
48 
31.31 (24 – 43) 
30.00 
Male 
Mean age (Range) 
Median age 
52 
31.92 (23 – 47) 
30.00 
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Females and males had comparable CD4+ T-cell activation under un-
stimulated and stimulated conditions (fig. 3.8). Males however did show 
higher CD19+ B-cell activation upon stimulation (p ≤ 0.050; fig. 3.9B and C). 
 
 
Figure 3.8: The effect 
of sex on CD4+ T-cell 
activation under 
unstimulated 
conditions (A), with 
CD3-stimulation alone 
(B) and combined with 
αδdex (C).  The Mann 
Whitney U test for non-
parametric data was 
used to investigate 
differences between 
males and females in A, 
B and C (n = 100).  Each 
data point corresponds 
to one individual. Data 
points are superimposed 
over median values in 
95% confidence 
intervals.  
Concentrations of 
stimulants used: 1μg/ml 
of αδdex, 0.1μg/ml anti-
CD3 alone, and 0.5μg/ml 
anti-CD3 in combination 
with 0.5μg/ml anti-CD28.  
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Figure 3.9: The effect of 
sex on CD19+ B-cell 
activation under 
unstimulated conditions 
(A), with αδdex-
stimulation alone (B) and 
T-cell help (C). The Mann 
Whitney U test for non-
parametric data was used 
to investigate differences 
between males and 
females  in A and B, whilst 
the Independent samples t-
test for parametric data 
was used to determine 
differences in C (n = 100). 
Each data point 
corresponds to one 
individual. Data points are 
superimposed over median 
values in 95% confidence 
intervals.  Concentrations 
of stimulants used: 1μg/ml 
of αδdex, 0.1μg/ml anti-
CD3 alone, and 0.5μg/ml 
anti-CD3 in combination 
with 0.5μg/ml anti-CD28.  
 (Where * p ≤ 0.050).  
 
  * 
  * 
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Having found sex-based differences in B-cell responses, the influence of 
ethnicity on T- and B-cell responses was investigated to further inform case-
control matching. 
 
3.3.3.2 The effects of ethnicity on CD4+ T- and CD19+ B-cell responses 
A group of healthy individuals (table 3.5) was recruited based on ethnicity to 
investigate T- and B-cell variable responses. 
 
Table 3.5: Age range of 18 individuals used to investigate the in vitro 
effects of ethnicity on T- and B-cell responses to CD3- and αδdex-
stimulation respectively. Age did not significantly differ between sexes or 
ethnicities. 
   Study cohort  
Number  18 
Mean age (Range)  
Median age 
34.39 (23 - 65) 
30.50  
         Female 
                   Mean age (Range) 
                   Median age      
8 
31.63 (24 – 46) 
30.50 
         Male 
                   Mean age (Range) 
                   Median age     
10 
36.60 (23 – 65) 
29 
         Black  
                   Mean age (Range) 
                   Median age      
8 
31.13 (23 – 46) 
30.50 
         White  
                   Mean age (Range) 
                   Median age     
10 
37.00 (24 – 65) 
30.00 
 
Data are presented as median values within confidence intervals, with each 
data point corresponding to one individual. Stimulation concentrations used 
were as described in chapter 2 (section 2.4 and 2.5): 1μg/ml of αδdex, 
0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 
0.5μg/ml anti-CD28. 
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While Black and White individuals had comparable CD4+ T-cell frequencies 
across un-stimulated and stimulated conditions (fig. 3.10), proliferation (fig. 
3.11) and activation (fig. 3.12) of CD4+ T-cells revealed ethnicity-based 
differences.
 
Figure 3.10: The effect of ethnicity on in vitro CD4+ T-cell frequencies 
under un-stimulated and stimulated conditions. The Mann Whitney U test 
was used to investigate ethnicity-based differences. (Black, n = 8; White, n = 
10). Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 
alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28.  
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Figure 3.11: The effect of ethnicity on in vitro CD4+ T-cell proliferation 
under un-stimulated and stimulated conditions. The Mann Whitney U test 
was used to investigate ethnicity-based differences. (Black, n = 8; White, n = 
10); (Where * p ≤ 0.050). Concentrations of stimulants used: 1μg/ml of 
αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 
0.5μg/ml anti-CD28.  
 
 * 
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Figure 3.12: The effect of ethnicity on in vitro CD4+ T-cell activation, in 
terms of CD25 expression, under un-stimulated and stimulated 
conditions. The Mann Whitney U test was used to investigate ethnicity-
based differences. (Black, n = 8; White, n = 10); (Where * p ≤ 0.050, ** p ≤ 
0.010, *** p ≤ 0.001). Concentrations of stimulants used: 1μg/ml of αδdex, 
0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 
0.5μg/ml anti-CD28.  
 
 * 
 *** 
 ** 
CHAPTER THREE 
89 
 
Similarly for CD19+ B-cells, there was no ethnicity-based variation for 
frequencies (fig. 3.13). However, proliferation (fig. 3.14) and activation (fig. 
3.15) revealed ethnicity-based variations.
 
Figure 3.13: The effect of ethnicity on in vitro CD19+ B-cell frequencies 
under un-stimulated and stimulated conditions. The Mann Whitney U test 
was used to investigate ethnicity-based differences. (Black, n = 8; White, n = 
10). Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 
alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28.  
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Figure 3.14: The effect of ethnicity on in vitro CD19+ B-cell proliferation 
under un-stimulated and stimulated conditions. The Mann Whitney U test 
was used to investigate ethnicity-based differences. (Black, n = 8; White, n = 
10); (Where * p ≤ 0.050). Concentrations of stimulants used: 1μg/ml of 
αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 
0.5μg/ml anti-CD28.  
 
 * 
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In terms of CD86 expression levels, both ethnicities were comparable in un-
stimulated conditions (fig 3.15 A). However, stimulation led to higher in vitro 
CD19+ B-cell activation in White individuals (fig. 3.15C, D and E). 
 
Figure 3.15: The effect of ethnicity on in vitro CD19+ B-cell activation, in 
terms of CD86 expression, under un-stimulated and stimulated 
conditions. The Mann Whitney U test was used to investigate ethnicity-
based differences. (Black, n = 8; White, n = 10); (Where * p ≤ 0.050, ** p ≤ 
0.010). Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-
CD3 alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28.  
 ** 
 * 
* 
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CD25 expression levels between Black and White individuals were 
comparable under in vitro un-stimulated and stimulated conditions (fig 3.16). 
 
Figure 3.16: The effect of ethnicity on in vitro CD19+ B-cell activation, in 
terms of CD25 expression, under un-stimulated and stimulated 
conditions. The Mann Whitney U test was used to investigate ethnicity-
based differences. (Black, n = 8; White, n = 10). Concentrations of stimulants 
used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in 
combination with 0.5μg/ml anti-CD28.  
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3.4  Discussion of Findings 
 
Using the anti-CD3- and αδdex-stimulation assay, a sample size of 10 
individuals at minimum is needed for statistical power (Darton et al., 2011). 
This consideration was at the forefront of recruitment during each stage of 
data collection presented in this chapter. 
 
3.4.1 T- and B-cell responses to the validated immunologic assay 
 
In a group of 12 healthy adults with an equal spread of females and males, 
stimulation had no effect on the in vitro frequency distribution (fig. 3.1 A) or 
proliferation (fig. 3.1 B) of CD4+ T-cells. In terms of activation, CD4+ T-cell 
responses showed up-regulation of CD25 expression to sub-optimal 
concentrations of plate-bound anti-CD3 (0.1μg/ml), relative to an un-
stimulated control (p ≤ 0.010; fig. 3.2 A). This sub-optimal concentration 
elicits minimal T-cell activation (Foster et al., 2009) and facilitates the 
detection of small differences between patient and control responses (Foster 
et al., 2009, Foster et al., 2010, Darton et al., 2011, Wing et al., 2012, 
Preciado-Llanes et al., 2015). This up-regulated CD25 expression was also 
seen when CD3-stimulation was boosted by costimulation of CD28 (p ≤ 
0.001; fig. 3.2 A). Further while αδdex dampened this CD4+ T-cell response, 
a significant increase in CD25 expression was still seen nonetheless relative 
to the un-stimulated (p ≤ 0.010; fig. 3.2 A). This immunosuppressive effect of 
αδdex-stimulated B-cells on T-cell activation has been reported previously by 
our group (Preciado-Llanes et al., 2015). Our group showed that while T-cell 
activation is up-regulated by anti-CD3 stimulation (alone, and with anti-CD28 
costimulation), the presence of αδdex-stimulated B-cells significantly reduces 
this T-cell activation (Preciado-Llanes et al., 2015).   
 
Our group had established an immunologic assay that has been used to 
study B-cell responses to αδdex, a TI- type 2 antigen mimic that elicits 
polyclonal B-cell responses. By using this mimic to activate B-cells alone, 
and in the presence of TCR-activated T-cells, cognate interactions between 
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B- and T-cells have been studied. This validated stimulation assay has 
enabled the elucidation of subtle immune defects in several patient groups 
including adult MenC sufferers (Foster et al., 2009), adolescent Meningitis C 
vaccine failures (Foster et al., 2010) and adult IPD survivors (Darton et al., 
2011) compared to healthy controls. 
 
The decision was made to include HLA-DR as an additional activation 
marker in this study. This is because along with the traditionally used CD25, 
HLA-DR is an indicator of late T-cell activation (Reddy et al., 2004, Starska 
et al., 2011). Furthermore, HLA-DR expression on T-cells has been shown to 
increase HIV-1 transcription (Saifuddin et al., 2000). In a cohort of HAART-
treated aviraemic HIV-infected patients, baseline percentage levels of CD4+ 
HLA-DR+ were significantly higher (p ≤ 0.050) than in HIV-negative controls. 
Moreover, though not significant, the levels of CD8+ HLA-DR+ cells were 
also increased in the patient group (Tincati et al., 2012). With the aim of 
studying differences in T-cell responses between HIV-infected individuals 
and controls later on in the study, HLA-DR would serve as a validated 
second marker of immune activation. 
 
CD4+ T-cells showed significant up-regulation of HLA-DR in the presence of 
sub-optimal anti-CD3 levels, and anti-CD3 combined with anti-CD28 (fig. 3.2 
B). Interestingly, this up-regulation of HLA-DR persisted even in the 
presence of αδdex combined with anti-CD3. Because αδdex on its own did 
not elicit up-regulation of CD25 (fig 3.2 A) or HLA-DR (fig 3.2 B) it can be 
concluded that αδdex itself has no effect on CD4+ T-cell activation, at least 
not with respect to these particular activation markers. This conclusion was 
also drawn previously in our group (Preciado-Llanes et al., 2015).  
 
Receptor-mediated endocytosis occurs to an extent when using antibody 
labelling protocols (Liao-Chan et al., 2015, Ingle et al., 2008), especially 
when cell populations are stimulated and activated. Therefore it cannot be 
concluded whether stimulations actually reduced the frequency of CD19+ B-
cells relative to the un-stimulated control (p ≤ 0.050; fig 3.3 A), or if receptor 
internalisation had occurred. If indeed αδdex suppressed CD19+ B-cell 
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frequency (p ≤ 0.050; fig 3.3 A), it is noteworthy that αδdex-stimulation still 
elicited significant up-regulation of CD86 expression (p ≤ 0.010; fig 3.4 A). 
These αδdex-stimulated CD19+ B-cells also showed further up-regulation of 
CD86 expression in the presence of CD3 stimulation alone and in 
combination with CD28-costimulation (both p ≤ 0.001; fig 3.4 A). These 
results mimic those found by Darton et al. (2011) in their healthy control 
group. However one difference is that while Darton’s work showed significant 
up-regulation in CD25 expression upon stimulation with αδdex plus anti-CD3 
and anti-CD28, the same was not the case in the present study (fig 3.4 B). 
Lastly, the additional HLA-DR activation marker showed significant up-
regulation across all stimulations relative to the un-stimulated control (p ≤ 
0.050; fig 3.5). 
 
These results indicated that the immune stimulation assay used in our group 
was reproducible. Also, that HLA-DR would be a relevant marker to include 
that could potentially provide interesting results from the HIV cohort. The 
next step was to determine how stringent matching of control subjects to 
patients needed to be. 
 
3.4.2  Age as an inherent influencer of T- and B-cell responses 
 
In a group of 106 individuals ranging in age from 23 – 57, results indicated 
that age did not significantly impact CD4+ T-cell activation responses under 
un-stimulated conditions, and upon CD3-stimulation (fig. 3.6 A and B). 
However, younger individuals showed significantly lower (p ≤ 0.050) CD3-
stimulated CD4+ T-cell activation in the presence of αδdex-stimulated 
CD19+ B-cells compared to older individuals (fig. 3.6 C). Our group had 
previously demonstrated that in the presence of in vitro αδdex-stimulated B-
cells, CD3-stimulated CD4+ T-cell CD25 expression is significantly 
suppressed (Preciado-Llanes et al., 2015). Considering the phenomenon of 
age-related immunosenescence being prominent in the T-cell population (Tu 
and Rao, 2016), rather than an increased activation of T-cells in the older 
individuals, it is likely that the B-cell immunosuppressive effect diminishes 
with age.  
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Further, un-stimulated CD19+ B-cells of older individuals showed 
significantly lower B-cell activation (p ≤ 0.050; fig. 3.7 A) compared to 
younger individuals. However, upon stimulation (fig. 3.7 B and C) responses 
in older and younger individuals were comparable. 
 
Due to the lack of ethnicity data for these 106 individuals, there was no way 
of knowing if there was an equal spread of ethnicities across the age 
spectrum. This limits conclusions that can be drawn. Another limitation to this 
portion of the study is that out of 106 individuals, only seven were beyond 40 
years of age, with one of these being 57. This would have excluded the age 
range ( ≥ 65 years) who are known to be predisposed to pneumococcal 
disease more so than younger individuals. The conclusion drawn from the in 
vitro responses in this group of 106 healthy individuals was that age did have 
an affect on T- and B-cell responses, though not dramatically. It was decided 
that a margin of 10 years at most between cases and controls would be used 
during the recruitment phase of this study. The choice of this 10 year margin 
would enable us to account for an age-effect on T- and B-cell responses, 
whilst facilitating feasibility of matching. 
 
3.4.3  Sex-based variation in T- and B-cell responses 
 
Firstly, because there was no significant difference between the ages of 
females and males (table 3.4), it was concluded that there would be no 
confounding effect of age on sex-based results.  
 
Sex had no effect on in vitro CD4+ T-cell activation. Thus, females and 
males had comparable CD25 expression under un-stimulated conditions (fig 
3.8 A), and upon CD3-stimulation alone (fig 3.8 B) and with αδdex (fig 3.8 C). 
While sex had no effect on in vitro un-stimulated CD19+ B-cell CD86 
expression (fig. 3.9 A), stimulation elicited sex-based differences. Males had 
significantly higher CD19+ B-cell CD86 expression upon αδdex-stimulation 
alone (p ≤ 0.050; fig. 3.9 B), and in combination with anti-CD3 (p ≤ 0.050; fig. 
3.9 C). Because αδdex combined with anti-CD3 did not elicit sex-based 
differences in CD4+ T-cell activation, the higher activation in males seen in 
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fig 3.9 C may likely be confined to CD19+ B-cells as opposed to cognate 
interactions between T- and B-cells. 
 
A limitation to this portion of the study is the absence of data for investigating 
sex-based differences in proliferation responses of T- and B-cells. This is 
because the parameter for reporting proliferation data in the present study 
(which accounts for only 12 individuals out of 100; table 3.4) which is 
proliferation index, differs from that used in the Wing study (2012) which was 
divisional index. Proliferation data could have strengthened a conclusive 
message from these results.  
 
Despite the lack of proliferation data, the activation data for CD19+ B-cells 
led to the conclusion that sex-matching for the case-control study further on 
would be appropriate. A mismatch could likely introduce sex-based variable 
CD19+ B-cell responses.  
 
3.4.4  Variations in T- and B-cell responses based on ethnicity 
 
Age did not significantly differ between the sexes or ethnicities amongst the 
cohort used to study ethnicity-based variations in T- and B-cell responses 
(table 3.5). Thus, age was not considered to be a confounding factor on the 
interpretation of results. 
 
A striking result uncovered was less T-cell activation in Black, as opposed to 
White, individuals under un-stimulated conditions (p ≤ 0.050; fig. 3.12 A), 
following CD3-stimulation alone (p ≤ 0.001; fig. 3.12 C) and combined with 
CD28-costimulation (p ≤ 0.010; fig. 3.12 E). This result was paralleled in B-
cell activation when relying upon T-cell help (p ≤ 0.050; fig. 3.15 C and E). It 
is likely that this poor T-cell activation in the Black individuals is reflected in 
the poor T-cell help to B-cells that was detected. Noteworthy also is that 
even while not significant, White individuals also had higher CD19+ B-cell 
activation under un-stimulated, αδdex-stimulated and αδdex with anti-CD3 
and anti-CD28-stimulation (fig. 3.15 A, B and F respectively). 
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However, while both ethnicities had comparable un-stimulated CD4+ T-cell 
proliferation (fig. 3.11 A), CD3-stimulation induced a significantly higher in 
vitro proliferation response in Black individuals compared to White individuals 
(p ≤ 0.050; fig. 3.11 C). Further, though White individuals had higher in vitro 
CD19+ B-cell proliferation under un-stimulated conditions compared to Black 
individuals (fig. 3.15 A), proliferation in Black individuals significantly 
surpassed that in White individuals upon αδdex-stimulation (p ≤ 0.050; fig. 
3.14 B).  
 
A study from the USA reported higher total IFNƴ ELISPOT and CD8+ IFNƴ 
ELISPOT responses in White compared to Black Americans, upon receipt of 
the Dryvax® smallpox vaccination (Haralambieva et al., 2013). Yet, another 
study found higher levels of rubella-specific neutralising antibody in Black 
compared to White Americans in response to rubella vaccination 
(Haralambieva et al., 2014). Ethnicity-based variations in BCR signalling 
pathways have also been found between healthy White and Black 
Americans. The Black individuals had lower in vitro anti-IgD-induced 
phosphorylation of multiple components of the BCR pathway, compared to 
White individuals (Longo et al., 2012). Taken together, these three studies 
highlight the existence of ethnicity-based differences in immune cell 
signalling and vaccine responses. And in the context of the findings of the 
present study, further emphasize ethnicity-based variations in adaptive 
immune responses. 
 
In the healthy cohort, Black individuals showed higher TCR-induced CD4+ T-
cell, and αδdex-induced CD19+ B-cell proliferation, compared to White 
individuals. In terms of activation however, it was White individuals who had 
higher responses. These results may indicate higher CD4+ T- and CD19+ B-
cell cognate interactions in White individuals, specifically upon TCR-
stimulation and CD28-costimulation. 
 
Presently, and to our knowledge, the literature does not have studies which 
have investigated differences between Black and White individuals 
specifically based on in vitro T- and B-cell counts, proliferation and activation 
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upon stimulation with a combination of anti-CD3 and αδdex. However, there 
is indication that ethnicity-based differences in cell count and function are an 
important consideration for research. Benign ethnic neutropenia, the 
phenomenon in which low leukocyte and neutrophil counts are found in 25 – 
50% of individuals of African descent, is well-established however (Haddy et 
al., 1999). Results from the present study also suggest that ethnicity-based 
variations at a cellular level could be crucial to immunological responses. 
This, especially in light of the 2016 work showing that genetic ancestry of 
African and European populations drives the differences in their immune 
responses to pathogens which may explain the differing incidence of specific 
diseases often found in these two populations (Nedelec et al., 2016). 
 
The limited number of study participants in the present study (Black, n = 8 
and White, n =10; table 3.5) restricted firm conclusions that can be drawn 
from these results. However, regardless of numbers the findings showing 
higher T-cell activation in White compared to Black  individuals (fig. 3.12) are 
very clear and strong. These warrant further investigation. These results 
highlighted the necessity of ethnicity-matching between cases and controls 
during patient recruitment. A mismatch could potentially introduce an 
ethnicity-based variation in responses to the stimulation assay.  
 
Still, one drawback to ethnicity-matching was the fact that unlike age which 
was absolute, and sex which was either male or female in the context of the 
study, ethnic identities are varied, even within one race. Thus, the conclusion 
made was to match-based on outward-presenting race together with self-
declared racial identity. 
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3.5  Conclusion 
 
After reproducing our group results showing αδdex-induced up-regulation of 
CD86 expression in CD19+ B-cells, age-, sex- and ethnicity-based variations 
in response to the immune stimulation assay were investigated. Results 
indicated a need for matching between cases and controls in terms of these 
three inherent factors. It was concluded that a margin of 10 years at most 
between cases and controls would be used, whilst sex- and ethnicity-
matching would be strict. 
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4.1  Introduction 
 
A 2016 report published by Public Health England (PHE, 2016) shows that 
HIV prevalence in the UK is currently at 1.6 per 1000 in the population. This 
equates to 101,200 people in total, of which over 13,000 are living 
undiagnosed. Antiretroviral therapy (ART) has currently been available for 
two decades within the UK, making HIV a chronic and manageable health 
condition and rendering infected individuals aviraemic (Cohen et al., 2011, 
Rodger et al., 2016). The increased susceptibility of HIV-infected individuals 
to Invasive pneumococcal disease (IPD) despite Antiretroviral therapy (ART) 
(Glennie et al., 2011, Micheloud et al., 2012) and with reported vaccine 
failures (Willocks et al., 1995, Begemann and Policar, 2001, Rives Ferreiro et 
al., 2008) warrants an investigation into the cellular mechanisms that put 
HIV-infected individuals at increased risk of disease compared to the general 
uninfected population.  
 
Cellular targets of HIV include CD4+ T cells, dendritic cells, monocytes and 
macrophages, astrocytes and renal epithelial cells.  Viral proteins interact 
with cellular membrane proteins: viral envelope protein gp120 recognizes 
and binds the CD4 receptor and chemokine co-receptors (CCR5 or CXCR4), 
facilitating exposure of gp41 on the viral envelope and its fusion to the cell 
membrane. The viral RNA genome and enzymes are then released into the 
host cell. Once inside, the RNA reverse transcribes and integrates into the 
host genome, as a proviral region. After transcription, cleavage and 
assembly of new viral polypeptides, a new virus is released from the cell as a 
mature viral particle (Wilen et al., 2012, Maartens et al., 2014). 
 
The CD4+ and CD8+ T-cells, and B-cells of HIV-infected individuals undergo 
polyclonal hyperactivation and increased apoptosis (activation-induced cell 
death) (Meyaard et al., 1992, Appay and Sauce, 2008, Day et al., 2006, 
Nicholas et al., 2013) likely stimulated by HIV proteins (Moir and Fauci, 
2009). Interestingly this hyperactivation of CD4+ T-cells is unaccompanied 
by increased proliferation (Gougeon and Montagnier, 1993). Polyclonal 
activators induce apoptosis in CD4+ and CD8+ T-cells even in asymptomatic 
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HIV-infected individuals (Gougeon and Montagnier, 1993, Groux et al., 
1992). Hyperactivation induces increased expression of the Apoptosis 
antigen-1 (APO-1) death receptor (CD95) on CD4+ T-cells (Bohler et al., 
1997) and the inhibitory receptor PD-1 on B-cells (Nicholas et al., 2013) 
leading to B-cell exhaustion (Moir and Fauci, 2009). HIV-induced B-cell 
polyclonal activation also leads to hypergammaglobulinemia, elevated levels 
of immunoglobulins in serum (Lane et al., 1983, Mizuma et al., 1988, Shirai 
et al., 1992). A landmark in disease progression is the rapid decline in both 
CD4+ and CD8+ T-cell populations, which is an indication of homeostasis 
failure, (Margolick et al., 1995) together with persistent hyperactivation and 
apoptosis (Hazenberg et al., 2000, Hazenberg et al., 2003, Appay and 
Sauce, 2008, Samuelsson et al., 1997a). This immune activation persists 
even with the use of Combination Antiretroviral Therapy (cART) and is likely 
due to microbial translocation across the gastrointestinal tract (Klatt et al., 
2013).  
 
Thus, HIV-infection causes impairment of both cellular (Okoye and Picker, 
2013) and humoral immunity (Samuelsson et al., 1997a, Samuelsson et al., 
1997b). HIV-1 infection further induces terminal differentiation of B-cells (in 
blood and Gut-Associated Lymphoid Tissue- GALT) (Levesque et al., 2009). 
Levesque and colleagues found that even in patients as early as 17 days 
post-HIV-1 infection, GALT memory B-cells produced HIV-1 specific 
antibodies in addition to autoreactive and influenza-specific antibodies. 
These results indicate polyclonal activation even in acute HIV-1 infection. 
 
Additionally in acute HIV-1 infection a cytokine storm occurs with elevated 
levels of IL-15 and IFNα, then TNF, IL-18 and IL-10 (McMichael et al., 2010). 
HIV-1 is also characterized by depletion of the CD4+ and CD8+ T-cell naive 
subsets (Roederer et al., 1995, Connors et al., 1997). While mature CD4+ T-
cells also get depleted and lead to disease progression (Hazenberg et al., 
2000, Cloyd et al., 2001, Fauci, 1993), there is an expansion of CD8+ T-cells 
compared to uninfected populations (Sachsenberg et al., 1998, Margolick et 
al., 1993). This decline in CD4+ T-cells is followed by replacement with newly 
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generated CD4+ T-cells, and eventually net replacement by CD8+ T-cells 
(Margolick et al., 1993).  
 
HIV-1 affects pulmonary innate immunity by impairing the phagocytic 
function and proteolytic activity of alveolar macrophages (Jambo et al., 
2014). This together with T- and B-cell immunity in HIV, has implications in 
pneumococcal disease susceptibility particularly as pneumococcal carriage 
significantly increases IL-17A-secreting CD4+ memory T-cells in the lung, 
which can enhance the killing of pneumococci by alveolar macrophages 
(Wright et al., 2013). Indeed, HIV-infected individuals show impaired 
bronchoalveolar lavage (BAL) CD4+ T-cell responses to Influenza virus- 
and M. tuberculosis. These in vitro results presented as lower total antigen-
specific CD4+ T cells and of poly-functional IFN-γ and TNF-α-secreting cells 
in HIV-infected individuals (Jambo et al., 2011).  
 
Some of these immune impairments are controlled by the use of ART, which 
also slows and reverses disease progression (Moir et al., 2008b). ART has 
been reported to resolve hypergammaglobulinemia, and reduce circulating 
immunoglobulin (Ig)G antibody-secreting cell (ASC) frequencies in both 
acute and chronic infections, whilst suppressing HIV-1 replication (Morris et 
al., 1998). ART initiation also reconstitutes absolute lymphocyte and CD4+ T-
cell counts, with reduced apoptosis in CD4+ and CD8+ T-cells even in 
viraemic patients (Bohler et al., 1997, Autran et al., 1997). Further, Art also 
dampens T-cell hyperactivation (Autran et al., 1997). Moreover, the ART-
mediated decrease of HIV viraemia has also been shown to elicit 
normalisation of certain B-cell activation markers (Moir and Fauci, 2009) 
particularly CD80 and CD86 (Malaspina et al., 2003) and increases B-cell 
counts (Moir et al., 2008b). ART also effectively inhibits viral replication to a 
large extent (Martinez-Picado and Deeks, 2016).  
 
However, even in the Highly Active Antiretroviral Therapy (HAART) era, HIV-
infected individuals are still at risk of lower respiratory tract infections. 
Patients are up to 35-fold more likely to develop IPD than their uninfected 
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counterparts (Heffernan et al., 2005, Westerink et al., 2012). Therefore 
improving pneumococcal vaccine efficacy in the context of HIV is imperative.  
 
Firstly, AIDS patients show reduced antibody levels to pneumococcal 
polysaccharide antigens before and after immunisation, compared to controls 
(Ammann et al., 1984). However in the context of HIV, HIV-specific IgA 
responses at mucosal sites are low (Moir and Fauci, 2009). There are also 
reported defects in IgM memory B-cells in HIV-1 infection (D'Orsogna et al., 
2007, Hart et al., 2007, Titanji et al., 2005) with the percentage of marginal 
zone B-cells remaining unrestored by ART.  IgM memory B-cell depletion in 
untreated HIV patients may increase their risk of pneumococcal infection 
(D’Orsogna et al., 2007). Furthermore, PPV23 responses (both IgM and IgG 
levels) in HIV-1 patients are impaired (Hart et al., 2007) with one study even 
showing that most vaccine non-responders were those on HAART 
(Tsachouridou et al., 2015). Moreover, in a cohort of HAART-naive HIV-
infected patients who had no history of pneumococcal disease or having 
received pneumococcal vaccination, no defective mucosal responses to 
pneumococcal antigens were found in BAL fluid or serum samples. In fact, 
the pneumolysin-  and PspA-specific IgG levels were significantly higher in 
patients compared to matched controls (p < 0.0001), with comparable levels 
for pneumolysin-  and PspA-specific IgA in BAL (Collins et al., 2013). As a 
result, Collins and colleagues concluded that an increase in anti-
pneumococcal IgG levels induced by vaccination would likely not be 
sufficient to prevent disease development in HIV patients. Indeed, a meta-
analysis of 19 studies found that seroprotection conferred by vaccine-
induced antibodies wanes more quickly in HIV patients (Kerneis et al., 2014). 
Specifically with pneumococcal vaccines, low CD4 counts at time of 
vaccination and failure to suppress virus were two factors contributing to 
poor response (Hung et al., 2010). 
 
PCV7 was however found to protect HIV-infected individuals who have 
recovered from a past episode of IPD, from vaccine serotypes or serotype 
6A (French et al., 2010). While one or two doses of PCV7 can elicit 
protective responses in HIV-treated individuals, two doses will likely be more 
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robust in areas with less cART coverage (Cheng et al., 2016). Another study 
showed that post-PCV7, HAART-naive HIV-infected Malawian adults showed 
serum and lung pneumococcal capsule-specific IgG responses (based on 
serum and BAL measurements). Further, this study concluded that 
circulating IgG had been transferred to the fluid lining the lung. Additionally, 
IgG did not correlate with CD4 counts (Gordon et al., 2007). These studies 
imply greater protection conferred by the conjugate vaccine.  
 
There is still much to be understood regarding the host-pathogen interactions 
and immune responses thereafter which render patients at risk to 
opportunistic infections and in the context of the present study particularly, 
pneumococcal disease. It is therefore imperative that while current research 
investigates mechanisms by which HIV reservoirs can be depleted, 
concurrent studies also investigate how HIV influences disease susceptibility 
at the level of T- and B-cell responses and cognate interactions.  
 
In light of our group uncovering subtle immune defects in previous sufferers 
of IPD with no known vaccination history (Darton et al., 2011), in adult MenC 
sufferers (Foster et al., 2009) and adolescent MenC vaccine failures (Foster 
et al., 2010), data presented in this chapter sought to uncover a defect in an 
HIV cohort with known predisposition to IPD (Glennie et al., 2011). 
 
Therefore, data gathered and presented in this chapter had two aims: The 
first was to investigate any in vitro differences in the proliferation and 
activation responses of HIV-infected CD4+ and CD8+ T-cells upon CD3-
stimulation; next, the responses of these T-cell populations in the presence 
of TI-type 2 stimulated B-cells. Thus, in vitro T-cell function alone, and 
cognate interactions with B-cells, in an HIV-infected cohort compared to 
matched HIV-negative controls. And as outlined in chapter three, the 
matching of HIV-infected individuals to HIV-negative controls was stringently 
regulated to minimize age-, sex- and ethnicity-based variations.  
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The second aim was to uncover in vitro differences in the proliferation and 
activation of the overall CD19+ B-cell population alone and with T-cell help, 
between the HIV-infected cohort and matched controls. Even subtle 
differences observed could contribute to an explanation for the higher 
predisposition to pneumococcal disease observed in this 
immunocompromised patient group and reported in the literature.  
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4.2  Methods 
 
4.2.1 Expansion of the stimulation assay 
 
The stimulation assay using αδdex mimics capsular polysaccharides by 
cross-linking B-cell receptors on all B-cells which express surface IgD 
(Pecanha et al., 1991).  This polyclonal stimulation has been used 
extensively by our group as a model for total B-cell stimulation. The inclusion 
of S. pneumoniae would target only a small population of cells that have 
already experienced class-switching due to previous exposure to capsular 
polysaccharide. The assay was expanded to include S. pneumoniae-
stimulation in order to investigate differences in antigen-specific responses 
between patients and controls, bearing in mind that differences in in vivo 
exposure to S. pneumoniae would have to be considered when interpreting 
results. Also, that the effect of pneumococcal-specific stimulation was likely 
to be minimal compared to polyclonal stimulation. 
 
In optimisation experiments, using live bacteria (MOI of 5 and 10) killed the 
entire culture of lymphocytes even as little as 24 hr after incubation. Thus 
using live bacteria for the 96 hr time point required for the assay would have 
been impractical. Following replication of the T- and B-cell immunologic 
assay using the same concentration of anti-CD3, anti-CD28 and αδdex as 
previously described (Foster et al., 2009, Darton et al., 2011), heat-killed S. 
pneumoniae D39 strain (HKD39) at an optimized multiplicity of infection 
(MOI; fig. 4.1) was included as a stimulant. In theory, heat-killing the bacteria 
should have no effect on the recognition of the bacterial capsular 
polysaccharide by the B-cells.  Further, antigen presentation of the bacteria 
to T-cells should proceed as normal. 
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Figure 4.1: Proliferation (A) and activation (B) of CD19+ B-cells after in 
vitro stimulation using four different concentrations of heat-killed S. 
pneumoniae D39 strain (HKD39). The Kruskal-Wallis H test was used to 
study variances, with post-hoc Bonferroni correction for multiple 
comparisons. (n = 5). 
 
A 
B 
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A multiplicity of infection (MOI) of 10 (Gordon et al., 2000) was chosen for 
use in further stimulation assays. It is noteworthy that the Gordon study used 
live bacteria, whilst the present study proceeded with heat-killed bacteria. 
Thus, it was expected that stimulations in the present study would occur to a 
different extent than if live bacteria was used.  
 
Once the MOI of 10 was chosen, statistical analysis was performed to study 
differences in responses of B-cells following αδdex and HKD39 stimulations 
(fig 4.2). 
                
A 
* *** 
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Figure 4.2: Frequency (A) and activation (B) of CD19+ B-cells after in 
vitro stimulation using 1μg/ml of αδdex and MOI 10 of HKD39. The 
Kruskal-Wallis H test was used to study variances with p values adjusted by 
Bonferroni correction (n = 12; study group described in table 3.2); (Where * p 
≤ 0.050, ** p ≤ 0.010, *** p ≤ 0.001).  
 
As expected, the αδdex activation response elicited by cross-linking of 
multiple B-cell receptors was significantly higher than the response to 
HKD39-stimulation from the small antigen-specific population (p ≤ 0.050; 
(Pecanha et al., 1991)). 
 
 
 
 
 
 
 
 
 
 
 
B ** * 
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4.2.2 Recruitment of patients and controls 
 
HIV-infected individuals were recruited from HIV clinics based at the 
Department of Infection and Tropical Medicine and Department of 
Genitourinary Medicine at the STH NHS Foundation Trust as described in 
chapter two (section 2.1). Age-, sex- and ethnicity-matched controls were 
recruited from amongst the staff of the Sheffield Medical School and the 
Royal Hallamshire Hospital (RHH). After informed consent was obtained, 
blood was drawn and PBMCs were cultured using aseptic technique. The 
stimulation assay was performed as described in chapter two (section 2.4 
and 2.5). The three cell populations of interest in this chapter, CD4+ T-cells 
and CD19+ B-cells, are shown in representative dot plots in fig. 2.3 (chapter 
two).  
 
Fig. 4.3 and table 4.1 outline the workflow used during patient recruitment 
and in vitro work, respectively, for this portion of the study.  
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Figure 4.3: Workflow for patient recruitment during this project (A). Of 
41 patients who initially indicated interest in participating in this project, 17 
were consented, and 16 were bled (B). All these patients were on Highly 
Active Antiretroviral Therapy (HAART), described in table 4.1. 
 
 
 
Clinical 
visits: first 
contact with 
patients
Follow up 
phone calls: 
booking in 
visits
Consenting 
process and 
phlebotomy
Maintenance 
of NHS site 
file
39% 
HIV cohort (n = 16) 
5 days – 13 months 
 
A 
B 
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Table 4.1: Antiretroviral therapy (ART) drug classifications from the US 
Department of Health and Human Services (2017)(AIDSInfo, 2017)  
Table 4.3 
classification 
Drug 
classification 
ART drug Mechanism of function 
A Combination HIV 
medicine 
Kivexa: 
Abacavir (Nucleoside Reverse 
Transcriptase Inhibitor; NRTI) and 
Lamivudine (NRTI) 
Combined functions of 
component classes. 
 
 
Pharmacokinetic 
enhancers increase HIV 
medicine effectiveness 
by interfering with drug 
breakdown. 
 
 
Rezolsta: 
Darunavir (Protease Inhibitor; PI) 
and Cobicistat (Pharmacokinetic 
enhancer) 
Atripla: 
Efavirenz (Non-Nucleoside 
Reverse Transcriptase Inhibitor; 
NNRTI), 
Emtricitabine (NRTI) and Tonofovir 
disoproxil fumarate (NRTI) 
Descovy: 
Emtricitabine (NRTI) and Tenofovir 
alafenamide (NRTI) 
Truvada: 
Emtricitabine (NRTI) and Tenofovir 
disoproxil fumarate (NRTI) 
Triumeq: 
Abacavir (NRTI), 
Dolutegravir (Integrase Inhibitor; 
II), and Lamuvidine (NRTI) 
B Non-Nucleoside 
Reverse 
Transcriptase 
Inhibitor (NNRTI) 
Efavirenz, Etravirine Alters viral reverse 
transcriptase enzyme 
after binding to it. 
C Protease Inhibitor 
(PI) 
Darunavir, 
Ritonavir, 
Atazanavir 
Prevents HIV replication 
by blocking HIV 
protease enzyme. 
D Integrase Inhibitor 
(II) 
Dolutegravir, 
Raltegravir 
Prevents HIV replication 
by blocking HIV 
integrase enzyme. 
E Nucleoside 
Reverse 
Transcriptase 
Inhibitor (NRTI) 
Zidovudine Prevents HIV replication 
by blocking HIV reverse 
transcriptase enzyme. 
F Entry Inhibitor Maraviroc Inhibits viral entry by 
binding to CD4+ T-cell 
CCR5 coreceptor.  
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Table 4.2: Brief description of the workflow and outcome measures for 
results presented in chapter four 
Aim Work Flow Outcome measures Results 
presented in 
figure*: 
HIV+ cohort 
number 
Investigate 
differences 
in T- and B-
cell 
responses 
between 
HIV-infected 
individuals 
and matched 
controls, 
based on 
our group 
immunologic 
assay 
CD4+ T-cell responses to 
TCR-stimulant; anti-CD3 
alone, and in combination 
with αδdex, and αδdex + 
anti-CD28 respectively. 
CD4+ T-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD25 
and HLA-DR expression).  
4.4 – 4.7 16 (except for 
HLA-DR, 
where n = 8) 
CD8+ T-cell responses to 
TCR-stimulant; anti-CD3 
alone, and in combination 
with αδdex, and αδdex + 
anti-CD28 respectively. 
CD8+ T-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD25 
and HLA-DR expression).  
4.8 – 4.11 16 (except for 
HLA-DR, 
where n = 8) 
CD19+ B-cell responses to 
anti-IgD-stimulation using 
αδdex alone, and in 
combination with anti-CD3, 
and anti-CD3 + anti-CD28 
respectively. 
CD19+ B-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD86, 
CD25 and HLA-DR 
expression). 
4.12 – 4.16 16 (except for 
HLA-DR, 
where n = 8) 
Investigate 
differences 
in T- and B-
cell 
responses 
between 
HIV-infected 
individuals 
and matched 
controls,  
based on the 
expanded 
immunologic 
assay 
including S. 
pneumoniae-
stimulation 
CD4+ T-cell responses to 
D39 strain of S. pneumoniae 
alone, and in combination 
with anti-CD3, and anti-CD3 
+ anti-CD28 respectively.  
CD4+ T-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD25 
and HLA-DR expression).  
4.4 – 4.7 8 
CD8+ T-cell responses to 
D39 strain of S. pneumoniae 
alone, and in combination 
with anti-CD3, and anti-CD3 
+ anti-CD28 respectively.  
CD8+ T-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD25 
and HLA-DR expression).  
4.8 – 4.11 8 
CD19+ B-cell responses to 
D39 strain of S. pneumoniae 
alone, and in combination 
with anti-CD3, and anti-CD3 
+ anti-CD28 respectively. 
CD19+ B-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD86, 
CD25 and HLA-DR 
expression). 
4.12 – 4.16 8 
  * All data was collected by Furaha Asani. 
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4.3  Results 
 
4.3.1 Characteristics of patient recruits and matched controls 
 
Table 4.2 outlines the patient and control characteristics, while table 4.3 
shows the current ART regimes used by each patient. 
 
Table 4.3: Characteristics of the HIV-infected cohort recruited for this 
study, with matched controls 
 HIV+  HIV- controls 
Number  16 16 
Mean age (Range)  50.45 (40 – 61) 50.65 (35 – 65) 
Sex: Female 
         Male  
2 
14 
2 
14 
Ethnicity: Black  
                  White  
2 
14  
2 
14 
Mean CD4 count (/mm3) (Range) 677.63 (359 – 921) N/A 
Mean total globulin levels (g/L) 
(Range) * 
27.38 (23 – 37) N/A 
*The normal range of total globulin in HIV-uninfected individuals 
visiting the Royal Hallamshire Hospital (RHH) is 18 – 36 g/L, 
indicating that this cohort of HIV-infected individuals fell within the 
normal range of total globulin levels expected at RHH. 
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Table 4.4: Clinical characteristics of the HIV-infected individuals who 
participated in this study. Information for some individuals was unavailable 
from records due to transferring from other hospitals or countries onto the 
Sheffield Teaching Hospitals (STH) database. 
Patient Age at 
bleed 
Sex 
* 
Ethnicity° CD4 
Count 
(/mm3) 
Total 
globulin 
count 
(g/L) 
Time post 
starting 
ART (years) 
Pre-
ART 
viral 
load 
(cp/ml) 
 † 
Current 
ART regime 
ª 
Time post 
last viral 
detection 
(years) 
1 55 M W 706 29 14 D Kivexa (A), 
Efavirenz 
(B) 
6 
2 50 M W 869 23 13 69,700 Etravirine 
(B), 
Darunavir 
(C), 
Ritonavir 
(C), 
Dolutegravir 
(D) 
N/A 
3 53 M W 359 29 20 D Zidovudine 
(E), 
Truvada (A) 
3 
4 43 M W 895 31 18 D Triumeq (A) 8 
5 40 F B 529 37 6 N/A Dolutegravir 
(D), 
Maraviroc 
(F) 
4 
6 42 M W 695 24 17 D Kivexa (A), 
Maraviroc 
(F) 
8 
7 50 F B 494 28 11 6630 Triumeq (A) 9 
8 61 M W 361 27 19 D Truvada (A), 
Dolutegravir 
(D) 
N/A 
9 42 M W 655 24 N/A 10,600 Rezolsta (A) N/A 
10 40 M W 793 26 7 38,071 Atripla (A) N/A 
11 52 M W 458 26 6 59,406 Descovy (A), 
Efavirenz 
(B) 
N/A 
12 59 M W 787 29 5 34,666 Truvada (A), 
Atazanavir 
(C), 
Ritonavir (C) 
5 
13 54 M W 631 28 8 N/A Triumeq (A) 1 
14 52 M W 921 28 6 43,318 Etravirine 
(B) 
4 
15 58 M W 691 26 11 30,100 Truvada (A), 
Raltegravir 
(D) 
N/A 
16 53 M W 827 26 8 122,431 Ritonavir 
(C), 
Atazanavir 
(C), 
Truvada (A) 
< 6 
months 
*Classification of sex by female (F) or male (M). 
°Classification of ethnicity by Black (B) or White (W). 
 † Records for some individuals merely stated ‘Detected’ regarding pre-ART 
viral load. This is represented as ‘D’ in the table. Notably, these five 
individuals had been diagnosed in the late nineties, or early two-thousands. 
ª ART classifications were expatiated upon in table 4.1. 
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Using the one-sample Kolmogorov-Smirnov test, some datasets presented in 
figures 4.4 to 4.16 were ascertained to contain both parametric and non-
parametric datasets. Thus the paired-samples t-test and the Wilcoxon signed 
ranks test were respectively used for statistical analyses of these data.  Pair-
wise comparisons between HIV-infected individuals and age-, sex- and 
ethnicity-matched HIV-negative controls were conducted. The p values 
shown are two-tailed, testing for differences in both directions. Paired data 
are presented as spot-line graphs not only to show differences between HIV-
infected individuals and matched controls, but inter-pair variations. Shaded 
circles represent one individual, with a line connecting matched patient- 
control pairs. The graph grid is organised to facilitate comparisons across 
rows, and down columns. (Patient n = 16 except for HKD39-stimulations, 
where patient n = 8). Each graph grid is accompanied by line graphs tracking 
patient cohort and control cohort responses separately, to facilitate 
visualisation of how individuals responded to the different stimulation 
conditions. 
 
Stimulation concentrations used were as described in chapter 2: 1μg/ml of 
αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 
0.5μg/ml anti-CD28 for 96 hr. HKD39 MOI used was 10, for 96 hr. 
Stimulation conditions are indicated per graph. 
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4.3.2 Variations in CD4+ T-cell responses to the stimulation assay, 
between HIV-infected individuals and matched controls 
 
CD4+ T-cell frequency percentages were higher in HIV-uninfected controls 
compared to patients (fig. 4.4i) but were comparable after all stimulations 
except for anti-CD3 combined with anti-CD28 (fig. 4.4i C) and αδdex (fig. 4.4i 
D). 
 
Figure 4.4i: Percentage frequencies of in vitro CD4+ T-cells in HIV-
infected individuals and matched controls under un-stimulated and 
stimulated conditions. Dots and lines match each patient-control pair. The 
paired-samples t-test and Wilcoxon signed ranks test were used for 
parametric and non-parametric datasets respectively. (Patient n = 16 except 
for HKD39-stimulations, where patient n = 8; Where * p ≤ 0.050). 
* 
* 
* 
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Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 
alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28. 
Patient cohort and control cohort tracking data for this graph grid is 
presented in fig. 4.4ii. 
                      
Figure 4.4ii: Tracking data showing the changes in in vitro CD4+ T-cell 
frequencies in HIV-infected individuals (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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The HIV-uninfected controls also had higher in vitro CD4+ T-cell proliferation 
under un-stimulated conditions (fig. 4.5i). 
 
Figure 4.5i: Proliferation of in vitro CD4+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 16 except for HKD39-
stimulations, where patient n = 8; Where * p ≤ 0.050). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 4.5ii. 
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Figure 4.5ii: Tracking data showing the changes in in vitro CD4+ T-cell 
proliferation in HIV-infected individuals (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
 
Differences in activation of CD4+ T-cells between patients and controls were 
determined by quantifying in vitro expression of CD25 (fig. 4.6i) and HLA-DR 
(fig. 4.7i). 
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Figure 4.6i: CD25 expression on in vitro CD4+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 16 except for HKD39-
stimulations, where patient n = 8; Where * p ≤ 0.050). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 4.6ii. 
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Figure 4.6ii: Tracking data showing the changes in in vitro CD4+ T-cell 
CD25 expression in HIV-infected individuals (A) and matched controls 
(B) upon stimulation. Matched patient-control pairs are represented using 
the same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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Figure 4.7i: HLA-DR expression on in vitro CD4+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 16 except for HKD39-
stimulations, where patient n = 8; Where * p ≤ 0.050). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 4.7ii. 
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Figure 4.7ii: Tracking data showing the changes in in vitro CD4+ T-cell 
HLA-DR expression in HIV-infected individuals (A) and matched 
controls (B) upon stimulation. Matched patient-control pairs are 
represented using the same colour across A and B. Conditions: 1; Un-
stimulated, 2; CD3-stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-
stimulated, 5; (αδdex +CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 
7; HKD39-stimulated, 8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-
stimulated. 
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4.3.3 CD3-stimulated hyperactivation in the CD8+ T-cells of HIV-infected 
individuals compared to matched controls 
 
Differences in CD8+ T-cell responses between patients and controls were 
investigated next. Percentage frequencies were analysed (fig. 4.8i), before 
proliferation (fig. 4.9i) and activation responses (fig. 4.10i and 4.11i). 
 
 
Figure 4.8i: Percentage frequencies of in vitro CD8+ T-cells in HIV-
infected individuals and matched controls under un-stimulated and 
stimulated conditions. Dots and lines match each patient-control pair. The 
paired-samples t-test and Wilcoxon signed ranks test were used for 
parametric and non-parametric datasets respectively. (Patient n = 16 except 
for HKD39-stimulations, where patient n = 8; Where * p ≤ 0.050; ** p ≤ 
0.010). Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-
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CD3 alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28. 
Patient cohort and control cohort tracking data for this graph grid is 
presented in fig. 4.8ii. 
                      
Figure 4.8ii: Tracking data showing the changes in in vitro CD8+ T-cell 
frequencies in HIV-infected individuals (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
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+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
 
CD8+ T-cell yielded mostly comparable responses between patients and 
controls (fig. 4.9i). 
Figure 4.9i: Proliferation of in vitro CD8+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 16 except for HKD39-
stimulations, where patient n = 8; Where * p ≤ 0.050). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 4.9ii. 
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Figure 4.9ii: Tracking data showing the changes in in vitro CD8+ T-cell 
proliferation in HIV-infected individuals (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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Activation responses in CD8+ T-cells were determined by quantifying CD25 
(fig. 4.10i) and HLA-DR (fig. 4.11i) expression. 
 
Figure 4.10i: CD25 expression on in vitro CD8+ T-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 16 except for HKD39-
stimulations, where patient n = 8; Where * p ≤ 0.050; *** p ≤ 0.001). 
Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 
alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28. 
Patient cohort and control cohort tracking data for this graph grid is 
presented in fig. 4.10ii. 
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Figure 4.10ii: Tracking data showing the changes in in vitro CD8+ T-cell 
CD25 expression in HIV-infected individuals (A) and matched controls 
(B) upon stimulation. Matched patient-control pairs are represented using 
the same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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Figure 4.11i: HLA-DR expression on in vitro CD8+ T-cells in HIV-
infected individuals and matched controls under un-stimulated and 
stimulated conditions. Dots and lines match each patient-control pair. The 
paired-samples t-test and Wilcoxon signed ranks test were used for 
parametric and non-parametric datasets respectively. (Patient n = 16 except 
for HKD39-stimulations, where patient n = 8; Where * p ≤ 0.050). 
Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 
alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28. 
Patient cohort and control cohort tracking data for this graph grid is 
presented in fig. 4.11ii. 
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Figure 4.11ii: Tracking data showing the changes in in vitro CD8+ T-cell 
HLA-DR expression in HIV-infected individuals (A) and matched 
controls (B) upon stimulation. Matched patient-control pairs are 
represented using the same colour across A and B. Conditions: 1; Un-
stimulated, 2; CD3-stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-
stimulated, 5; (αδdex +CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 
7; HKD39-stimulated, 8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-
stimulated. 
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4.3.4 Increased proliferation in the CD19+ B-cells of HIV-infected 
individuals compared to matched controls after T-cell-helped 
pneumococcal-stimulation 
 
The percentage frequency of in vitro CD19+ B-cells, and differences between 
patients and controls was analysed (fig. 4.12i). Thereafter, differences in 
CD19+ B-cell proliferation (fig. 4.13i). 
 
Figure 4.12i: Percentage frequencies of in vitro CD19+ B-cells in HIV-
infected individuals and matched controls under un-stimulated and 
stimulated conditions.  Dots and lines match each patient-control pair. The 
paired-samples t-test and Wilcoxon signed ranks test were used for 
parametric and non-parametric datasets respectively. (Patient n = 16 except 
for HKD39-stimulations, where patient n = 8). Concentrations of stimulants 
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used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in 
combination with 0.5μg/ml anti-CD28. Patient cohort and control cohort 
tracking data for this graph grid is presented in fig. 4.12ii. 
                     
Figure 4.12ii: Tracking data showing the changes in in vitro CD19+ B-
cell frequencies in HIV-infected individuals (A) and matched controls 
(B) upon stimulation. Matched patient-control pairs are represented using 
the same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
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+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
 
 
Figure 4.13i: Proliferation of in vitro CD19+ B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 16 except for HKD39-
stimulations, where patient n = 8; Where * p ≤ 0.050). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 4.13ii. 
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Figure 4.13ii: Tracking data showing the changes in in vitro CD19+ B-
cell proliferation in HIV-infected individuals (A) and matched controls 
(B) upon stimulation. Matched patient-control pairs are represented using 
the same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
 
Activation of CD19+ B-cells was determined by quantifying CD86 (fig. 4.14i), 
CD25 (fig. 4.15i), and HLA-DR (fig. 4.16i) expression. 
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Figure 4.14i: CD86 expression on in vitro CD19+ B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 16 except for HKD39-
stimulations, where patient n = 8). Concentrations of stimulants used: 1μg/ml 
of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination 
with 0.5μg/ml anti-CD28. Patient cohort and control cohort tracking data for 
this graph grid is presented in fig. 4.14ii. 
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Figure 4.14ii: Tracking data showing the changes in in vitro CD19+ B-
cell CD86 expression in HIV-infected individuals (A) and matched 
controls (B) upon stimulation. Matched patient-control pairs are 
represented using the same colour across A and B. Conditions: 1; Un-
stimulated, 2; CD3-stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-
stimulated, 5; (αδdex +CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 
7; HKD39-stimulated, 8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-
stimulated. 
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Figure 4.15i: CD25 expression on in vitro CD19+ B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 16 except for HKD39-
stimulations, where patient n = 8; Where * p ≤ 0.050). The significance seen 
in the un-stimulated control conditions (A) was likely due to the single outlier 
in the control group. Concentrations of stimulants used: 1μg/ml of αδdex, 
0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 
0.5μg/ml anti-CD28. Patient cohort and control cohort tracking data for this 
graph grid is presented in fig. 4.15ii. 
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Figure 4.15ii: Tracking data showing the changes in in vitro CD19+ B-
cell CD25 expression in HIV-infected individuals (A) and matched 
controls (B) upon stimulation. Matched patient-control pairs are 
represented using the same colour across A and B. Conditions: 1; Un-
stimulated, 2; CD3-stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-
stimulated, 5; (αδdex +CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 
7; HKD39-stimulated, 8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-
stimulated. 
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Fig 4.16i: HLA-DR expression on in vitro CD19+ B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 16 except for HKD39-
stimulations, where patient n = 8; Where * p ≤ 0.050). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 4.16ii. 
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Figure 4.16ii: Tracking data showing the changes in in vitro CD19+ B-
cell HLA-DR expression in HIV-infected individuals (A) and matched 
controls (B) upon stimulation. Matched patient-control pairs are 
represented using the same colour across A and B. Conditions: 1; Un-
stimulated, 2; CD3-stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-
stimulated, 5; (αδdex +CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 
7; HKD39-stimulated, 8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-
stimulated. 
 
CHAPTER FOUR 
145 
 
4.4  Discussion of Findings 
 
4.4.1 Clinical characteristics of patient recruits 
 
T- and B-cell in vitro responses to polyclonal and pneumococcal stimulation 
were studied in a cohort of 16 HIV-infected individuals with a mean age, CD4 
count and total globulin count of 50.45, 677.63 /mm3 and 27.38 g/L 
respectively (table 4.2). Responses investigated were confined to CD4+ and 
CD8+ T-cell, and CD19+ B-cell populations. Furthermore, these responses 
were compared to age-, sex- and ethnicity-matched HIV-uninfected controls, 
who were also matched to the patients in terms of date of bleed. 
 
Except for one individual who had a viral detection blip within six months of 
participating in the study (patient 16; table 4.3), most of the patients had 
been virally-suppressed for a number of years. Thus, these individuals fell 
within the study inclusion criteria and had given consent prior to and on the 
day of bleeding. Most of the patient cohort comprised White males, while 
there were two Black females. 
 
4.4.2 CD4+ T-cell responses in HIV-infected individuals compared to 
matched controls 
 
CD4+ T-cells are known to be suppressed in HIV patients and CD8+ to be 
expanded (Margolick et al., 1993), and CD19+ B-cells to be hyperactivated 
(Moir and Fauci, 2009) with perturbations of B-cell subsets (Moir and Fauci, 
2013). This knowledge necessitated a study into any differences in the 
percentage frequencies at which these cell populations occurred between 
the patients and controls. Only after this could the proliferation and activation 
responses of the T- and B-cells be analysed. 
 
The percentage frequency of un-stimulated CD4+ T-cells in patients was 
significantly lower compared to controls (p ≤ 0.050; fig. 4.4i A). Interestingly, 
while CD3-stimulation did not yield different responses between patients and 
controls (fig. 4.4i B), the addition of costimulatory anti-CD28 induced a higher 
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CD4+ T-cell percentage frequency in controls (p ≤ 0.050; fig. 4.4i C). Another 
finding was that while αδdex-stimulation itself has no effect on CD4+ T-cell 
frequency, proliferation, or activation (chapter three: fig. 3.2 and 3.3), the 
controls had significantly higher CD4+ T-cell percentage frequency in the 
presence of αδdex, compared to patients (p ≤ 0.050; fig. 4.4i D). Stimulation 
with HKD39 alone, and further with CD3 and CD28 (fig. 4.4i G, H, I) yielded 
comparable responses within the cohort. These results suggested that 
interpretation of any differences in CD4+ T-cell proliferation and activation 
responses for the un-stimulated, CD3- and CD28-costimulated and αδdex-
stimulated conditions between patients and controls would have to be carried 
out with caution. 
 
Indeed, un-stimulated and αδdex-stimulated CD4+ T-cell proliferation was 
significantly higher in controls compared to patients (both p ≤ 0.050; fig. 4.5i 
D). As such a clear conclusion cannot be drawn as to whether this higher 
response was due to stimulation or merely due to the higher percentage of 
CD4+ T-cells present in controls in vitro. Further, the significantly higher 
CD4+ T-cell proliferation seen upon αδdex and CD3-stimulation (p ≤ 0.050; 
fig. 4.4i E) was likely due to the single outlier control response. 
 
CD3-stimulated hyperactivation (in terms of CD25 expression) has been 
shown in vitro in CD4+ T-cells of viraemic HIV-infected individuals off ART, 
with a weak negative correlation of CD25 expression to viral load (p = 0.056; 
Nicholas et al., 2013). While the patients in this study were virally-
suppressed and on ART, they showed in vitro hyperactivation in CD4+ T-
cells upon CD3-stimulation, in terms of up-regulated CD25 expression 
compared to controls (p ≤ 0.050; fig. 4.6i B). Further, patients also had 
increased HLA-DR expression upon stimulation with αδdex alone (p ≤ 0.050; 
fig. 4.7i D) and in combination with anti-CD3 (p ≤ 0.050; fig. 4.6i E). These 
results suggest that in line with what is known about HIV patients having 
increased T-cell hyperactivation and exhaustion phenotypes (Haas et al., 
2011, Okoye and Picker, 2013, Mauricio Rueda et al., 2012, Ott et al., 1997), 
in vitro hyperactivation still occurs in patients on HAART. Haas and 
colleagues (2011) already concluded that viral replication cannot be the sole 
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controller of T-cell hyperactivation in HIV patients. Indeed, results from this 
cohort of virally-suppressed individuals echo this conclusion. 
 
4.4.3 CD8+ T-cell responses in HIV-infected individuals compared to 
matched controls 
 
Patients had higher frequencies of CD8+ T-cells elicited by CD3-stimulation 
alone (p ≤ 0.050; fig. 4.8i B), combined with CD28-costimulation (p ≤ 0.010; 
fig. 4.8i C), and further with HKD39 (p ≤ 0.050; fig. 4.8i I). Similar to the case 
with CD4+ T-cells (fig. 4.5i D), proliferation in CD8+ T-cells following αδdex-
stimulation was significantly lower in patients compared to controls (p ≤ 
0.050; fig. 4.9i D). Proliferation following all other stimulations elicited 
comparable responses within the cohort (fig. 4.9i). The patients showed a 
strong hyperactivation response in CD8+ T-cells following stimulation with 
anti-CD3 alone (p ≤ 0.001; fig. 4.10i B), combined with anti-CD28 (p ≤ 0.050; 
fig. 4.10i C), and combined with HKD39 (p ≤ 0.050; fig. 4.10i H). This 
hyperactivation also extended to CD8+ T-cell expression of HLA-DR in the 
patients compared to controls. Patients had higher levels of CD8+ HLA-DR 
expression upon stimulation with anti-CD3 alone (p ≤ 0.050; fig. 4.11i B), 
combined with αδdex and CD28-costimulation (p ≤ 0.050; fig. 4.11i F), and 
combined with HKD39 (p ≤ 0.050; fig. 4.11i H).  
 
The in vitro hyperactivation response in the patient CD8+ T-cells upon 
stimulation with anti-CD3 and HKD39 is noteworthy especially in light of the 
lack of a similar response to αδdex alone or combined with anti-CD3 for 
CD25 expression (fig. 4.10i D and E). Both αδdex and HKD39 are antigens 
recognised by the B-cell receptor (BCR). In the case of the former, polyclonal 
recognition ensures that the entire population of B-cells should be activated 
in a TI-type 2 manner by the polysaccharide antigen mimic. With the latter, 
only a specific population of class-switched B-cells with prior exposure to the 
S. pneumoniae capsular proteins would mount a response. Consequently, 
the stimulation conditions comprising both anti-CD3 and HKD39 showcase 
cognate interactions between the MHC class II molecule on the antigen-
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presenting B-cell (Obukhanych and Nussenzweig, 2006), and the T-cell 
receptor (TCR) on the CD8+ T-cell thus, T-dependent antigen recognition. A 
limitation to the interpretation of these results is the absence of data detailing 
Streptococcal colonisation in the study cohort. Such data could have 
illuminated whether this HKD39-dependent in vitro hyperactivation in patient 
CD8+ T-cells was a true response, or merely as a coincidental result of the 
controls not being previously exposed to S. pneumoniae. Especially in light 
of adults having S. pneumoniae carriage rates of 3 – 4% (Mehr and Wood, 
2012). Another factor confounding result interpretation is that the HKD39 
stimulations in this study may not have been optimal. However, HKD39 on its 
own did not induce upregulation of either CD8+ T-cell CD25 or HLA-DR 
expression in a healthy study group (data not shown). It is thus likely that the 
HKD39-dependent results obtained from the patient group are indeed 
indicative of a true hyperactivation response. 
 
The in vitro infection of human peripheral blood lymphocytes and stimulation 
of T-cell CD3 and CD28 receptors has been shown to lead to increased 
production of IL-2, of which the CD25 molecule is a receptor (Ott et al., 
1997). Therefore, uncovering hyperactivation in CD4+ and CD8+ T-cell 
populations of HIV-infected individuals upon in vitro stimulation of CD3 and 
CD28 echo what has already been shown. The significance of these results 
is that hyperactivation persists in vitro, even with ART usage. Of greater 
interest in the present study were any differences within the in vitro CD19+ 
B-cell population in the patient cohort. 
 
4.4.4 CD19+ B-cell responses in HIV-infected individuals compared to 
matched controls 
 
The initial hypothesis of this study sought to uncover a defect primarily in the 
CD19+ B-cell responses in patients, compared to controls. Specifically, a 
hyperactivation response in B-cells of patients following IgD-stimulation using 
the polyclonal antigen mimic, αδdex, was expected. Finding such a defect 
may, in part, provide some explanation as to why even in the era of HAART 
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HIV-infected individuals still have a 35-fold increased relative risk of 
succumbing to IPD compared to their healthy counterparts (Heffernan et al., 
2005). 
 
Studying CD19+ B-cells after in vitro stimulation revealed comparable 
frequencies between patients and controls (fig. 4.12i). In terms of 
proliferation, only after stimulation with a combination of anti-CD3, anti-CD28 
and HKD39 did patients show a significantly higher response compared to 
controls (p ≤ 0.050; fig. 4.13i I). Activation in terms of CD86 (fig. 4.14i) and 
CD25 expression (fig. 4.15i) expression was also comparable within the 
cohort except for a seemingly higher CD25 expression response in controls 
under un-stimulated conditions (fig. 4.15i A). This was however likely due to 
a single control outlier response. Results in fig. 3.6 show that anti-CD3 
significantly upregulates HLA-DR expression in CD19+ B cells of healthy 
individuals (p ≤ 0.010; fig. 3.6). The present study also revealed a CD3-
induced increase in in vitro HLA-DR expression in patients compared to 
controls (p ≤ 0.050; fig. 4.16i B). 
 
Because B-cell perturbations occur in HIV patients (Moir and Fauci, 2013), 
and αδdex-stimulation did not induce any hyper- or hypo-responsiveness in 
the overall CD19+ B-cell population in the patient group, we sought to 
determine if such polyclonal defects could be uncovered within B-cell 
subsets. 
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4.5  Conclusion 
 
CD3-stimulated in vitro hyperactivation was shown in the CD4+ and CD8+ T-
cells in HIV-infected individuals, indicating persistent in vitro hyperactivation 
even with ART usage. HKD39, in the presence of anti-CD3, also induced a 
hyperactivation response in the CD8+ T-cells of patients most likely due to 
increased cognate interactions with CD19+ B-cells. This was concluded 
because CD8+ T-cells themselves remain unaffected by HKD39 and further, 
the HKD39 did not stimulate hyperactivation in the CD19+ B-cells of patients. 
However, an increased proliferation response in patient CD19+ B-cells was 
uncovered upon stimulation with HKD39 in the presence of CD3-stimulation 
and CD28-costimulation of T-cells. In conclusion, hyperactivation responses 
to TCR and pneumococcal stimulation were uncovered in the T- and B-cells 
of a virally-suppressed cohort of 16 HIV-infected individuals with at least few 
years of ART-usage. 
 
Because preliminary findings at the start of this project suggested αδdex-
induced variation in B-cell responses between the HIV-infected individuals 
and the controls, CD19+ B-cell subsets which could potentially be 
responsible for these variations were investigated. 
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5.1  Introduction 
 
Ongoing HIV replication induces immune activation which, early on in the 
disease, drives perturbations of all major lymphocyte cell populations. Most 
of the knowledge gained about these dysregulations has been from 
peripheral blood. A focus on B-cell subsets could inform the development of 
an antibody-based HIV vaccine (Moir and Fauci, 2013). In the context of the 
present study, investigating B-cell subsets could provide some clues as to 
how the HIV-infected humoral immune response can be boosted specifically 
against pneumococcal disease. 
 
B-cell subset perturbations in HIV are likely the cause for the ineffective 
antibody response to the virus and other antigens (Moir and Fauci, 2009). 
Additionally, these perturbations are not the result of new or different B-cell 
subsets in HIV, but rather an imbalance in B-cell subsets that would be 
present in healthy individuals of all ages to varying degrees (Moir and Fauci, 
2013). These B-cell subsets are classed according to their encounters with 
antigen. Consequently, of all CD19+ B-cells, those that are CD10+ are 
immature/transitional. Furthermore, within the CD19+CD10- population, five 
subsets can be identified: Plasmablasts (PB), Activated-Memory (AM), 
Resting Memory (RM), naive, and Tissue-Like Memory (TLM) B-cells based 
on expression of CD20, CD21 and CD27 (Moir and Fauci, 2013). 
 
The PB population is increased in HIV-viraemic patients (Moir and Fauci, 
2013). HIV-viraemic patients also show premature exhaustion in the TLM 
subset (CD27negCD20hiCD21lo) compared to aviraemic patients and HIV-
uninfected controls (Moir et al., 2008a). These TLMs from the peripheral 
blood of viraemic individuals expressed increased levels of Fc-receptor-like-4 
(FCRL4). The FCRL4 protein is a putative inhibitory receptor with an 
unknown ligand, whose over-expression on tissue-like and classical memory 
B-cells in blood uniquely features in HIV infection. Moir et al (2008) further 
showed this FCRL4 to be increased on TLMs, compared to classical memory 
(CD27+) and naive B-cells (CD27negCD21hi). In spite of specific B-cell 
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stimulus, the TLMs of viraemic individuals proliferated poorly in vitro (Moir et 
al., 2008). 
 
The frequency distribution of these B-cell subsets has also been studied in 
the context of the HIV timeline: early and chronic infection, pre- and post-
ART. Uninfected controls had higher baseline peripheral B-cell counts 
compared to early and chronic HIV-infected patients. ART usage increased 
B-cell counts in both patient groups (as is the case with CD4+ but not CD8+ 
T-cells (Moir et al., 2010)). With regards to the B-cell subset compartments 
present in each stage, early stage patients had higher baseline plasmablasts 
and resting memory B-cells compared to chronically-infected patients. 
Additionally, the chronic patients had higher levels of exhausted and 
immature/transitional B-cells. One year post-ART, the ‘early’ patients still had 
higher resting memory percentages compared to the chronic patients, 
indicating the necessity for an early ART initiation (Moir et al., 2010). Another 
study found a normalisation of B-cell subsets in 43 asymptomatic HAART-
treated HIV patients (Fogli et al., 2012). Both these studies highlight that 
even within a cohort of HIV-infected individuals, B-cell subset compartments 
differ based on ART-usage. 
 
An aberrant response due to B-cell perturbations in HIV patients is 
hyperactivation (Nicholas et al., 2013), resulting in over-expression of 
activation markers and hypergammaglobulinemia (De Milito, 2004). B-cells 
from HIV-infected samples are also primed for apoptosis (De Milito, 2004). 
Increased apoptosis in samples from HIV patients has also been reported 
when compared to controls (Samuelsson et al., 1997a, Samuelsson et al., 
1997b), with memory B-cells of patients expressing increased Fas/Fas ligand 
(De Milito et al., 2001), Samuelsson et al., 1997b) and PD-1 (Nicholas et al., 
2013). This study aimed not only to investigate potential hyperactivation in 
the B-cell subsets of the HIV-infected patient cohort, but also increased 
expression of apoptosis markers. 
 
At the start of this project a flow cytometry panel was optimised to investigate 
the five CD19+CD10- B-cell subsets described by Moir and Fauci (2013) to 
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uncover which of the B-cell subsets in the HIV-infected cohort may be 
associated with aberrant responses to a polyclonal stimulus and/or 
pneumococci. Using CD10, CD20, CD21 and CD27 (Moir and Fauci, 2013, 
Wheatley et al., 2016) and a caspase probe, in addition to the optimised flow 
cytometry panel presented in chapter 2, B-cell subsets in the cohort were 
studied. 
 
Therefore, data gathered and presented in this chapter had three aims: The 
first was to investigate any in vitro effects of culture on the frequency 
distribution and activation of B-cell subsets. Secondly, to quantify any in vitro 
differences in the proliferation and activation responses of HIV-infected B-cell 
subsets to the αδdex TI-type 2 antigen mimic and pneumococcal stimulation 
(with and without T-cell help), compared to age-, sex- and ethnicity-matched 
controls. Finally, to investigate differences in apoptosis levels between the 
patients and controls. Subsequently the decision was made to utilize a pan-
caspase probe capable of detecting caspases-1, -2, -3, -6, -8, -9, and -10.  
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5.2  Methods 
 
The HIV-infected cohort described in chapter four (sections 4.2.2 and 4.3) 
were used to study CD19+ B-cell subset responses to polyclonal and 
pneumococcal stimulation, compared to age-, sex- and ethnicity-matched 
controls. Clinical characteristics of this cohort were described in table 4.2. 
Table 5.1 outlines the workflow used for this portion of the study. 
 
Table 5.1: Brief description of the workflow and outcome measures for 
results presented in chapter five.  
Aim Cell populations of 
interest and stimulations 
Outcome measures Results 
presented 
in †: 
Study 
group 
number 
Investigate the effects of 
culture and stimulation 
on the frequency 
distribution and 
activation of B-cell 
subsets in a healthy 
group. 
Baseline and un-
stimulated CD19+ B-cell 
subset responses, 
compared to responses 
after anti-IgD-stimulation 
using αδdex alone, and in 
combination with anti-
CD3. 
CD19+ B-cell frequency, 
and activation based on 
CD86 expression. 
Tables 5.2 – 
5.3 
4 
Investigate differences 
in HIV-infected and HIV-
uninfected B-cell subset  
responses to polyclonal 
and pneumococcal 
stimulationl using 
αδdex- and S. 
pneumoniae-stimulation 
respectively. 
CD19+ B-cell responses to 
αδdex and heat-killed D39 
strain of S. pneumoniae 
(HKD39) both alone, and 
in combination with anti-
CD3, and anti-CD3 + anti-
CD28 respectively. 
CD19+CD10- B-cell 
subset frequency, 
proliferation (based on 
CFSE median 
fluorescence intensity; 
MFI*), and activation 
(based on CD86 
expression). 
Fig. 5.3 – 
5.10 
Patient n = 12 
(except for 
HKD39-
stimulation, 
2here n = 8) 
Investigate differential 
apoptosis levels 
between patients and 
controls after polyclonal 
stimulation. 
CD19+ B-cell responses to 
αδdex, compared to the 
un-stimulated control. 
CD19+CD10- B-cell 
subset caspase+ 
frequency. 
Fig. 5.11 Patient n = 5 
*Due to a lower number of events per B-cell subset quadrant, the decision was made to quantify CFSE MFI rather 
than use proliferation index. Our group had previously ascertained that using CFSE MFI to describe the proliferation 
within a population of low cell count provided more accurate data than using proliferation index (data not shown). 
CFSE intensity is inversely proportional to proliferation (Evrard et al., 2010) due to undivided cell populations 
retaining the dye, and dye splitting evenly between proliferating cells (Lyons and Parish, 1994). 
† All data was collected by Furaha Asani. 
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The cell populations of interest in this chapter were CD19+CD10- B-cell 
subsets namely: Plasmablasts (PB), Activated memory cells (AM), Resting 
memory cells (RM), Naive cells, and Tissue-like memory cells (TLM) 
described in fig. 5.1. 
 
                                        
                        
 
Figure 5.1: Gating strategy to separate B-cell subsets.  Q1 comprises 
Plasmablasts (PB) and Activated Memory cells (AM), Q2; Resting Memory 
cells (RM), Q3; Naive B-cells, and Q4: Tissue-Like Memory cells (TLM) (A) 
(Moir and Fauci, 2013). The Q1 compartment was separated into PB and AM 
subsets using the CD20 marker (B). Thus, the Q1 compartment was always 
analysed prior to separating it into PB and AM populations. As indicated by 
the gates, PBs are CD27hiCD21loCD20lo while AMs are CD27intCD21loCD20hi 
(Moir and Fauci, 2013; Wheatley et al, 2016). Technical support in selecting 
PB and AM gates was provided by the Flow Cytometry Core Facility within 
the Sheffield Medical School.  
 
 
A 
 
B 
CD27 
 CD20 
 
CD27 
 CD21 
PB + 
AM 
TLM 
RM 
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Q1 
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B 
C 
After gating on the 
populations of interest 
and quantifying 
proliferation and 
activation levels based on 
CFSE MFI and CD86 
expression (chapter two; 
sections 2.4 and 2.7.3 
respectively), Caspase 
detection was conducted 
by gating on Caspase-
positive cells (fig. 5.2). 
 
Figure 5.2: Gating 
strategy showing a 
CD19+CD10-Caspase+ 
population in a 20% 
ethonal-treated 
apoptosis positive 
control (B) and an un-
stimulated control (C), 
relative to an unstained 
control (A). 
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5.3  Results 
 
5.3.1 The effect of culture and stimulation on CD19+CD10- B-cell subset 
compartments 
 
Prior to investigating differential B-cell subset responses between patients 
and controls, the effect culture and stimulation had on B-cell subsets from 
healthy controls was investigated. The inclusion of anti-CD3 and anti-CD28 
to αδdex in one condition served the purpose of quantifying T-cell help to B-
cell subsets (in addition to T-cell and B-cell proliferation/activation 
separately) (Foster et al., 2009, Foster et al., 2010, Darton et al., 2011, Wing 
et al., 2012, Preciado-Llanes et al., 2014). 
 
The frequency distribution and CD86 expression levels were compared 
across four healthy individuals, for baseline (cells extracted from whole blood 
then processed through the flow cytometry protocol ex vivo; chapter two, on 
the same day), un-stimulated and stimulated conditions (both at 96 hr).  
 
Stimulation concentrations used were as described in chapter 2: 1μg/ml of 
αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 
0.5μg/ml anti-CD28 for 96 hr. HKD39 MOI used was 10, for 96 hr. 
Stimulation conditions are indicated per figure on top of each graph. 
 
Using the one-sample Kolmogorov-Smirnov test, some datasets presented in 
tables 5.2 and 5.3 were ascertained to contain both parametric and non-
parametric datasets. Thus the paired-samples t-test and the Wilcoxon signed 
ranks test were respectively used for statistical analyses of these data. 
Comparisons were made between the ex vivo baseline and the 96 hr un-
stimulated condition per individual (table 5.2), as well as the un-stimulated 
versus stimulated conditions (αδdex alone and with CD3-stimulated T-cell 
help) (table 5.3) per individual. The Q1 quadrant was analysed as a single 
population (fig. 5.1) before being analysed as its constituent B-cell subsets: 
plasmablasts (PB) and activated memory cells (AM).  
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Table 5.2: The effect of culture on the frequency distribution of B-cell 
subsets (n = 4). A 96 hr period of culture significantly reduced the frequency 
distribution of resting memory B-cells (p = 0.008). The frequency distribution 
of the rest of the B-cell subsets were unaffected by culture. Baseline and 96 
hr un-stimulated conditions were paired per individual. 
 
 B-cell subsets Baseline 
Mean 
(Range) 
96 hr un-
stimulated Mean 
(Range) 
p  
value 
Frequency 
distribution (%) 
Q1 compartment 
(Plasmablasts + Activated 
Memory cells) 
9.35 (2.53 – 
18.8) 
21.7 (1.27 – 47) 0.465 
Plasmablasts 0.093 (0 – 
0.37) 
0.82 (0.05 – 2.13) 0.273 
Activated Memory  84.93 (67.1 – 
98.7) 
40.52 (6.96 – 
73.8) 
0.068 
Resting Memory 56.93 (46.2 – 
72.3) 
19.44 (2.58 – 
37.7) 
0.008* 
Naive 27.83 (12.8 – 
43.4) 
30.5 (0.5 – 63) 0.923 
Tissue-like Memory 5.9 (3.04 – 
10.2) 
28.4 (2.88 – 56.6) 0.465 
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Table 5.3: The effect of stimulation on the frequency distribution of, and 
CD86 expression on, B-cell subsets (n = 4). Stimulation with αδdex 
significantly up-regulated CD86 expression in resting memory B-cells only. 
The 96 hr un-stimulated and stimulated conditions were paired per individual. 
 B-cell subsets Un-stimulated 
Mean (Range) 
αδdex-
stimulated 
Mean 
(Range) 
p  
value 
(αδdex + 
anti-CD3)- 
stimulated 
Mean 
(Range) 
p  
value 
Frequency 
distribution 
(%) 
Q1 
compartment 
(Plasmablasts 
+ Activated 
Memory cells) 
21.7 (1.27 – 
47) 
29.1 (1.85 
– 56.5) 
0.068 25.71 (1.33 
– 51.7) 
0.068 
Plasmablasts 0.82 (0.05 – 
2.13) 
0.1 (0.05 – 
2.13) 
0.715 1.23 (0 – 
4.05) 
0.465 
Activated 
Memory  
40.52 (6.96 – 
73.8) 
34.65 (29.2 
– 37) 
0.465 29.2 (18.2 
– 37.6) 
0.465 
Resting 
Memory 
19.44 (2.58 – 
37.7) 
39.2 (9.09 
– 71.1) 
0.074 36.5 (11.2 
– 69.2) 
0.081 
Naive 30.5 (0.5 – 63) 14.67 (2.47 
– 32.2) 
0.212 19.5 (3.76 
– 41.8) 
0.309 
Tissue-like 
Memory 
28.4 (2.88 – 
56.6) 
17.02 (1.78 
– 34.7) 
0.068 18.31 (1.37 
– 38.3) 
0.068 
CD86 
expression 
(MFI) 
Q1 
compartment 
(Plasmablasts 
+ Activated 
Memory cells) 
75.83 (-109 – 
274) 
2269 (1250 
– 4265) 
0.067 1981 (851 
– 3700) 
0.062 
Plasmablasts 140.15 (90.6 – 
196) 
225.6 (0 – 
877) 
0.715 412.33 (0 – 
1407) 
1 
Activated 
Memory  
208 (19.3 – 
399) 
2693.25 
(873 – 
6192) 
0.068 2186.25 
(841 – 
3605) 
0.068 
Resting 
Memory 
653 (471 – 
784) 
1713.5 
(1130 – 
2267) 
0.022* 2995.5 
(1558 – 
5133) 
0.064 
Naive 316.5 (111 – 
580) 
1857.5 
(1298 – 
2568) 
0.068 4634.5 
(2245 – 
8949) 
0.068 
Tissue-like 
Memory 
-62.4 (-110 – 
20) 
2893.25 
(1029 – 
6706) 
0.068 5112.75 
(2439 – 
11700) 
0.068 
 
 
Frequency distribution of the B-cell subsets remained unaffected by 
stimulation, compared to the 96 hr un-stimulated condition (table 5.3). This 
indicates that the frequency of most of the B-cell subsets remain constant 
across the stimulation conditions used in this portion of the project. 
Additionally, neither frequency distribution nor CD86 expression significantly 
CHAPTER FIVE 
161 
 
differed for any B-cell subsets between αδdex-stimulation alone, and with T-
cell help. 
 
Furthermore, the frequency distribution trend of B-cell subsets in the study 
group comprising HIV-infected individuals and matched controls (table 4.2) 
were compared to those in representative HIV-viraemic and HIV-negative 
individuals studied ex vivo by Moir and Fauci (2013). These comparisons are 
presented in table 5.4. 
 
Table 5.4: Comparison of B-cell subset frequency distribution trends 
between the present study and Moir and Fauci’s study (2013) 
Increasing 
frequency 
One HIV-
viraemic 
individual 
(Moir and 
Fauci, 2013)  
% frequency 
(Moir and 
Fauci, 2013)* 
Mean from 12 
ART-
controlled 
HIV-infected 
individuals 
(Present 
study)  
% frequency 
in present 
study° 
 TLM  34 TLM 62.45 
Naive 34 Naive 27 
PB + AM 21 PB + AM 5.6 
RM 11 RM 5 
Increasing 
frequency 
One HIV-
negative 
individual 
(Moir and 
Fauci, 2013)  
% frequency 
(Moir and 
Fauci, 2013)* 
Mean from 12 
HIV-
uninfected 
individuals 
(Present 
study) 
% frequency 
in present 
study° 
 Naive 66 TLM 62 
RM 28 Naive 24.9 
PB + AM 3.4 PB + AM 6.7 
TLM 2.6 RM 6.3 
*Studies carried out ex vivo. 
°Studies carried out 96 hr post-culture. 
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Differences in the frequency distribution seen between the Moir and Fauci 
study and the present study (table 5.4) are likely due to: 1. The different 
timeline at which cells were harvested (baseline versus 96 hr post-culture); 2. 
Only one individual per patient and control group being investigated in the 
Moir and Fauci study, versus 12 per group in the present study, and; 3. The 
patient being viraemic in the Moir and Fauci study, versus the cohort in the 
present study being ART-controlled and virally suppressed. 
 
5.3.2 Differences in B-cell subsets between HIV-infected individuals and 
matched controls after polyclonal and pneumococcal stimulation 
 
Using the one-sample Kolmogorov-Smirnov test, some datasets presented in 
figures 5.3 to 5.11 were ascertained to contain both parametric and non-
parametric datasets. Thus the paired-samples t-test and the Wilcoxon signed 
ranks test were respectively used for statistical analyses of these data.  Pair-
wise comparisons between HIV-infected individuals and age-, sex- and 
ethnicity-matched HIV-negative controls were conducted. The p values 
shown are two-tailed, testing for differences in both directions. Paired data 
are presented as spot-line graphs not only to show differences between HIV-
infected individuals and matched controls, but inter-pair variations. Shaded 
circles represent one individual, with a line connecting matched patient- 
control pairs. The graph grid is organised to facilitate comparisons across 
rows and down columns, with the un-stimulated condition presented first. 
(Patient n = 12 except for HKD39-stimulations, where patient n = 8 and 
Caspase detection, where patient n = 5). Each graph grid is accompanied by 
line graphs tracking patient cohort and control cohort responses separately, 
to facilitate visualisation of how individuals responded to the different 
stimulation conditions. 
 
The proliferation (CFSE MFI) of the Q1 compartment comprising 
plasmablasts (PB) and activated memory cells (AM) was investigated (fig. 
5.3i). 
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Figure 5.3i: Proliferation of in vitro Plasmablasts and Activated Memory 
B-cells in HIV-infected individuals and matched controls under un-
stimulated and stimulated conditions.  Dots and lines match each patient-
control pair. The paired-samples t-test and Wilcoxon signed ranks test were 
used for parametric and non-parametric datasets respectively. (Patient n = 
12 except for HKD39-stimulations, where patient n = 5). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 5.3ii. 
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Figure 5.3ii: Tracking data showing the changes in in vitro Plasmablast 
and Activated Memory B-cell proliferation in HIV-infected individuals 
(A) and matched controls (B) upon stimulation. Matched patient-control 
pairs are represented using the same colour across A and B. Conditions: 1; 
Un-stimulated, 2; CD3-stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-
stimulated, 5; (αδdex +CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 
7; HKD39-stimulated, 8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-
stimulated. 
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CD86 expression on the B-cell subsets within the Q1 compartment was 
investigated next, revealing differences between the patients and controls 
(fig. 5.4i). 
 
 
Figure 5.4i: CD86 expression on in vitro Plasmablasts and Activated 
Memory B-cells in HIV-infected individuals and matched controls under 
un-stimulated and stimulated conditions.   Dots and lines match each 
patient-control pair. The paired-samples t-test and Wilcoxon signed ranks 
test were used for parametric and non-parametric datasets respectively. 
(Patient n = 12 except for HKD39-stimulations, where patient n = 5; Where * 
p ≤ 0.050). Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml 
anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-
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CD28. Patient cohort and control cohort tracking data for this graph grid is 
presented in fig. 5.4ii. 
 
                  
Figure 5.4ii: Tracking data showing the changes in in vitro Plasmablast 
and Activated Memory B-cell CD86 expression in HIV-infected 
individuals (A) and matched controls (B) upon stimulation. Matched 
patient-control pairs are represented using the same colour across A and B. 
Conditions: 1; Un-stimulated, 2; CD3-stimulated, 3; (CD3+CD28)-stimulated, 
4; αδdex-stimulated, 5; (αδdex +CD3)-stimulated, 6; (αδdex +CD3+CD28)-
stimulated, 7; HKD39-stimulated, 8; (HKD39+CD3)-stimulated, 9; 
(CD3+CD28+HKD39)-stimulated. 
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In order to ascertain which of the two populations (PB or AM) was 
responsible for the higher in vitro activation responses uncovered in patients 
in the Q1 compartment, PBs and AMs were separated based on the CD20 
marker (fig. 5.1 B). PBs were analysed first for proliferation (fig. 5.5i). 
 
Figure 5.5i: Proliferation of in vitro Plasmablasts in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions.  Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 12 except for HKD39-
stimulations, where patient n = 5). Concentrations of stimulants used: 1μg/ml 
of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination 
with 0.5μg/ml anti-CD28. Patient cohort and control cohort tracking data for 
this graph grid is presented in fig. 5.5ii. 
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Figure 5.5ii: Tracking data showing the changes in in vitro Plasmablast 
proliferation in HIV-infected individuals (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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However, αδdex-stimulation of the PB B-cell subset uncovered greater 
activation in PB B-cells from HIV-infected patients  (fig. 5.6i).  
 
 
Figure 5.6i: CD86 expression on in vitro in HIV-infected individuals and 
matched controls under un-stimulated and stimulated conditions.  Thus 
the PB subset was most likely responsible for the hyperactivation signal seen 
in the Q1 compartment comprising PBs and AMs, in fig. 5.9i D. Dots and 
lines match each patient-control pair. The paired-samples t-test and 
Wilcoxon signed ranks test were used for parametric and non-parametric 
datasets respectively. (Patient n = 12 except for HKD39-stimulations, where 
patient n = 5; Where * p ≤ 0.050). Concentrations of stimulants used: 1μg/ml 
of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination 
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with 0.5μg/ml anti-CD28. Patient cohort and control cohort tracking data for 
this graph grid is presented in fig. 5.6ii. 
                     
 
Figure 5.6ii: Tracking data showing the changes in in vitro Plasmablast 
CD86 expression in HIV-infected individuals (A) and matched controls 
(B) upon stimulation. Matched patient-control pairs are represented using 
the same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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The AM subset was investigated next, and no significant differences were 
found between patients and controls in terms of proliferation (fig. 5.7i). 
 
 
 
Figure 5.7i: Proliferation of in vitro Activated Memory B-cells in HIV-
infected individuals and matched controls under un-stimulated and 
stimulated conditions.   Dots and lines match each patient-control pair. The 
paired-samples t-test and Wilcoxon signed ranks test were used for 
parametric and non-parametric datasets respectively. (Patient n = 12 except 
for HKD39-stimulations, where patient n = 5). Concentrations of stimulants 
used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in 
combination with 0.5μg/ml anti-CD28. Patient cohort and control cohort 
tracking data for this graph grid is presented in fig. 5.7ii. 
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Figure 5.7ii: Tracking data showing the changes in in vitro Activated 
Memory B-cell proliferation in HIV-infected individuals (A) and matched 
controls (B) upon stimulation. Matched patient-control pairs are 
represented using the same colour across A and B. Conditions: 1; Un-
stimulated, 2; CD3-stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-
stimulated, 5; (αδdex +CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 
7; HKD39-stimulated, 8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-
stimulated. 
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Investigating CD86 expression revealed that the AM subset in patients (fig. 
5.8i) was responsible for the un-stimulated hyperactivation response seen in 
the Q1 compartment (fig. 5.4i). 
 
 
Figure 5.8i: CD86 expression on in vitro Activated Memory B-cells in 
HIV-infected individuals and matched controls under un-stimulated and 
stimulated conditions.  Further, activated memory cells were determined to 
be the subset giving off the higher activation signal in the un-stimulated 
condition (A) seen in patients in the Q1 compartment (fig. 5.9i). Dots and 
lines match each patient-control pair. The paired-samples t-test and 
Wilcoxon signed ranks test were used for parametric and non-parametric 
datasets respectively. (Patient n = 12 except for HKD39-stimulations, where 
patient n = 5; Where * p ≤ 0.050). Concentrations of stimulants used: 1μg/ml 
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of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination 
with 0.5μg/ml anti-CD28. Patient cohort and control cohort tracking data for 
this graph grid is presented in fig. 5.8ii. 
                  
Figure 5.8ii: Tracking data showing the changes in in vitro Activated 
Memory B-cell CD86 expression in HIV-infected individuals (A) and 
matched controls (B) upon stimulation. Matched patient-control pairs are 
represented using the same colour across A and B. Conditions: 1; Un-
stimulated, 2; CD3-stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-
stimulated, 5; (αδdex +CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 
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7; HKD39-stimulated, 8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-
stimulated. 
 
No difference was found between patients and controls for proliferation or 
activation of resting memory or tissue-like memory cells (data not shown). 
Further, patients and controls did not significantly differ in the proliferation of 
their naive B-cells (fig. 5.9i).  
 
Figure 5.9i: Proliferation of in vitro Naive B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions.   Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 12 except for HKD39-
stimulations, where patient n = 5). Concentrations of stimulants used: 1μg/ml 
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of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination 
with 0.5μg/ml anti-CD28. Patient cohort and control cohort tracking data for 
this graph grid is presented in fig. 5.9ii. 
                 
Figure 5.9ii: Tracking data showing the changes in in vitro Naive B-cell 
proliferation in HIV-infected individuals (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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CD86 expression on naive B-cells yielded a difference between patients and 
controls upon pneumococcal-stimulation (fig. 5.10i).  
 
 
Figure 5.10i: CD86 expression on in vitro Naive B-cells in HIV-infected 
individuals and matched controls under un-stimulated and stimulated 
conditions.  Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 12 except for HKD39-
stimulations, where patient n = 5; Where * p ≤ 0.050). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 5.10ii. 
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Figure 5.10ii: Tracking data showing the changes in in vitro Naive B-cell 
CD86 expression in HIV-infected individuals (A) and matched controls 
(B) upon stimulation. Matched patient-control pairs are represented using 
the same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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The last phase of B-cell subset analysis involved investigating differences in 
caspase levels between patients and controls (fig. 5.11i). 
 
 
 
 
 
           
  
 
 
  
 
Figure 5.11i: Percentage frequencies of caspase positive Plasmablasts 
(PB) and Activated Memory (AM) B-cells, AMs alone, and Naïve B-cells 
under un-stimulated and αδdex-stimulated conditions. Neither PBs 
alone, RMs nor TLMs showed any differences in percentage of caspase 
positive cells between patients and controls (data not shown). Dots and lines 
match each patient-control pair. The paired-samples t-test and Wilcoxon 
signed ranks test were used for parametric and non-parametric datasets 
respectively. (Patient n = 5). Concentrations of stimulants used: 1μg/ml of 
αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 
0.5μg/ml anti-CD28. Patient cohort and control cohort tracking data for this 
graph grid is presented in fig. 5.11ii, 5.11iii and 5.11iv. 
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Figure 5.11ii: Tracking data showing the changes in percentage 
frequencies of in vitro caspase positive Plasmablast and Activated 
Memory B-cells in HIV-infected individuals (A) and matched controls 
(B) upon stimulation. Matched patient-control pairs are represented using 
the same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated. 
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Figure 5.11iii: Tracking data showing the changes in percentage 
frequencies of in vitro caspase positive Activated Memory B-cells in 
HIV-infected individuals (A) and matched controls (B) upon stimulation. 
Matched patient-control pairs are represented using the same colour across 
A and B. Conditions: 1; Un-stimulated, 2; CD3-stimulated. 
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Figure 5.11iv: Tracking data showing the changes in percentage 
frequencies of in vitro caspase positive Naive B-cells in HIV-infected 
individuals (A) and matched controls (B) upon stimulation. Matched 
patient-control pairs are represented using the same colour across A and B. 
Conditions: 1; Un-stimulated, 2; CD3-stimulated. 
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5.4  Discussion of Findings 
 
Significantly higher in vitro T-cell-helped pneumococcal-induced proliferation 
was uncovered in the CD19+ B-cell population of eight HIV-infected 
individuals compared to controls (p ≤ 0.050; fig. 4.14i). With no paralleled 
hyperactivation in this overall CD19+ B-cell population after polyclonal and 
pneumococcal stimulation, in terms of CD86 or HLA-DR expression, patient 
responses at the level of B-cell subsets were investigated next. 
 
5.4.1 Culture does not affect B-cell subset distribution 
 
The first aim of this portion of the study was to investigate what effects 
culture and stimulation had on CD19+CD10- B-cell subsets. To achieve this, 
frequency distribution and CD86 expression were quantified in baseline, un-
stimulated and stimulated healthy samples from four individuals (section 
3.3.1). For the five B-cell subsets investigated: plasmablasts (PB), activated 
memory (AM), resting memory (RM), naive, and tissue-like memory (TLM) 
cells, culture only significantly affected the frequency distribution of RM B-
cells (table 5.2); RM B-cell frequency distribution was reduced upon 96 hr 
culture. Stimulation induced up-regulated CD86 expression only in RM B-
cells (table 5.3) as well. These results suggest that most of the B-cell subsets 
remain constant in culture, and post-stimulation. 
 
5.4.2 Subtle defects uncovered in the B-cell subsets of HIV-infected 
individuals 
 
Once the effect of culture and stimulation on healthy B-cell subsets was 
ascertained, differences in subset responses between HIV-infected 
individuals and age-, sex- and ethnicity-matched controls were investigated. 
Results presented show subsets in which differences between patient and 
control responses were uncovered. Therefore, the Q1 quadrant (PBs and 
AMs), PBs and AMs alone, and naive B-cells were presented in section 
3.3.2. 
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Within the Q1 compartment, the patients expressed significantly higher levels 
of CD86 under un-stimulated conditions (p ≤ 0.050; fig. 5.4i A) and further, 
αδdex-induced hyperactivation (p ≤ 0.050; fig. 5.4i B) compared to controls. 
Another noteworthy finding is the lack of hyperactivation in patients following 
pneumococcal-stimulation (fig. 5.4i E) even though αδdex induced 
hyperactivation. This may however be due to the low study numbers for the 
pneumococcal-stimulation (patient n = 5) or due to suboptimal HKD39 
stimulation. Further, T-cell-helped activation did not differ between patients 
and controls (fig. 5.4i C, D, F and G).  
 
Using the CD20 marker, the Q1 compartment was split into PBs and AMs 
(fig. 5.1 B) to investigate which of these B-cell subsets was producing 
differential responses between patients and controls. PBs and AMs are 
increased in HIV-viraemic patients (Moir et al., 2001, Moir et al., 2004, Moir 
and Fauci, 2009, Moir and Fauci, 2013). However, evidence suggests that 
irreversible damage of the immune system can be prevented by early 
initiation of ART (Moir et al., 2010). While data on the time difference 
between diagnosis and ART-initiation in the HIV-infected cohort was not 
accessed, except for one individual with a viral blip less than six months 
before partaking in the study, the cohort comprised aviraemic individuals 
(table 4.3). Supporting ART-control of B-cell subset responses to an extent 
was the proliferation in the patient Q1 compartment (fig. 5.3i) which did not 
significantly differ to that of controls. In addition, whilst PBs (fig. 5.5i) and 
AMs (fig. 5.7i) of patients in this study showed higher proliferation compared 
to controls, this was not statistically significant. Whereas, highly viraemic 
patients show defective B-cell proliferation capabilities (Moir et al., 2001). 
 
While un-stimulated CD86 expression on PBs was also comparable between 
patients and controls (fig. 5.6i), it was the AM subset that expressed higher 
levels of the CD86 activation marker under un-stimulated conditions (p ≤ 
0.050; fig. 5.8i A) seen in the Q1 compartment (fig. 5.4i A). Further, αδdex-
stimulation induced significant hyperactivation in patient PBs compared to 
controls (p ≤ 0.050; fig. 5.6i B) that was seen in the Q1 compartment (fig. 5.4i 
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B). Patient AMs also showed increased CD86 expression upon 
pneumococcal stimulation (p ≤ 0.050; fig. 5.8i E) compared to controls. While 
αδdex-stimulation did not induce significant hyperactivation in the patient  
AMs compared to controls (fig. 5.8i B), the p value obtained (0.094) is 
suggestive of a trend.  Further, adding T-cell help to both PBs (fig. 5.6i C and 
D) and AMs (fig. 5.8i F and G) resulted in the disappearance of 
hyperactivation responses in the patients. AMs in viraemic patients express 
increased levels of the apoptosis marker CD95 (Moir and Fauci, 2013), and 
increased expression of apoptosis markers in HIV has been associated with 
B-cell hyperactivation (Nicholas et al., 2013). Therefore the polyclonal- and 
pneumococcal-stimulated hyperactivation uncovered in the patient cohort 
may be indicative of a subtle defect in the HIV patient Q1 compartment, 
comprising PBs and AMs, despite ART-usage. 
 
Resting memory cells (RMs) found to be depleted in HIV-viraemic individuals 
(Moir and Fauci, 2013), showed comparable in vitro proliferation and 
activation between patients and controls, as did tissue-like memory cells 
(data not shown). Other than a decrease in frequency in HIV-viraemic 
patients (Moir et al., 2008a, Moir et al., 2008b, Moir and Fauci, 2008), the 
naive B-cell compartment has had few abnormalities reported in the context 
of HIV (Moir and Fauci, 2013). Hence, it was interesting to find that in vitro 
stimulation with HKD39 resulted in significantly higher CD86 expression in 
the naive cells of controls compared to patients (p ≤ 0.010; fig. 5.10i E). 
However, proliferation responses (fig. 5.9i) between the naive B-cells of 
patients and controls yielded no significant differences.  
 
The last phase of the B-cell subset investigation involved quantifying levels 
of caspases-1, -2, -3, -6, -8, -9 and -10. Because B-cell apoptosis marker 
expression is increased in HIV (Samuelsson et al., 1997a, Samuelsson et al., 
1997b, De Milito et al., 2001, Nicholas et al., 2013), it was hypothesized that 
an over-expression of caspases would be found in the HIV-infected cohort. 
However, with this portion of the study only being conducted on five patients, 
results needed to be interpreted with caution. And while three of the 
compartments presented (Q1: PBs and AMs, AMs alone and naive B-cells) 
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had higher un-stimulated and αδdex-stimulated caspase in at least three 
individuals (fig. 5.11i), this was not statistically significant. Extending this 
caspase-detection portion of the study to include more numbers would make 
conclusions drawn more robust. Especially in light of the initial findings of our 
group which showed statistical power of the αδdex-based immunologic assay 
requiring a minimum study number of 10 (Darton et al. 2011). 
 
5.4  Conclusion 
 
The overall CD19+ B-cell population studied was separated into B-cell 
subsets based on the CD10, CD20, CD21 and CD27 markers. These 
populations comprised mature B-cells, most of which were memory cells. 
Gating into four quadrants based on FMO controls and a well-established 
gating strategy (Moir and Fauci, 2013) resulted in subsets of Plasmablasts 
(PB), Activated Memory (AM), Resting Memory (RM), Naive, and Tissue-Like 
Memory (TLM) B-cells.   
 
Culture was shown to have no impact on the in vitro frequency distribution of 
B-cell subsets investigated in a healthy group of four individuals. Data 
presented in this study show αδdex-induced hyperactivation in patient PBs, 
and pneumococcal-induced hyperactivation in patient AMs. This could 
represent a subtle defect in these B-cell subsets, in spite of ART-usage.  
 
Lastly, in hypothesizing an increased level of apoptosis in patient B-cell 
subsets, a pan-caspase probe was incorporated into the study. Only five 
patient samples (with matched controls) were used for this phase of the 
study. No significant differences were found between the patients and 
controls in terms of caspase levels. This could be indicative of ART-control to 
an extent within this patient cohort, or simply a need for increased study 
numbers. 
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6.1  Introduction 
 
The association of IPD with underlying disease, particularly in the context of 
compromised immunity, extends to solid tumours, malignancies, and 
hematologic malignancies (Fukusumi et al., 2017, Kyaw et al., 2005). The 
present study was interested in investigating the role in vitro B-cell responses 
(with and without T-cell help) play in predisposing myeloma patients to 
pneumococcal disease. Particularly because aberrant B-cell expansion 
underpins haematologic malignancies. And these malignancies exist on a 
progressive spectrum, such that Monoclonal Gammopathy of Undetermined 
Significance (MGUS) may or may not progress to malignancies (Kyle, 1978, 
Kyle et al., 2003, Kyle et al., 2010, Kyle et al., 2011, Landgren et al., 2009, 
Korde et al., 2011, San Miguel, 2015) including Multiple Myeloma (MM), 
Lymphoproliferative Disorder, AL Amyloidosis, and Waldenstrom’s 
macroglobulinemia (Kyle et al., 2010). 
 
Thus, MGUS is a premalignant condition caused by a disorder in the 
proliferation of plasma cells resulting in the presence of a monoclonal 
immunoglobulin- M-protein (Kyle, 1978, Kyle et al., 2003, Kyle et al., 2010, 
Kyle et al., 2011, Landgren et al., 2009, Korde et al., 2011, San Miguel, 
2015). However, the terminology ‘Monoclonal Gammopathy of Renal 
Significance’ has been proposed for use when the disease pathology shows 
a causal relationship between the monoclonal gammopathy and renal 
damage (Leung et al., 2012). The progression from asymptomatic MGUS 
and smoldering myeloma to symptomatic myeloma (MM) depends upon the 
stability of the quiescent clone (San Miguel, 2015).  
 
The pathogenesis of MM involves myelomatous plasma cells interacting with 
their microenvironment, and genetic lesions. Cytogenic abnormalities have 
been identified in MM patients, many of which dictate drug resistance and 
outcome of the disease (San Miguel, 2015). And even though MGUS often 
precedes MM, it is not known if all MM cases are preceded by MGUS 
(Landgren et al., 2009).  
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In terms of clinically detectable parameters, MGUS is characterised by an M-
protein detection rate below 3 g/dL, less than 10% bone marrow plasma 
cells, no related impairment to other tissues/organs, and no other disorder in 
B-cell proliferation. Advancement to smoldering myeloma involves an 
increase in M-protein levels and bone marrow plasma cells. Finally, MM 
patients have detecatable M-protein in their serum and urine, with related 
impairment of tissues and organs (Kyle et al., 2003, Kyle et al., 2010, Kyle et 
al., 2011, Mateos and Landgren, 2016). 
 
The leading cause of death in myeloma patients is infection (King, 1980), 
with a study conducted in Japan finding that over a two-decade period, 
34.6% of autopsied MM patients had had pneumonia which was the most 
common bacterial infection (Oshima et al., 2001). Already in 1954, recurrent 
bacterial pneumonia was reported in MM patients. Whilst pneumonia 
episodes promptly responded to antibiotic treatment, there were recurrent 
episodes caused by the same organism with one patient having 13 bouts. 
Additionally, the patients in this study showed feeble antibody responses 
following subcutaneous immunisation with pneumococcal polysaccharides. 
(Zinneman and Hall, 1954). This same research group also reported an 
emphasis on pneumonia whilst reviewing the cases of 59 MM patients 
(Glenchur et al., 1959).  
 
And even in the era of pneumococcal vaccines, MM patients still have a 
significantly higher risk (p <0.001) of IPD compared to an adult control 
population. And as some of the reported pneumococcal isolates responsible 
for infection are contained in PPV23 and PCV13, this warrants an expanded 
valency conjugate vaccine for this patient group (Wong et al., 2010). 
Especially as MM patients showed reduced responses to a 14-valent PPV 
compared to healthy controls, and in some cases no protective antibody 
concentration (Lazarus et al., 1980). And in more recent times, elderly MM 
patients still showed suboptimal responses to PPV23 (Karlsson et al., 2013). 
 
The correlation of IPD incidence in patients with chronic illness to advancing 
age (Kyaw et al., 2005) once again highlighted the need for age-matching 
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within the MGUS cohort. In addition, Ethnicity has also been shown to play a 
role in risk of myeloma with a report of a two-fold higher age-adjusted 
incidence of MM in African-Americans compared to White individuals. This 
study conducted by Landgren and colleagues (2006) also suggested that this 
increased MM risk in African-Americans was less likely due to progression of 
MGUS to MM, but rather due to an initial increased risk of MGUS (Landgren 
et al., 2006). Black adults have been reported to have higher IPD incidence 
rates both in a healthy population and in chronically ill cohorts (Kyaw et al., 
2005). These studies highlight an interplay of age, ethnicity and comorbidity 
with IPD, further emphasizing the need for matching of controls to MGUS 
patients in this portion of the study. 
 
Data gathered and presented in this chapter had two aims based upon the 
findings within the HIV-infected cohort (chapter’s four and five): The first was 
to assess the effectiveness of in vitro T- and B-cell responses in an MGUS 
cohort to polyclonal stimulation alone, and cognate interactive help 
thereafter. The second was to use the expanded immunologic assay to study 
in vitro T- and B-cell responses in the MGUS cohort to pneumococcal 
stimulation using heat-killed S. pneumoniae, D39 strain (HKD39). 
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6.2  Methods 
 
Patients with Monoclonal Gammopathy of Undetermined Significance 
(MGUS) were recruited from cohorts under outpatient follow up within the 
Department of Haematology, STH (section 2.1). Age-, sex- and ethnicity-
matched controls were recruited from amongst the staff of the Sheffield 
Medical School and the Royal Hallamshire Hospital (RHH). Over the two 
year-long recruitment within this clinic, of the 10 patients who registered 
interest in participating in this study, five proceeded to donate blood for the 
study. After informed consent was obtained, blood was drawn and PBMCs 
were cultured using aseptic technique. The stimulation assay was performed 
as described in chapter two (section 2.4 and 2.5). The three cell populations 
of interest in this chapter, CD4+ and CD8+ T-cells and CD19+ B-cells, were 
gated according to the strategy outlined in fig. 4.3. Table 6.1 details the 
workflow used for this portion of the study.  
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Table 6.1: Brief description of the workflow and outcome measures for 
results presented in chapter six 
Aim Work Flow Outcome measures Results 
presented in 
figure*: 
MGUS 
cohort 
number 
Investigate 
differences 
in T- and B-
cell 
responses 
between 
MGUS 
patients and 
matched 
controls, 
based on 
our group 
immunologic 
assay. 
CD4+ T-cell responses to 
TCR-stimulant; anti-CD3 
alone, and in combination 
with αδdex, and αδdex + 
anti-CD28 respectively. 
CD4+ T-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD25 
and HLA-DR expression).  
6.1 – 6.4 5 
CD8+ T-cell responses to 
TCR-stimulant; anti-CD3 
alone, and in combination 
with αδdex, and αδdex + 
anti-CD28 respectively. 
CD8+ T-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD25 
and HLA-DR expression).  
6.5 – 6.8 5 
CD19+ B-cell responses to 
anti-IgD-stimulation using 
αδdex alone, and in 
combination with anti-CD3, 
and anti-CD3 + anti-CD28 
respectively. 
CD19+ B-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD86, 
CD25 and HLA-DR 
expression). 
6.9 – 6.13 5 
Investigate 
differences 
in T- and B-
cell 
responses 
between 
MGUS 
patients and 
matched 
controls, 
based on the 
expanded 
immunologic 
assay, 
including S. 
pneumoniae-
stimulation. 
CD4+ T-cell responses to 
D39 strain of S. pneumoniae 
alone, and in combination 
with anti-CD3, and anti-CD3 
+ anti-CD28 respectively.  
CD4+ T-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD25 
and HLA-DR expression).  
6.1 – 6.4 5 
CD8+ T-cell responses to 
D39 strain of S. pneumoniae 
alone, and in combination 
with anti-CD3, and anti-CD3 
+ anti-CD28 respectively.  
CD8+ T-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD25 
and HLA-DR expression).  
6.5 – 6.8 5 
CD19+ B-cell responses to 
D39 strain of S. pneumoniae 
alone, and in combination 
with anti-CD3, and anti-CD3 
+ anti-CD28 respectively. 
CD19+ B-cell frequency, 
proliferation (based on CFSE 
proliferation index), and 
activation (based on CD86, 
CD25 and HLA-DR 
expression). 
6.9 – 6.13 5 
  * All data was collected by Furaha Asani. 
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6.3  Results 
 
Table 6.2 outlines the MGUS patient and control characteristics. 
 
Table 6.2: Characteristics of the MGUS cohort recruited for this study, 
with matched controls. All participants in the MGUS cohort were White. 
 MGUS  Control subjects 
Number  5 5 
Mean age (Range)  69.20 (53 – 77) 59.80 (52 – 67) 
Sex: Female 
         Male  
2 
3 
2 
3 
 
Using the one-sample Kolmogorov-Smirnov test, some datasets presented in 
figures 6.1 to 6.13 were ascertained to contain both parametric and non-
parametric datasets. Thus the paired-samples t-test and the Wilcoxon signed 
ranks test were respectively used for statistical analyses of these data.  Pair-
wise comparisons between MGUS patients and age-, sex- and ethnicity-
matched controls were conducted. The p values shown are two-tailed, 
testing for differences in both directions. Paired data are presented as spot-
line graphs not only to show differences between patints and matched 
controls, but inter-pair variations. Shaded circles represent one individual, 
with a line connecting matched patient- control pairs. The graph grid is 
organised to facilitate comparisons across rows, and down columns. (Patient 
n = 5). 
 
Stimulation concentrations used were as described in chapter 2: 1μg/ml of 
αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in combination with 
0.5μg/ml anti-CD28 for 96 hr. HKD39 MOI used was 10, for 96 hr. 
Stimulation conditions are indicated per graph. 
 
Before the in vitro proliferation and activation responses of CD4+ T-cells 
could be analysed, the frequency distribution of CD4+ T-cells in both MGUS 
patients and matched controls was investigated (fig. 6.1i). 
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Figure 6.1i: Percentage frequencies of in vitro CD4+ T-cells in MGUS 
patients and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 5). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 6.1ii. 
  MGUS    Control             MGUS    Control             MGUS    Control 
 
 
 MGUS    Control               MGUS    Control             MGUS    Control 
 
 
MGUS    Control                MGUS    Control            MGUS    Control 
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Figure 6.1ii: Tracking data showing the changes in in vitro CD4+ T-cell 
frequencies in MGUS patients (A) and matched controls (B) upon 
stimulation. Matched patient-control pairs are represented using the same 
colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-stimulated, 3; 
(CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex +CD3)-stimulated, 
6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 8; (HKD39+CD3)-
stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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While no differences in in vitro proliferation (fig. 6.2i) or CD25 expression (fig. 
6.3i)  was found between the five MGUS patients and matched controls, a 
difference in HLA-DR expression was uncovered (fig. 6.4i). 
 Figure 6.2i: Proliferation of in vitro CD4+ T-cells in MGUS patients and 
matched controls under un-stimulated and stimulated conditions. Dots 
and lines match each patient-control pair. The paired-samples t-test and 
Wilcoxon signed ranks test were used for parametric and non-parametric 
datasets respectively. (Patient n = 5). Concentrations of stimulants used: 
1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in 
combination with 0.5μg/ml anti-CD28. Patient cohort and control cohort 
tracking data for this graph grid is presented in fig. 6.2ii. 
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  MGUS    Control              MGUS    Control               MGUS    Control 
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Figure 6.2ii: Tracking data showing the changes in in vitro CD4+ T-cell 
proliferation in MGUS patients (A) and matched controls (B) upon 
stimulation. Matched patient-control pairs are represented using the same 
colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-stimulated, 3; 
(CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex +CD3)-stimulated, 
6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 8; (HKD39+CD3)-
stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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Figure 6.3i: CD25 expression on in vitro CD4+ T-cells in MGUS patients 
and matched controls under un-stimulated and stimulated conditions. 
Dots and lines match each patient-control pair. The paired-samples t-test 
and Wilcoxon signed ranks test were used for parametric and non-parametric 
datasets respectively. (Patient n = 5). Concentrations of stimulants used: 
1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in 
combination with 0.5μg/ml anti-CD28. Patient cohort and control cohort 
tracking data for this graph grid is presented in fig. 6.3ii. 
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Figure 6.3ii: Tracking data showing the changes in in vitro CD4+ T-cell 
CD25 expression in MGUS patients (A) and matched controls (B) upon 
stimulation. Matched patient-control pairs are represented using the same 
colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-stimulated, 3; 
(CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex +CD3)-stimulated, 
6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 8; (HKD39+CD3)-
stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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Figure 6.4i: HLA-DR expression on in vitro CD4+ T-cells in MGUS 
patients and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 5). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 6.4ii. 
* 
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Figure 6.4ii: Tracking data showing the changes in in vitro CD4+ T-cell 
HLA-DR expression in MGUS patients (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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Following the analysis of in vitro responses in CD4+ T-cells in this study 
cohort, CD8+ T-cells were investigated beginning with frequency distribution 
(fig. 6.5i). 
 
Figure 6.5i: Percentage frequencies of in vitro CD8+ T-cells in MGUS 
patients and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 5). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 6.5ii. 
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Figure 6.5ii: Tracking data showing the changes in in vitro CD8+ T-cell 
frequencies in MGUS patients (A) and matched controls (B) upon 
stimulation. Matched patient-control pairs are represented using the same 
colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-stimulated, 3; 
(CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex +CD3)-stimulated, 
6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 8; (HKD39+CD3)-
stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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However, differences were uncovered for proliferation (fig. 6.6i) and 
activation in terms of CD25 expression (fig. 6.7i). 
 
Figure 6.6i: Proliferation of in vitro CD8+ T-cells in MGUS patients and 
matched controls under un-stimulated and stimulated conditions. Dots 
and lines match each patient-control pair. The paired-samples t-test and 
Wilcoxon signed ranks test were used for parametric and non-parametric 
datasets respectively. (Patient n = 5; Where * p ≤ 0.050). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 6.6ii. 
* 
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Figure 6.6ii: Tracking data showing the changes in in vitro CD8+ T-cell 
proliferation in MGUS patients (A) and matched controls (B) upon 
stimulation. Matched patient-control pairs are represented using the same 
colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-stimulated, 3; 
(CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex +CD3)-stimulated, 
6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 8; (HKD39+CD3)-
stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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Activation responses also yielded differences between MGUS patients and 
controls (fig. 6.7i). 
 
Figure 6.7i: CD25 expression on in vitro CD8+ T-cells in MGUS patients 
and matched controls under un-stimulated and stimulated conditions. 
Dots and lines match each patient-control pair. The paired-samples t-test 
and Wilcoxon signed ranks test were used for parametric and non-parametric 
datasets respectively. (Patient n = 5; Where * p ≤ 0.050; ** p ≤ 0.010). 
Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 
alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28. 
Patient cohort and control cohort tracking data for this graph grid is 
presented in fig. 6.7ii. 
  * 
 * 
      ** 
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Figure 6.7ii: Tracking data showing the changes in in vitro CD8+ T-cell 
CD25 expression in MGUS patients (A) and matched controls (B) upon 
stimulation. Matched patient-control pairs are represented using the same 
colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-stimulated, 3; 
(CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex +CD3)-stimulated, 
6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 8; (HKD39+CD3)-
stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
 
CHAPTER SIX 
208 
 
A paralleled response in terms of HLA-DR expression was not found, 
however (fig. 6.8i). 
 
Figure 6.8i: HLA-DR expression on in vitro CD4+ T-cells in MGUS 
patients and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 5). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 6.8ii. 
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Figure 6.8ii: Tracking data showing the changes in in vitro CD8+ T-cell 
HLA-DR expression in MGUS patients (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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The third cell population to be investigated was CD19+ B-cells. Once again, 
frequency distribution (fig. 6.9i) was investigated prior to proliferation and 
activation responses. 
 
Figure 6.9i: Percentage frequencies of in vitro CD19+ B-cells in MGUS 
patients and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 5). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 6.9ii. 
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Figure 6.9ii: Tracking data showing the changes in in vitro CD19+ B-cell 
frequencies in MGUS patients (A) and matched controls (B) upon 
stimulation. Matched patient-control pairs are represented using the same 
colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-stimulated, 3; 
(CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex +CD3)-stimulated, 
6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 8; (HKD39+CD3)-
stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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In parallel, comparable responses between MGUS patients and matched 
controls were found for proliferation (fig. 6.10i). 
 
Figure 6.10i: Proliferation of in vitro CD19+ B-cells in MGUS patients 
and matched controls under un-stimulated and stimulated conditions. 
Dots and lines match each patient-control pair. The paired-samples t-test 
and Wilcoxon signed ranks test were used for parametric and non-parametric 
datasets respectively. (Patient n = 5). Concentrations of stimulants used: 
1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml anti-CD3 in 
combination with 0.5μg/ml anti-CD28. Patient cohort and control cohort 
tracking data for this graph grid is presented in fig. 6.10ii.  
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Figure 6.10ii: Tracking data showing the changes in in vitro CD19+ B-
cell proliferation in MGUS patients (A) and matched controls (B) upon 
stimulation. Matched patient-control pairs are represented using the same 
colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-stimulated, 3; 
(CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex +CD3)-stimulated, 
6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 8; (HKD39+CD3)-
stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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Further, in vitro CD25 expression was comparable between MGUS patients 
and controls (fig. 6.11i). 
 
Figure 6.11i: CD25 expression on in vitro CD19+ B-cells in MGUS 
patients and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 5). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 6.11ii. 
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Figure 6.11i: Tracking data showing the changes in in vitro CD19+ B-
cell CD25 expression in MGUS patients (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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Two more CD19+ B-cell activation markers, CD86 (fig. 6.12i) and HLA-DR 
(fig. 6.13i) were analysed for any differential responses between patients and 
controls. 
 
Figure 6.12i: CD86 expression on in vitro CD19+ B-cells in MGUS 
patients and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 5; Where * p ≤ 0.050). 
Concentrations of stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 
alone, and 0.5μg/ml anti-CD3 in combination with 0.5μg/ml anti-CD28. 
Patient cohort and control cohort tracking data for this graph grid is 
presented in fig. 6.12ii. 
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Figure 6.12ii: Tracking data showing the changes in in vitro CD19+ B-
cell CD86 expression in MGUS patients (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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Figure 6.13i: HLA-DR expression on in vitro CD19+ B-cells in MGUS 
patients and matched controls under un-stimulated and stimulated 
conditions. Dots and lines match each patient-control pair. The paired-
samples t-test and Wilcoxon signed ranks test were used for parametric and 
non-parametric datasets respectively. (Patient n = 5). Concentrations of 
stimulants used: 1μg/ml of αδdex, 0.1μg/ml anti-CD3 alone, and 0.5μg/ml 
anti-CD3 in combination with 0.5μg/ml anti-CD28. Patient cohort and control 
cohort tracking data for this graph grid is presented in fig. 6.13ii. 
  MGUS    Control             MGUS    Control             MGUS    Control 
 
 
  MGUS    Control              MGUS    Control             MGUS    Control 
 
 
  MGUS    Control               MGUS    Control            MGUS    Control 
 
 
CHAPTER SIX 
219 
 
             
Figure 6.13ii: Tracking data showing the changes in in vitro CD19+ B-
cell HLA-DR expression in MGUS patients (A) and matched controls (B) 
upon stimulation. Matched patient-control pairs are represented using the 
same colour across A and B. Conditions: 1; Un-stimulated, 2; CD3-
stimulated, 3; (CD3+CD28)-stimulated, 4; αδdex-stimulated, 5; (αδdex 
+CD3)-stimulated, 6; (αδdex +CD3+CD28)-stimulated, 7; HKD39-stimulated, 
8; (HKD39+CD3)-stimulated, 9; (CD3+CD28+HKD39)-stimulated. 
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6.4  Discussion of Findings 
 
Hypothesizing that patients from different points on the myeloma spectrum 
would likely have variable in vitro T- and B-cell responses to polyclonal and 
pneumococcal stimulation, recruitment was focused on MGUS patients. In a 
cohort comprising five MGUS patients and age-, sex- and ethnicity-matched 
controls, no differential responses were found for CD4+ T-cell frequency (fig. 
6.1i), proliferation (fig. 6.2i), or CD25 expression (fig. 6.3i). It is important to 
note that the immunologic assay based on αδdex had previously been 
powered at a sample size of 10 (Foster et al., 2009, Foster et al., 2010, 
Darton et al., 2011). Therefore results presented in this chapter need to be 
interpreted with caution. Furthermore, because MGUS falls at the beginning 
of the myeloma spectrum, the five patients studied would show different 
outcomes: some may respond more like controls than others. Interestingly, in 
vitro TCR stimulation and CD28 co-stimulation of CD4+ T-cells, in the 
presence of HKD39, elicited significantly higher HLA-DR expression levels in 
controls, compared to patients (p ≤ 0.050; fig. 6.4i I). 
 
And while no significantly different responses between MGUS patients and 
controls were found for CD8+ T-cell frequency distribution (fig. 6.5i) or HLA-
DR expression (fig. 6.8i), proliferation (fig. 6.4i) and CD25 expression (fig. 
6.5i) yielded differences. The MGUS patients had significantly higher in vitro 
CD8+ T-cell proliferation than controls under un-stimulated conditions (p ≤ 
0.050; fig. 6.6i A) which became comparable to control responses upon 
stimulation (fig. 6.6i). This echoes the findings of Halapi and colleagues, 
showing significant CD8+ T-cell expansions (p < 0.001) in MGUS patients 
(Halapi et al., 1997). Further, the MGUS patients also expressed significantly 
higher in vitro levels of CD25 on CD8+ T-cells under un-stimulated conditions 
(p ≤ 0.050; fig. 6.7i A) compared to controls. However, upon stimulation with 
anti-CD3 and CD28-costimulation, it was control CD8+ T-cells that 
expressed higher levels of CD25 in vitro (p ≤ 0.010; fig. 6.7i C). In addition, 
stimulation with HKD39 also led to higher in vitro levels of CD25 on CD8+ T-
cells of controls compared to patients (p ≤ 0.050; fig. 6.7i G). 
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To investigate if defects could be detected within the CD19+ B-cell 
population of MGUS patients, frequency distribution of B-cells, proliferation, 
and activation were studied. No significant differences were found between 
MGUS patients and controls for in vitro CD19+ B-cell frequency distribution 
(fig. 6.9i), proliferation (fig. 6.10i), CD25 expression (fig. 6.11i), or HLA-DR 
expression (fig. 6.13i). Further, the significance emerging after αδdex-
stimulation in terms of CD86 expression within the MGUS patient cohort (p ≤ 
0.050; fig. 6.12i D) was most likely due to one outlier patient data point.  
 
6.5  Conclusion 
 
In a cohort of five MGUS patients and age-, sex- and ethnicity-matched 
controls, differential T-cell responses were detected. Control CD4+ T-cells 
stimulated by anti-CD3 and costimulated by anti-CD28 in the presence of 
HKD39 expressed higher levels of HLA-DR, compared to patients. The CD8+ 
T-cell subset also yielded differential responses. MGUS patients had higher 
in vitro proliferation of CD8+ T-cells and CD25 expression, both under un-
stimulated conditions. Upon stimulation with anti-CD3 and anti-CD28, and 
with HKD39 alone, control CD8+ T-cells expressed higher CD25 levels 
compared to patients. No significant differences were found for the B-cell 
parameters measured, between MGUS patients and controls. Only in the 
case of αδdex-stimulated CD86 expression which was likely due to one 
outlier data point. It cannot be concluded that within this cohort of five MGUS 
patients a defect in B-cells was detected. However, this should not rule out 
the possibility of such a defect existing within this patient group, or within 
other patient groups that fall in the symptomatic myeloma spectrum. An 
increase in sample size of MGUS patients (n ≥ 10), and investigation within 
other myeloma patient groups would shed more light on T- and B-cell defects 
in this immunocompromised group, which potentially contributes to their 
predisposition to pneumococcal disease. 
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Because a discussion of the main findings was provided in each results 
chapter, the aim of this overall discussion chapter is to provide a summary of 
the findings within this research project. Also, to outline some methodological 
criticisms which may have impacted on data collection and interpretation. 
Finally, to detail the future direction this work could take to provide deeper 
insight, as well as the clinical implications of the main findings. 
 
This project aimed to investigate T- and B-cell responses in HIV-infected 
individuals and MGUS patients to polyclonal- and pneumococcal-stimulation, 
compared to matched controls, with the aim of uncovering subtle defects in 
vitro in patients which could be responsible for their higher risk of developing 
pneumococcal disease. 
 
7.1 Main findings 
 
7.1.1 Chapter 3- The effect of age, sex and ethnicity on T- and B-cell 
responses 
 
Chapter three reports reproducibility in the immunologic stimulation assay 
that our group developed (Foster et al., 2009). The main findings highlighted 
in this chapter however are that age significantly correlates with in vitro CD4+ 
T-cell activation upon stimulation with αδdex and anti-CD3. There is a 
significant reduction in the in vitro un-stimulated CD86 expression on CD19+ 
B-cells with advancing age that disappears upon stimulation with αδdex 
alone and in combination with T-cell help. A limitation to this portion of the 
study was the small numbers amongst individuals older than 40 years. 
 
Sex was also shown to impact in vitro B-cell responses, with males showing 
significantly higher B-cell activation (in terms of CD86 expression) upon 
stimulation with αδdex alone and in combination with T-cell help. No 
differences between females and males was found for T-cell activation. 
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Finally, strong ethnicity-based variations were found in in vitro T-cell 
responses. White individuals showed higher un-stimulated T-cell activation 
(in terms of CD25 expression) compared to Black individuals which persisted 
after anti-CD3-stimulation alone and with anti-CD28 costimulation. 
Interestingly, αδdex-stimulation elicited higher B-cell proliferation in Black 
compared to White individuals, which was absent under un-stimulated 
conditions and which disappeared upon T-cell help. Further, White 
individuals once more exhibited higher B-cell activation in the presence of T-
cell help. 
 
The implications of these findings are that age, sex and ethnicity are factors 
that need to be strictly accounted for in case-control studies. 
 
 
7.1.2 Chapter 4- T- and B-cell responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation 
 
There were three cell populations of interest to be studied in the HIV-infected 
cohort: CD4+ and CD8+ T-cells, and CD19+ B-cells. Based on finding 
defective B-cell responses in previous sufferers of IPD (Darton et al., 2011) 
and MenC disease (Foster et al., 2009) as well as MenC adolescent vaccine 
failures (Foster et al., 2010), this portion of the study hypothesized that 
immunocompromised patients would likely also exhibit defective B-cell 
responses that increase their likelihood of developing pneumococcal 
disease.  
 
The in vitro work conducted on 16 HIV-infected individuals and matched 
controls did indeed reveal strong anti-CD3-stimulated hyperactivation in the 
patient CD8+ T-cell population. Further, T-cell-helped pneumococcal-
stimulation induced higher B-cell proliferation in patients. In the context of 
pneumococcal disease, this CD19+ B-cell proliferation was noteworthy in 
light of the B-cell subset perturbations that have been reported in viraemic 
HIV (Moir and Fauci, 2013). The results in this portion of the study indicated 
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hyperactivation of CD8+ T-cells and aberrant proliferation of CD19+ B-cells 
in HIV-infected individuals inspite of ART-usage and viral suppression. 
 
The association of defective B-cell responses to an increased risk of 
pneumococcal disease (Foster et al., 2009; Darton et al., 2011), the 35-fold 
increased likelihood of HIV patients developing pneumococcal disease 
compared to their uninfected counterparts even in the HAART era (Heffernan 
et al., 2005), and B-cell subset perturbations in viraemic HIV (Moir and Fauci, 
2013) necessitated further investigation into B-cell subset responses within 
the 16 HIV-infected individuals in the present study. 
 
7.1.3 Chapter 5- B-cell subset responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation 
 
Chapter five demonstrates that even with ART-usage and viral suppression, 
hyperactivation after αδdex-stimulation occurs particularly within the 
plasmablast B-cell subset population of HIV-infected. Further, higher in vitro 
CD86 expression under un-stimulated conditions was uncovered in the 
patient activated memory B-cells, which persisted upon pneumococcal-
stimulation. Because caspase levels correlate with B-cell exhaustion in HIV-
viraemic patients (Nicholas et al., 2013) the present study hypothesized an 
increase in caspase levels within the patient group. While most of the 
patients did show higher un-stimulated and αδdex-stimulated caspase levels 
compared to controls, these were not significant (patient n = 5). Nonetheless, 
the hyperactivation in plasmablasts and activated memory B-cells represent 
a subtle defect uncovered in 16 ART-using, virally-suppressed HIV-infected 
individuals. 
 
 7.1.4 Chapter 6- The effect of polyclonal and pneumococcal stimulation 
on T- and B-cells in a cohort of MGUS patients 
 
To investigate the effectiveness of T- and B-cell responses to the 
immunologic stimulation assay in a second immunocompromised patient 
group, MGUS patients were recruited with matched controls. Before data 
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analysis was conducted, it was clear that conlusions would have to be drawn 
with caution due to the small numbers within the study (patient n = 5). 
Despite these small numbers however, a strong CD3-stimulated and CD28-
costimulated higher in vitro expression of CD25 was found on the CD8+ T-
cells of controls, compared to the patients. While numbers would have to be 
increased before conclusively stating that this represents a defect in MGUS 
patients CD8+ T-cell responses, the strength of the significance (p ≤ 0.010) 
suggests that further study is warranted. The results however do suggest 
that in the case of the MGUS patients, a defect is present in T-cells, rather 
than B-cells. This could pose a significant problem during the cytotoxic 
effector arm of immune responses (Andersen et al., 2006). 
 
 
7.2 Methodological criticisms 
 
7.2.1 Chapter 3- The effect of age, sex and ethnicity on T- and B-cell 
responses 
 
One of the areas in which variability could have been introduced into this 
portion of the study lies within the recruitment of individuals for studying the 
effects of age, sex and ethnicity on T- and B-cell responses. Due to the fact 
that individuals were recruited across a number of years for the age and sex 
studies (due to incorporating data previously collected by James Wing; a 
member of our group), there was room for human error to be introduced first 
from two different individuals handling sample acquisition and data 
processing. The day-to-day variability in the assay would have further added 
a margin of error to these two studies, and to the ethnicity study. 
 
7.2.2 Chapter 4- T- and B-cell responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation 
 
Pre-handling data, one of the points at which error could have been 
introduced into this portion of the study was during control recruitment. 
Controls were recruited under the assumption of HIV-uninfected status at the 
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time of bleed. Had any of these controls been infected, this would have 
counteracted any difference to be seen in their particular patient-control pair. 
In order to minimise day-to-day variability in the assay and enable the usage 
of statistical paired testing, patient-control pairs were bled on the same day, 
usually within one hour of each other. From then on samples were handled in 
the same way.  
 
It is possible however that error was introduced during the flow cytometry 
protocol. Firstly, antibodies produced from the same clone and across 
different lots can exhibit bioactivity variation, even when produced by the 
same company (Li et al., 2010). Thus, the use of different antibody lots within 
the time frame of this project could have introduced variability. Second, 
compensation in multi-colour flow cytometry can introduce another margin of 
error into data (Roederer, 2002). To circumvent this, the FACSDiva™ 
software package was used in conjunction with compensation controls and 
optimised voltages. The third point at which error could have been introduced 
was at the point of flow cytometry gating, which can be subjective. The use 
of fluorescence-minus-one (FMO) controls per experiment should have 
minimised this error however. 
 
7.2.3 Chapter 5- B-cell subset responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation 
 
Much like chapter four, errors could have been introduced into this portion of 
the study during patient recruitment and the flow cytometry protocol. 
Specifically as the gating strategy used in chapter five was more detailed, 
and called for the separation of plasmablasts and activated memory cells 
based on ‘high’ and ‘intermediate’ levels of CD27 expression. The use of 
FMO controls and consultation with technical staff at the Flow Cytometry 
Core Facility at Sheffield Medical School during optimisation of the gating 
strategy should have minimised these errors. 
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7.2.4 Chapter 6- The effect of polyclonal and pneumococcal stimulation 
on T- and B-cells in a cohort of MGUS patients 
 
The points raised for the patients recruitment and flow cytometry protocol 
within the HIV cohort are applicable to the MGUS cohort. 
 
 
7.3 Future work and clinical considerations 
 
7.3.1 Chapter 3- The effect of age, sex and ethnicity on T- and B-cell 
responses 
 
The sex-based variability in B-cell activation seen in this study may have 
implications on the influence of sex in vaccine responses. Particularly as sex-
differential effects of vaccines have been reported, perhaps with a future for 
personalised vaccines that will account for these differences (Flanagan and 
Plebanski, 2017). Importantly also, the ethnicity-based influence on T-cell 
activation uncovered in this study may contribute towards the ongoing 
debate on the influence of ethnicity on disease susceptibility and treatment 
outcomes (Feller et al., 2014).  
 
One way this study can be taken forward is to include more numbers per 
age, sex and ethnicity study groups. More ethnicities could also be included. 
Furthermore, to expand these functional studies, more parameters other than 
the markers used in the present study could be included. 
 
7.3.2 Chapter 4- T- and B-cell responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation 
 
While much is known about the polyclonal hyperactivation of T- and B-cells 
in HIV-viraemic patients (Meyaard et al., 1992, Appay and Sauce, 2008, Day 
et al., 2006, Nicholas et al., 2013), the present study sought to elucidate why 
even in the era of HAART, HIV-infected individuals are still 35-fold more 
likely to develop IPD than uninfected individuals (Heffernan et al., 2005, 
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Westerink et al., 2012). Results in chapter four demonstrate that even with 
ART-usage and viral suppression, hyperactivation of T- and B-cells still 
persists. Most notably in the context of pneumococcal disease, the results 
showing increased B-cell proliferation in patients upon T-cell-helped 
pneumococcal-stimulation. The CD3-stimulated hyperactivation in the patient 
CD8+ T-cell population also has implications regarding T-cell exhaustion 
(Haas et al., 2011, Okoye and Picker, 2013, Mauricio Rueda et al., 2012, Ott 
et al., 1997). In conjunction with studies into improved adjuvantion for 
pneumococcal vaccines specifically for HIV-infected individuals, it would be 
beneficial to study mechanisms in which hyperactivation inspite of ART-
usage can be dampened. 
 
A transcriptomics study to investigate gene expression changes (Lowe et al., 
2017) between HIV-infected individuals and matched controls after in vitro 
polyclonal- and pneumococcal-stimulation, compared to ex vivo samples, 
may provide more clues about mechanisms underlying pneumococcal 
disease development. Additionally, an expanded cohort in which nasal 
swabs are included to ascertain carriage/colonisation could strengthen 
conclusions drawn. Lastly, extending this study to include HIV-infected 
individuals (and controls) with known history of pneumococcal vaccination 
and comparing the effectiveness of their T- and B-cell responses to their 
unvaccinated counterparts may provide important information regarding how 
vaccine adjuvants can be improved. 
 
7.3.3 Chapter 5- B-cell subset responses in HIV-infected individuals 
following polyclonal and pneumococcal stimulation 
 
Plasmablasts and activated memory B-cells in HIV viraemia arise as a result 
of HIV-induced immune activation (Moir and Fauci, 2013). While HAART has 
been found to normalise B-cell subsets in asymptomatic individuals (Fogli et 
al., 2012), results in chapter five suggest that a subtle defect in B-cell 
subsets still persists despite ART-usage. These results may have clinical 
implications in terms of which B-cell subsets can be targeted to suppress 
hyperactivation in the context of pneumococcal vaccine-induced immunity. 
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Plasmablast responses have been speculated to be predictive for later 
immunity, most probably deriving from memory B-cells and circulating in 
peripheral blood 6 – 7 days post-infection or immunisation (Fink, 2012). The 
polyclonal-induced hyperactivation in PBs and antigen-specific activation in 
AMs of HIV-infected individuals in the present study have implications on 
anti-pneumococcal immunity. This hyperactivation could trend both PBs 
(Nicholas et al., 2013) and AMs in the patients to exhaustion (Moir and 
Fauci, 2017). These results suggest that the PB and AM B-cell subsets may 
play a significant role in the increased likelihood of HIV-infected individuals 
developing pneumococcal disease. 
 
There is still the need for these results to be reproduced however. In 
addition, for the numbers in the cohort to be increased. It would be 
interesting to see if this expanded cohort of patients would show significantly 
higher caspase levels compared to controls. It may also be useful to include 
a cohort of viraemic patients and study how their responses differ to ART-
users. 
 
7.3.4 Chapter 6- The effect of polyclonal and pneumococcal stimulation 
on T- and B-cells in a cohort of MGUS patients 
 
A study across the spectrum of haematological malignancies (including 
asymptomatic and symptomatic patients) may highlight T- and B-cell defects 
in patients. This may provide more clarity on how these patients’ immunity to 
pneumococcal disease can be boosted. 
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7.4 Overall considerations 
 
Work conducted in this project uncovered a subtle in vitro defect in the B-cell 
subsets of ART-using, virally suppressed HIV-infected individuals, which 
presented as a hyperactivation response. Particularly, the plasmablast and 
activated memory B-cell subsets which showed αδdex-stimulated and 
HKD39-stimulated hyperactivion, respectively. Conversley, in vitro 
hypoactivation in polyclonally-stimulated CD8+ T-cells of MGUS patients was 
uncovered. Both these patient groups are known to have a higher risk of 
developing pneumococcal disease. Thus, results presented in this thesis 
suggest that immunocompromised individuals may exhibit either hyper- or 
hypoactivation responses to polyclonal-stimulation. If these in vitro 
responses mimic those in vivo, these may represent subtle defects which put 
these immunocompromised patients at risk of developing pneumococcal 
disease. 
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